Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors

ABSTRACT

Provided herein are triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same. For example, provided herein are compounds of Formula (I) and pharmaceutically acceptable salts and compositions including the same. The compounds disclosed herein may be used, for example, in the treatment of diseases including inflammation and/or cancer.

BACKGROUND Field of the Invention

The present disclosure relates to triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors, including methods of making and using the same.

INCORPORATION BY REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

This application contains, as a separate part of disclosure, a sequence listing in computer-readable form (filename 40056_Seqlisting.txt; 20,275 bytes; created Feb. 14, 2019) which is incorporated by reference in its entirety.

DESCRIPTION OF RELATED TECHNOLOGY

Protein translocation into the endoplasmic reticulum (“ER”) constitutes the first step of protein secretion. ER protein import is essential in all eukaryotic cells and is particularly important in fast-growing tumour cells. Thus, the process of protein secretion can serve as a target both for potential cancer drugs and for bacterial virulence factors. See Kalies and Römisch, Traffic, 16(10):1027-1038 (2015).

Protein transport to the ER is initiated in the cytosol when N-terminal hydrophobic signal peptides protrude from the ribosome. Binding of signal recognition particle (“SRP”) to the signal sequence allows targeting of the ribosome-nascent chain-SRP complex to the ER membrane where contact of SRP with its receptor triggers handing over of the signal peptide to Sec61. Sec61 is an ER membrane protein translocator (aka translocon) that is doughnut-shaped with 3 major subunits (heterotrimeric). It includes a “plug,” which blocks transport into or out of the ER. The plug is displaced when the hydrophobic region of a nascent polypeptide interacts with the “seam” region of Sec61, allowing translocation of the polypeptide into the ER lumen. In mammals, only short proteins (<160 amino acids) can enter the ER posttranslationally, and proteins smaller than 120 amino acids are obliged to use this pathway. Some of the translocation competence is maintained by the binding of calmodulin to the signal sequence. Upon arrival at the Sec61 channel, the signal peptide or signal anchor intercalates between transmembrane domains (“TMDs”) 2 and 7 of Sec61a, which form the lateral portion of the gate, allowing the channel to open for soluble secretory proteins. As the Sec61 channel consists of 10 TMDs (Sec61a) surrounded by a hydrophobic clamp formed by Sec61γ, channel opening is dependent on conformational changes that involve practically all TMDs.

Inhibition of protein transport across the ER membrane has the potential to treat or prevent diseases, such as the growth of cancer cells and inflammation. Known secretion inhibitors, which range from broad-spectrum to highly substrate-specific, can interfere with virtually any stage of this multistep process, and even with transport of endocytosed antigens into the cytosol for cross-presentation. These inhibitors interact with the signal peptide, chaperones, or the Sec61 channel to block substrate binding or to prevent the conformational changes needed for protein import into the ER. Examples of protein secretion inhibitors include, calmodulin inhibitors (e.g., E6 Berbamine and Ophiobolin A), Lanthanum, sterols, cyclodepsipeptides (e.g., HUN-7293, CAM741, NFI028, Cotrainsin, Apratoxin A, Decatransin, Valinomycin), CADA, Mycolactone, Eeyarestatin I (“ESI”), and Exotoxin A. However, the above secretion inhibitors suffer from one or more of the following: lack selectivity for the Sec61 channel, challenging manufacture due to structural complexity, and molecular weight limited administration, bio-availability and distribution.

Thus, a need exists for new small molecule inhibitors of protein secretion.

SUMMARY

In one aspect, provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof:

wherein: each of R^(a) and R^(b) is independently H or C₁₋₃alkyl; R¹ is H, OH, C₁₋₃alkyl, OC₁₋₃alkyl, ═CH₂, or ═NOR⁵; or R¹ is C₃₋₆cycloalkyl or C₃₋₆heterocycloalkyl and forms a spiro group with the ring carbon to which it is attached; each of R^(1a) and R^(1b) is independently H or C₁₋₃alkyl; R² is C₁₋₆alkyl, N(R⁵)₂, C₃₋₈cycloalkyl, C₃₋₉heterocycloalkyl, C₃₋₉heterocycloalkenyl, or C₆₋₁₀aryl; R³ is H, C₁₋₆alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, C₃₋₇heterocycloalkyl, C₆₋₁₀aryl, or C₂₋₆heteroaryl; R⁴ is C₃₋₈cycloalkyl, C₃₋₉heterocycloalkyl, C₆₋₁₀aryl, or C₂₋₉heteroaryl; each R⁵ independently is H, C₁₋₃alkyl, or C₀₋₂alkylene-C₆₋₁₀aryl; X is absent, C₁₋₃alkylene, C═O, or (C═O)O; Y is SO or SO₂; each heterocycloalkyl, heterocycloalkenyl, and heteroaryl group independently has 1, 2, or 3 ring heteroatoms selected from N, O, and S.

In some embodiments, each Y is SO. In various embodiments, each Y is SO₂.

In various cases, R^(a) is H. In some cases, R^(a) is C₁₋₃alkyl. In some embodiments, R^(a) is CH₃. In some embodiments, R^(b) is H. In various embodiments, R^(b) is C₁₋₃alkyl. In various cases, R^(b) is CH₃. In various cases, each of R^(a) and R^(b) is H.

In some cases, R¹ is H, OH, or ═NOR⁵. In various cases, R⁵ is each R⁵ independently is H, C₁₋₃alkyl, or C₀₋₂alkylene-C₆₋₁₀aryl. In some cases, R⁵ is H or CH₃. In some embodiments, R¹ is C₁₋₃alkyl or OC₁₋₃alkyl. In various embodiments, R¹ is CH₃ or OCH₃. In some cases, R¹ is CH₃ and exhibits S stereochemistry. In various embodiments, R¹ is C₃₋₆cycloalkyl or C₃₋₆heterocycloalkyl and forms a spiro group with the ring carbon to which it is attached. In some cases, R¹ together with the ring atom to which it is attached forms

In various cases, R¹ is CH₂.

In some cases, each of R^(1a) and R^(1b) is H. In some cases, at least one of R^(1a) and R^(1b) is C₁₋₃alkyl. In some cases, each of R^(1a) and R^(1b) is CH₃.

In some embodiments, R² is C₁₋₆alkyl or N(R⁵)₂. In various cases, each R⁵ independently comprises H, C₁₋₃ alkyl or benzyl. In various embodiments, R² is Et, iPr, N(CH₃)₂,

In some cases, R² comprises C₃₋₈cycloalkyl. In various cases, R² comprises cyclopentyl or cyclohexyl. In some embodiments, R² is C₃₋₉heterocycloalkyl or C₃₋₉heterocycloalkenyl. In various embodiments, R² comprises oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, pyranyl, piperidinyl, piperazinyl, azepanyl, morpholinyl, or tetrahydropyridinyl. In various embodiments, the C₃₋₉heterocycloalkyl or C₃₋₉heterocycloalkenyl comprises a bridge or a spiro group. In some cases, the C₃₋₉heterocycloalkyl comprising a bridge or a spiro group is selected from the group consisting of

and R⁶ is C₁₋₆alkyl, C₃₋₈cycloalkyl, or CO₆₋₁₀aryl. In some cases, R⁶ is phenyl optionally substituted with one to three groups independently selected from halo, C₁₋₃alkyl, C₁₋₃alkoxy, and CN. In various cases, R² is selected from the group consisting of

In some cases, R² is selected from the group consisting of

In various cases, R² is C₆₋₁₀aryl. In some embodiments, R² is

In various embodiments, X is absent. In some embodiments, R³ comprises C₁₋₆alkyl or H. In some cases, R³ is 2-methylbutyl, isopropyl, isopentyl, CH₂CH₂OCH₃, CH₂C(CH₃)₂CN, CH₂CF₃, or CH₂CH₂CF₃. In various cases, R³ is isobutyl.

In some embodiments, X is C₁₋₃alkylene. In some cases, X is CH₂, CH₂CH₂, or CH(CH₃). In various cases, R³ comprises C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, C₃₋₇heterocycloalkyl, C₆₋₁₀aryl, or C₂₋₆heteroaryl. In some embodiments, R³ comprises cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, furanyl, thiophenyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrazinyl, or pyrimidinyl. In various embodiments, X—R³ is selected from the group consisting of

In some cases, X—R³ is

In some cases, X—R³ is

In some embodiments, X is C═O or (C═O)O. In various embodiments, R³ comprises C₁₋₆alkyl or C₆₋₁₀aryl. In some cases, X—R³ is

In various cases, R⁴ comprises C₃₋₈cycloalkyl or C₃₋₉heterocycloalkyl. In some embodiments, R⁴ is

In various embodiments, R⁴ comprises C₆₋₁₀aryl or C₂₋₉heteroaryl, and R⁴ is optionally substituted with one to three groups independently selected from halo, C₁₋₃alkyl, C₁₋₃alkoxy, C(O)N(R^(N))₂, and N(R^(N))₂, and each R^(N) is independently H or C₁₋₃alkyl. In some embodiments, R⁴ is selected from the group consisting of

In various embodiments, R⁴ is

In some embodiments, R^(a), R^(b), R^(1a), and R^(1b) are each H; R¹ is ═CH₂ or CH₃; R² is

X—R³ is isobutyl,

R⁴ is

and each Y is SO₂.

In some embodiments, R is in a (S) configuration.

Also provided herein are compounds listed in Table A, Table B, and pharmaceutically acceptable salts thereof. In some embodiments, provided herein is a compound is selected from the group consisting of:

Further provided herein is a pharmaceutical composition comprising a compound of Formula (I), a compound listed in Table A, a compound listed in Table B, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Also provided herein is a method of inhibiting protein secretion in a cell comprising contacting the cell with the compound or salt of Formula (I), the compound listed in Table A or a pharmaceutically acceptable salt thereof, a compound listed in Table B or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition described herein in an amount effective to inhibit secretion. In some cases, the contacting comprises administering the compound or the composition to a subject.

Further provided herein is a method for treating inflammation in a subject comprising administering to the subject a therapeutically effective amount of a compound or salt of Formula (I), a compound listed in Table A or a pharmaceutically acceptable salt thereof, a compound listed in Table B or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition described herein.

Also provided herein is a method for treating or preventing cancer or precancerous conditions in a subject comprising administering to the subject a therapeutically effective amount of the compound or salt of Formula (I), a compound listed in Table A or a pharmaceutically acceptable salt thereof, a compound listed in Table B or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition described herein.

Further aspects and advantages will be apparent to those of ordinary skill in the art from a review of the following detailed description, taken in conjunction with the drawings. The description hereafter includes specific embodiments with the understanding that the disclosure is illustrative, and is not intended to limit the invention to the specific embodiments described herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts B16F10 efficacy data for compound A87 compared to an anti-PD-1 therapy. Compound A87 exhibited superior efficacy with once-a-week dosing over the anti-PD-1 therapy in the refractory model with respect to tumor growth inhibition and percent body weight.

Further aspects and advantages will be apparent to those of ordinary skill in the art from a review of the following detailed description. While the compounds and methods disclosed herein are susceptible of embodiments in various forms, the description hereafter includes specific embodiments with the understanding that the disclosure is illustrative, and is not intended to limit the invention to the specific embodiments described herein.

DETAILED DESCRIPTION

Provided herein are compounds that inhibit protein secretion. The compounds described herein can be used to treat or prevent diseases associated with excessive protein secretion, such as inflammation and cancer, improving the quality of life for afflicted individuals.

The compounds described herein have a structure of Formula (I)

wherein the substituents are described in detail below.

Without being bound by any particular theory, the compounds described herein inhibit protein secretion by binding to and disabling components of the translocon, including but not limited to Sec61, and in some cases, disrupting in a sequence specific fashion interactions between the nascent signaling sequence of translated proteins with components of the translocon including but not limited to Sec61. The compounds described herein can bind specifically to the signal sequence with little to no interaction with the translocon itself.

The compounds described herein can advantageously inhibit the secretion of TNFα with an IC₅₀ of up to 5 μM, or up to 3 μM, or up to 1 μM. In various cases, the compounds disclosed herein can inhibit the secretion of IL-2 with an IC₅₀ of up to 5 μM, or up to 3 μM, or up to 1 μM. In some cases, the compounds disclosed herein can inhibit the secretion of PD-1 with an IC₅₀ of up to 5 μM, or up to 3 μM, or up to 1 μM.

The compounds described herein are efficacious in reducing tumor growth and body weight. For example, compound A87 showed superior efficacy in reducing tumor growth with once-a-week dosing in a refractory model compared to anti-PD-1 therapy. See the Examples section and FIG. 1 .

Chemical Definitions

As used herein, the term “alkyl” refers to straight chained and branched saturated hydrocarbon groups containing one to thirty carbon atoms, for example, one to twenty carbon atoms, or one to ten carbon atoms. The term C_(n) means the alkyl group has “n” carbon atoms. For example, C₄ alkyl refers to an alkyl group that has 4 carbon atoms. C₁₋₇alkyl refers to an alkyl group having a number of carbon atoms encompassing the entire range (i.e., 1 to 7 carbon atoms), as well as all subgroups (e.g., 1-6, 2-7, 1-5, 3-6, 1, 2, 3, 4, 5, 6, and 7 carbon atoms). Nonlimiting examples of alkyl groups include, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl (2-methylpropyl), t-butyl (1,1-dimethylethyl), 3,3-dimethylpentyl, and 2-ethylhexyl. Unless otherwise indicated, an alkyl group can be an unsubstituted alkyl group or a substituted alkyl group.

As used herein, the term “alkylene” refers to a bivalent saturated aliphatic radical. The term C_(n) means the alkylene group has “n” carbon atoms. For example, C₁₋₆alkylene refers to an alkylene group having a number of carbon atoms encompassing the entire range, as well as all subgroups, as previously described for “alkyl” groups.

As used herein, the term “alkenyl” is defined identically as “alkyl” except for containing at least one carbon-carbon double bond, and having two to thirty carbon atoms, for example, two to twenty carbon atoms, or two to ten carbon atoms. The term C_(n) means the alkenyl group has “n” carbon atoms. For example, C₄ alkenyl refers to an alkenyl group that has 4 carbon atoms. C₂₋₇alkenyl refers to an alkenyl group having a number of carbon atoms encompassing the entire range (i.e., 2 to 7 carbon atoms), as well as all subgroups (e.g., 2-6, 2-5, 3-6, 2, 3, 4, 5, 6, and 7 carbon atoms). Specifically contemplated alkenyl groups include ethenyl, 1-propenyl, 2-propenyl, and butenyl. Unless otherwise indicated, an alkenyl group can be an unsubstituted alkenyl group or a substituted alkenyl group.

As used herein, the term “cycloalkyl” refers to an aliphatic cyclic hydrocarbon. The term C_(n) means the cycloalkyl group has “n” carbon atoms. For example, C cycloalkyl refers to a cycloalkyl group that has 5 carbon atoms in the ring. C₅₋₈ cycloalkyl refers to cycloalkyl groups having a number of carbon atoms encompassing the entire range (i.e., 5 to 8 carbon atoms), as well as all subgroups (e.g., 5-6, 6-8, 7-8, 5-7, 5, 6, 7, and 8 carbon atoms). Nonlimiting examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Unless otherwise indicated, a cycloalkyl group can be an unsubstituted cycloalkyl group or a substituted cycloalkyl group.

As used herein, the term “cycloalkenyl” is defined similarly to “cycloalkyl” except for containing at least one carbon-carbon double bond, but is not aromatic. The term C_(n) means the cycloalkenyl group has “n” carbon atoms. For example, C₅ cycloalkenyl refers to a cycloalkenyl group that has 5 carbon atoms in the ring. C₅₋₈ cycloalkenyl refers to cycloalkenyl groups having a number of carbon atoms encompassing the entire range (i.e., 5 to 8 carbon atoms), as well as all subgroups (e.g., 5-6, 6-8, 7-8, 5-7, 5, 6, 7, and 8 carbon atoms). Nonlimiting examples of cycloalkenyl groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Unless otherwise indicated, a cycloalkenyl group can be an unsubstituted cycloalkenyl group or a substituted cycloalkenyl group.

As used herein, the term “heterocycloalkyl” is defined similarly as cycloalkyl, except the ring contains one to three heteroatoms independently selected from oxygen, nitrogen, or sulfur. Nonlimiting examples of heterocycloalkyl groups include piperdine, tetrahydrofuran, tetrahydropyran, dihydrofuran, morpholine, oxazepaneyl, and the like. Cycloalkyl and heterocycloalkyl groups can be saturated or partially unsaturated ring systems optionally substituted with, for example, one to three groups, independently selected alkyl, alkyleneOH, C(O)NH₂, NH₂, oxo (═O), aryl, haloalkyl, halo, and OH. Heterocycloalkyl groups optionally can be further N-substituted as described herein.

As used herein, the term “aryl” refers to monocyclic or polycyclic (e.g., fused bicyclic and fused tricyclic) carbocyclic aromatic ring systems. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, phenanthrenyl, biphenylenyl, indanyl, indenyl, anthracenyl, fluorenyl, tetralinyl. Unless otherwise indicated, an aryl group can be an unsubstituted aryl group or a substituted aryl group.

As used herein, the term “heteroaryl” refers to monocyclic or polycyclic (e.g., fused bicyclic and fused tricyclic) aromatic ring systems, wherein one to four-ring atoms are selected from oxygen, nitrogen, or sulfur, and the remaining ring atoms are carbon, said ring system being joined to the remainder of the molecule by any of the ring atoms. Nonlimiting examples of heteroaryl groups include, but are not limited to, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, tetrazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, furanyl, thienyl, quinolinyl, isoquinolinyl, benzoxazolyl, benzimidazolyl, benzofuranyl, benzothiazolyl, triazinyl, triazolyl, purinyl, pyrazinyl, purinyl, indolinyl, phthalzinyl, indazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, naphthyridinyl, pyridopyridinyl, indolyl, 3H-indolyl, pteridinyl, and quinooxalinyl. Unless otherwise indicated, a heteroaryl group can be an unsubstituted heteroaryl group or a substituted heteroaryl group.

As used herein, the term “hydroxy” or “hydroxyl” as used herein refers to the “—OH” group.

As used herein, the term “alkoxy” or “alkoxyl” refers to a “—O-alkyl” group.

As used herein, the term “halo” is defined as fluoro, chloro, bromo, and iodo.

As used herein, the term “carboxy” or “carboxyl” refers to a “—COOH” group.

As used herein, the term “amino” refers to a —NH₂ or —NH— group, wherein any hydrogen can be replaced with an alkyl, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl group.

As used herein, the term “sulfonyl” refers to a

group.

A “substituted” functional group (e.g., a substituted alkyl, alkyleneyl, cycloalkyl, aryl, or heteroaryl) is a functional group having at least one hydrogen radical that is substituted with a non-hydrogen radical (i.e., a substitutent). Examples of non-hydrogen radicals (or substituents) include, but are not limited to, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, ether, aryl, heteroaryl, heterocycloalkyl, hydroxyl, oxy (or oxo), alkoxyl, ester, thioester, acyl, carboxyl, cyano, nitro, amino, sulfhydryl, and halo. When a substituted alkyl group includes more than one non-hydrogen radical, the substituents can be bound to the same carbon or two or more different carbon atoms.

Protein Secretion Inhibitors

In one aspect, the compounds of the disclosure have a structure of Formula (I), or a pharmaceutically acceptable salt thereof:

wherein:

-   -   each of R^(a) and R^(b) is independently H or C₁₋₃alkyl;     -   R¹ is H, OH, C₁₋₃alkyl, OC₁₋₃alkyl, ═CH₂, or ═NOR⁵; or R¹ is         C₃₋₆cycloalkyl or C₃₋₆heterocycloalkyl and forms a spiro group         with the ring carbon to which it is attached;     -   each of R^(1a) and R^(1b) is independently H or C₁₋₃alkyl;     -   R² is C₁₋₆alkyl, N(R⁵)₂, C₃₋₈cycloalkyl, C₃₋₉heterocycloalkyl,         C₃₋₉heterocycloalkenyl, or C₆₋₁₀aryl;     -   R³ is H, C₁₋₆alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl,         C₃₋₇heterocycloalkyl, C₆₋₁₀aryl, or C₂₋₆heteroaryl;     -   R⁴ is C₃₋₈cycloalkyl, C₃₋₉heterocycloalkyl, C₆₋₁₀aryl, or         C₂₋₉heteroaryl;     -   each R⁵ independently is H, C₁₋₃alkyl, or         C₀₋₂alkylene-C₆₋₁₀aryl;     -   X is absent, C₁₋₃alkylene, C═O, or (C═O)O;     -   Y is SO or SO₂;     -   each heterocycloalkyl, heterocycloalkenyl, and heteroaryl group         independently has 1, 2, or 3 ring heteroatoms selected from N,         O, and S.

In some embodiments, each Y is SO. In various embodiments, each Y is SO₂.

In various cases, R^(a) is H. In some cases, R^(a) is C₁₋₃alkyl. In some embodiments, R^(a) is CH₃. In some embodiments, R^(b) is H. In various embodiments, R^(b) is C₁₋₃alkyl. In various cases, R^(b) is CH₃. In some cases, both R^(a) and R^(b) are H.

In some cases, R¹ is H, OH, or ═NOR⁵. In various cases, R⁵ is H or CH₃. Therefore, suitable R¹ groups can include H, OH, ═NOH, and ═NORCH₃. In some embodiments, R¹ is C₁₋₃alkyl or OC₁₋₃alkyl. For example, R¹ can be CH₃ or OCH₃. In some cases, R¹ is CH₃ and exhibits S stereochemistry. In various embodiments, R¹ is C₃₋₆cycloalkyl or C₃₋₆heterocycloalkyl and forms a spiro group with the ring carbon to which it is attached. Suitable R¹ spiro groups can include

In various cases, R¹ is ═CH₂. In some embodiments, each of R^(1a) and R^(1b) is H. In some embodiments, at least one of R^(1a) and R^(1b) is C₁₋₃alkyl. In some embodiments, each of R^(1a) and R^(1b) is CH₃. In some embodiments, R^(a) is H, R^(b) is H, and R¹ is CH₃. In various embodiments, R^(a) is CH₃, R^(b) is H, and R¹ is H. In some cases, R^(a) is H, R^(b) is CH₃, and R¹ is H. In various cases, R^(a) is CH₃, R^(b) is H, and R¹ is CH₃. In some embodiments, R^(a) is H, R^(b) is CH₃, and R¹ is CH₃. In various embodiments, R^(a) is CH₃, R^(b) is CH₃, and R¹ is H.

In some embodiments, R² is C₁₋₆alkyl or N(R⁵)₂. In some cases, each R⁵ independently comprises H, C₁₋₃alkyl, or benzyl. Suitable R² groups can include Et, iPr, N(CH₃)₂,

In some cases, R² comprises C₃₋₈cycloalkyl. In various cases, R² comprises cyclopentyl or cyclohexyl. In some embodiments, R² is C₃₋₉heterocycloalkyl or C₃₋₉heterocycloalkenyl. In various embodiments, R² comprises oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, pyranyl, piperidinyl, piperazinyl, azepanyl, morpholinyl, or tetrahydropyridinyl. In various embodiments, the C₃₋₉heterocycloalkyl or C₃₋₉heterocycloalkenyl comprises a bridge or a spiro group. In some cases, the C₃₋₉heterocycloalkyl comprising a bridge or a spiro group is selected from the group consisting of

and R⁶ is C₁₋₆alkyl, C₃₋₈cycloalkyl, or C₆₋₁₀aryl. In some cases, R⁶ is phenyl optionally substituted with one to three groups independently selected from halo, C₁₋₃alkyl, C₁₋₃alkoxy, and CN. Examples of suitable R² groups include

In some cases, R² is selected from the group consisting of

In various cases, R² is C₆₋₁₀aryl. In some embodiments, R² is

In various embodiments, X is absent. In some embodiments, R³ comprises C₁₋₆alkyl or H. In some cases, R³ is C₁₋₆alkyl, such as methyl, ethyl, propyl, butyl, pentyl, or hexyl. In some cases, R³ is 2-methylbutyl, isopropyl, isopentyl, CH₂CH₂OCH₃, CH₂C(CH₃)₂CN, CH₂CF₃, or CH₂CH₂CF₃. In various cases, R³ is isobutyl.

In some embodiments, X is C₁₋₃alkylene. In some cases, X is CH₂, CH₂CH₂, or CH(CH₃). In various cases, R³ comprises C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, C₃₋₇heterocycloalkyl, C₆₋₁₀aryl, or C₂₋₆heteroaryl. In some embodiments, R³ comprises cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, tetrahydropyranyl, phenyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, furanyl, thiophenyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrazinyl, or pyrimidinyl. Examples of suitable X—R³ include

In some cases, X—R³ is

In some cases, X—R³ is

In some embodiments, X is C═O or (C═O)O. In various embodiments, R³ comprises C₁₋₆alkyl or C₆₋₁₀aryl. In some cases, X—R³ is

In various cases, R⁴ comprises C₃₋₈cycloalkyl or C₃₋₉heterocycloalkyl, such as

or In various embodiments, R⁴ comprises C₆₋₁₀aryl or C₂₋₉heteroaryl, and R⁴ is optionally substituted with one to three groups independently selected from halo, C₁₋₃alkyl, C₁₋₃alkoxy, C(O)N(R^(N))₂, and N(R^(N))₂, and each R^(N) is independently H or C₁₋₃alkyl. In some embodiments, R⁴ is selected from the group consisting of

In various embodiments, R⁴ is

In some embodiments, R^(a), R^(b), R^(1a), and R^(1b) are each H, R¹ is ═CH₂ or CH₃; R² is

X—R³ is isobutyl,

R⁴ is

and each Y is SO₂. In some cases, R¹ is in a (S) configuration. In some cases, provided herein are compounds comprising a structure

wherein R² is

and R³ is cyclobutyl, cyclopentyl, or cyclohexyl.

Examples of compounds of Formula (I) are shown in Table A, as compounds A1-A210, or a pharmaceutically acceptable salt thereof. In some cases, the compound is a compound of A1-A151, or pharmaceutically acceptable salt thereof.

TABLE A No. Structure A1

A2

A3

A4

A5

A6

A7

A8

A9

A10

A11

A12

A13

A14

A15

A16

A17

A18

A19

A20

A21

A22

A23

A24

A25

A26

A27

A28

A29

A30

A31

A32

A33

A34

A35

A36

A37

A38

A39

A40

A41

A42

A43

A44

A46

A47

A48

A49

A50

A51

A52

A53

A54

A55

A56

A57

A58

A59

A60

A61

A63

A64

A65

A66

A67

A68

A69

A70

A71

A72

A73

A74

A75

A76

A77

A78

A79

A80

A81

A82

A83

A84

A85

A86

A87

A88

A89

A90

A91

A92

A93

A94

A95

A96

A97

A98

A99

A100

A101

A102

A013

A104

A105

A106

A107

A108

A109

A110

A111

A112

A113

A114

A115

A116

A117

A118

A119

A120

A121

A122

A123

A124

A125

A126

A127

A128

A129

A130

A131

A132

A133

A134

A135

A136

A137

A138

A140

A141

A142

A143

A144

A145

A146

A147

A148

A149

A150

A151

A152

A153

A154

A155

A156

A157

A160

A161

A162

A163

A164

A165

A166

A167

A168

A169

A170

A171

A172

A173

A174

A175

A176

A177

A178

A179

A180

A181

A182

A183

A184

A185

A187

A188

A189

A190

A191

A192

A193

A194

A195

A196

A197

A198

A199

A200

A201

A202

A203

A204

A205

A206

A207

A208

A209

A210.

In some embodiments, the compounds of the disclosure include

or a pharmaceutically acceptable salt thereof.

Additional compounds of the disclosure are shown in Table B as compounds B1-B22, or a pharmaceutically acceptable salt thereof. In some cases, the compound is a compound of B1-B20, or a pharmaceutically acceptable salt thereof.

TABLE B No. Structure B1

B2

B3

B4

B5

B6

B7

B8

B9

B10

B11

B12

B13

B14

B15

B16

B17

B18

B19

B20

B21

B22

The chemical structures having one or more stereocenters depicted with dashed and bolded (i.e.,

and

) are meant to indicate absolute stereochemistry of the stereocenter(s) present in the chemical structure. Bonds symbolized by a simple line do not indicate a stereo-preference. Unless otherwise indicated to the contrary, chemical structures that include one or more stereocenters which are illustrated herein without indicating absolute or relative stereochemistry, encompass all possible stereoisomeric forms of the compound (e.g., diastereomers, enantiomers) and mixtures thereof. Structures with a single bold or dashed line, and at least one additional simple line, encompass a single enantiomeric series of all possible diastereomers.

Synthesis of Protein Secretion Inhibitors

The compounds provided herein can be synthesized using conventional techniques readily available starting materials known to those skilled in the art. In general, the compounds provided herein are conveniently obtained via standard organic chemistry synthesis methods.

Synthesis of Final Compounds

In some cases, the compounds described herein can be synthesized by reacting a sulfonyl chloride having a desired R² group with propane-1,3-diamine, and reacting the resulting product with an aldehyde having a desired R³ group to form N-substituted propyl amine compound. A propyl amino group can be introduced to the N-substituted propyl amine at the R⁴ position via reaction with 2-(3-bromopropyl)isoindoline-1,3-dione followed by hydrazine, and a desired R⁴ group can be coupled to the compound by reacting the compound with a sulfonyl chloride functionalized with the desired R⁴ group. Finally, the compound can be cyclized via a cyclization agent having a desired R¹ group, such as 3-chloro-2-chloromethyl-1-propene, 2-methylpropane-1,3-diyl diethanesulfonate, cyclopropane-1,1-diylbis(methylene) diethanesulfonate, 1,3-dichloropropane, or 1,4-dichlorobutane.

In some embodiments, compounds having a methylene group at R¹ can be synthesized by coupling a (3-aminopropyl)propane-1,3-diamine group derivatized with the desired R³ and R⁴ groups with a desired R²-sulfamoyl chloride or R²-sulfanyl chloride group, and then reacting the resulting compound with 3-chloro-2-chloromethyl-1-propene to form the described triazacyclododecansulfonamide compound, as exemplified by Route 1 in the Examples section.

In various embodiments, compounds having a methylene group at R¹ can be synthesized by coupling protected butane-1,3-diamine with an aldehyde having a desired R³ group to form a 3-(azaneyl)-N-butan-1-amine, reacting the amino group at the R² position with a chloro group functionalized with a desired R² group, introducing a propyl amino group to the 3-(azaneyl)-N-butan-1-amine at the R⁴ position via reaction with 2-(3-bromopropyl)isoindoline-1,3-dione followed by hydrazine, reacting the resulting amino group at the R⁴ position with a chloro group functionalized with a desired R⁴ group, and then reacting the resulting compound with 3-chloro-2-chloromethyl-1-propene to form the desired triazacyclododecansulfonamide compound, as exemplified by Route 2 in the Examples section.

In some cases, compounds having a spiro group at R¹ can be synthesized by reacting a N-(3-(azaneyl)propyl)propane-1,3-diamino group derivatized with the desired R², R³, and R⁴ groups with 1,1-diylbis(methylene)diethanesulfonate derivatized with the desired spiro group, as exemplified by Routes 3, 8, and 9 in the Examples section.

In various cases, compounds provided herein can be synthesized by reducing a benzyl group at R² on N-(3-(azaneyl)propyl)propane-1,3-diamino functionalized with the desired R³ and R⁴ groups, and then reacting the resulting product with a desired aldehyde derivatized with a desired R² group (e.g., dimethyl cyclohexyl), as exemplified by Route 4 in the Examples section.

In some embodiments, compounds having a carboxylate group at R² can be prepared by reacting triazacyclododensulfonyl group derivatized with desired R¹, R³, and R⁴ groups with a desired alkyl group and triphosgene under basic conditions, as exemplified by Route 5 in the Examples section.

In various embodiments, compounds having piperidinyl group at R² can be prepared by reacting with DBU/mercaptoethanol a triazacyclododensulfonyl compound having desired R¹, R³, and R⁴ groups and functionalized at R² with a nitrophenyl group, and then coupling the resulting product with piperidinyl sulfonyl chloride, as exemplified by Route 6 in the Examples section.

In some embodiments, compounds having a hydrogen group at R¹ can be synthesized by coupling N-(3-(azaneyl)propyl)propane-1,3-diamino functionalized with the desired R², R³, and R⁴ groups with 1,3-dichloropropane or 1,4-dichlorobutane, as exemplified by Route 7 and Route 17 in the Examples section.

In some cases, compounds having a chlorophenylmethanone group at R² can be synthesized by reacting triazacyclododensulfonyl functionalized with desired R¹, R³, and R⁴ groups with 4-chlorobenzoyl chloride under basic conditions, as exemplified by Route 10 in the Examples section.

In various cases, compounds having a 4-(dimethylamino)-2-methylbenzyl group at R⁴ and a spiro group at R¹ can be prepared by reacting a N-(3-(azaneyl)propyl)propane-1,3-diamino compound functionalized with the desired R² and R³ groups with 4-(dimethylamino)-2-methylbenzenesulfonyl chloride, and then cyclizing the compound via coupling with 1,1-diylbis(methylene)diethanesulfonate derivatized with the desired spiro group using methods previously described herein, as exemplified by Route 11 in the Examples section.

In some embodiments, the compounds described herein can be prepared by reacting a sulfonyl chloride having a desired R² group with propane-1,3-diamine, and reacting the resulting product with an aldehyde having a desired R³ group to form a 3-(azaneyl)-N-butan-1-amine compound. A propyl amino group can be introduced to the 3-(azaneyl)-N-butan-1-amine at the R⁴ position via reaction with 2-(3-bromopropyl)isoindoline-1,3-dione followed by hydrazine, and a desired R⁴ group can be coupled to the compound by reacting the compound with desired sulfonyl chloride (e.g., 4-(dimethylamino)-2-methylbenzenesulfonyl chloride). Finally, the compound can be cyclized via an appropriate cyclization agent, such as 3-chloro-2-chloromethyl-1-propene, 2-methylpropane-1,3-diyl diethanesulfonate, cyclopropane-1,1-diylbis(methylene) diethanesulfonate, 1,3-dichloropropane, or 1,4-dichlorobutane, as previously described herein, as exemplified by Route 12 in the Examples section.

In various embodiments, compounds having a 4-phenylpiperidineyl-1-yl sulfonyl group at R² can be synthesized by reacting a triazacyclododensulfonyl group functionalized with desired R¹, R³, and R⁴ groups with 3-methyl-1-((4-phenylpiperidin-1-yl)sulfonyl)-1H-imidazol-3-ium trifluoromethanesulfonate, as exemplified by Route 14 in the Examples section.

In some cases, compounds having a 4-phenylpiperidineyl-1-yl sulfonyl group at R² can be synthesized by reacting N-(3-(azaneyl)propyl)propane-1,3-diamino functionalized with the desired R³ and R⁴ groups with 3-methyl-1-((4-phenylpiperidin-1-yl)sulfonyl)-1H-imidazol-3-ium trifluoromethanesulfonate, and then cyclizing the compound with an appropriate cyclization agent, such as 2-methylpropane-1,3-diyl diethanesulfonate, 3-chloro-2-chloromethyl-1-propene, cyclopropane-1,1-diylbis(methylene) diethanesulfonate, 1,3-dichloropropane or 1,4-dichlorobutane, as previously described herein, as exemplified by Route 15 in the Examples section. Analogous compounds having a methyl group adjacent to the R⁴ nitrogen can be similarly synthesized using 3-chloro-2-(chloromethyl)prop-1-ene, as exemplified by Route 18 in the Examples section.

In some cases, compounds having an alcohol group for R¹ can be synthesized by cyclizing a N-(3-(azaneyl)propyl)propane-1,3-diamino compound with protected 1,3-dichloropropan-2-ol under basic conditions, as exemplified by Route 19 in the Examples section. The alcohol group at R¹ can be methylated via reaction with MeI and NaH in toluene, as exemplified by Route 21 in the examples section. The alcohol group at R¹ can be oxidized to a carbonyl via reaction with Dess-Martin periodinane, as exemplified by Route 22 in the examples section. The carbonyl group at R¹ can be reacted with hydroxylamine hydrochloride to form the oxime compound, as exemplified by Route 25 in the Examples section.

In various cases, compounds having an S-methyl group at R¹ can be synthesized by reacting an amino group functionalized with a desired R² group with 2,3-dimethyl-1-((2-methyl-1H-imidazol-1-yl)sulfonyl)-1H-imidazol-3-ium trifluoromethanesulfonate, followed by CF₃SO₃Me, to form 2,3-dimethyl-1H-imidazol-3-ium trifluoromethanesulfonate functionalized with a desired R² group. The product can be reacted with (R)—N-(3-amino-2-methylpropyl) functionalized with a desired R⁴ group to form (S)—N,N′-(2-methylpropane-1,3-diamino functionalized with the desired R² and R⁴ groups. The resulting product can then be reacted with (azanediyl)bis(propane-3,1-diyl) dimethanesulfonate functionalized with a desired R³ group to result in the desired compound, as exemplified by Route 27 in the Examples section.

Synthesis of Intermediates

The intermediates used to prepare the compounds described herein also can be prepared by standard methods known to those skilled in the art, as described in the Examples, section below (e.g., Route 13, Route 16, Route 20, Route 24, Route 26, Route 28, Route 30, Route 31, Route 32, Route 33).

Methods of Use

The compounds disclosed herein (e.g., the compounds of Formula (I), the compounds listed in Tables A and B, and pharmaceutically acceptable salts of the foregoing) can inhibit protein secretion of a protein of interest. The compounds disclosed herein can interfere with the Sec61 protein secretion machinery of a cell. In some cases, a compound as disclosed herein inhibits secretion of one or more of TNFα, VCAM, PRL, IL-2, INFg, CD4, insulin, and PD-1 (mouse and/or human), or each of TNFα, VCAM, PRL, IL-2, INFg, CD4, insulin, and PD-1 (mouse and/or human). In some cases, a compound as disclosed herein can inhibit secretion of a checkpoint protein, or inhibits secretion of a cell surface protein, endoplasmic reticulum-associated protein, or secreted protein involved in regulation of anti-tumor immune responses. In various cases, a compound disclosed herein can inhibit secretion of one or more of PD-1, PD-L1, TIM-1, LAG-3, CTLA4, BTLA, OX-40, B7H1, B7H4, CD137, CD47, CD96, CD73, CD40, VISTA, TIGIT, LAIR1, CD160, 2B4, TGFRβ and combinations thereof. Protein secretion activity can be assessed in a manner as described in the Examples section below.

As used herein, the term “inhibitor” is meant to describe a compound that blocks or reduces an activity of a pharmacological target (for example, a compound that inhibits Sec61 function in the protein secretion pathway). An inhibitor can act with competitive, uncompetitive, or noncompetitive inhibition. An inhibitor can bind reversibly or irreversibly, and therefore, the term includes compounds that are suicide substrates of a protein or enzyme. An inhibitor can modify one or more sites on or near the active site of the protein, or it can cause a conformational change elsewhere on the enzyme. The term inhibitor is used more broadly herein than scientific literature so as to also encompass other classes of pharmacologically or therapeutically useful agents, such as agonists, antagonists, stimulants, co-factors, and the like.

Thus, provided herein are methods of inhibiting protein secretion in a cell. In these methods, a cell is contacted with a compound described herein (e.g., a compound of Formula (I) or a compound listed in Table A or B, and pharmaceutically acceptable salts of the foregoing), or pharmaceutical formulation thereof, in an amount effective to inhibit secretion of the protein of interest. In some embodiments, the cell is contacted in vitro. In various embodiments, the cell is contacted in vivo. In various embodiments, the contacting includes administering the compound or pharmaceutical formulation to a subject.

The biological consequences of Sec61 inhibition are numerous. For example, Sec61 inhibition has been suggested for the treatment or prevention of inflammation and/or cancer in a subject. Therefore, pharmaceutical formulations for Sec61 specific compounds, provide a means of administering a drug to a subject and treating these conditions. As used herein, the terms “treat,” “treating,” “treatment,” and the like refer to eliminating, reducing, or ameliorating a disease or condition, and/or symptoms associated therewith. Although not precluded, treating a disease or condition does not require that the disease, condition, or symptoms associated therewith be completely eliminated. As used herein, the terms “treat,” “treating,” “treatment,” and the like may include “prophylactic treatment,” which refers to reducing the probability of redeveloping a disease or condition, or of a recurrence of a previously-controlled disease or condition, in a subject who does not have, but is at risk of or is susceptible to, redeveloping a disease or condition or a recurrence of the disease or condition. The term “treat” and synonyms contemplate administering a therapeutically effective amount of a compound of the invention to an individual in need of such treatment. Within the meaning of the invention, “treatment” also includes relapse prophylaxis or phase prophylaxis, as well as the treatment of acute or chronic signs, symptoms and/or malfunctions. The treatment can be orientated symptomatically, for example, to suppress symptoms. It can be effected over a short period, be oriented over a medium term, or can be a long-term treatment, for example within the context of a maintenance therapy. As used herein, the terms “prevent,” “preventing,” “prevention,” are art-recognized, and when used in relation to a condition, such as a local recurrence (e.g., pain), a disease such as cancer, a syndrome complex such as heart failure or any other medical condition, is well understood in the art, and includes administration of a composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition in a subject relative to a subject which does not receive the composition. Thus, prevention of cancer includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving a prophylactic treatment relative to an untreated control population, and/or delaying the appearance of detectable cancerous growths in a treated population versus an untreated control population, e.g., by a statistically and/or clinically significant amount. Prevention of an infection includes, for example, reducing the number of diagnoses of the infection in a treated population versus an untreated control population, and/or delaying the onset of symptoms of the infection in a treated population versus an untreated control population. Prevention of pain includes, for example, reducing the magnitude of, or alternatively delaying, pain sensations experienced by subjects in a treated population versus an untreated control population. As used herein, the terms “patient” and “subject” may be used interchangeably and mean animals, such as dogs, cats, cows, horses, and sheep (i.e., non-human animals) and humans. Particular patients are mammals (e.g., humans). The term patient includes males and females.

Inhibition of Sec61-mediated secretion of inflammatory proteins (e.g., TNFα) can disrupt inflammation signaling. Thus, provided herein is a method of treating inflammation in a subject by administering to the subject a therapeutically effective amount of a compound described herein, (i.e., a compound of Formula (I) or a compound listed in Table A or B, or a pharmaceutically acceptable salt of the foregoing).

Further, the viability of cancer cells relies upon increased protein secretion into the ER for survival. Therefore, non-selective or partially selective inhibition of Sec61 mediated protein secretion may inhibit tumor growth. Alternatively, in the immune-oncology setting, selective secretion inhibitors of known secreted or transmembrane immune checkpoint proteins (e.g., PD-1, TIM-3, LAG3, etc.) can result in activation of the immune system to against various cancers.

Accordingly, also provided herein is a method of treating cancer in a subject by administering to the subject a therapeutically effective amount of a compound described herein, (e.g., a compound of Formula (I), a compound listed in Table A or B, or a pharmaceutically acceptable salt of the foregoing). Specifically contemplated cancers that can be treated using the compounds and compositions described herein include, but are not limited to melanoma, multiple myeloma, prostate, lung, non small cell lung carcinoma, squamous cell carcinoma, leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, lymphoma, NPM/ALK-transformed anaplastic large cell lymphoma, diffuse large B cell lymphoma, neuroendocrine tumors, breast, mantle cell lymphoma, renal cell carcinoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, small cell carcinoma, adenocarcinoma, gastric carcinoma, hepatocellular carcinoma, pancreatic cancer, thyroid carcinoma, anaplastic large cell lymphoma, hemangioma, head and neck cancer, bladder, and colorectal cancers. In some cases, the cancer is a solid tumor. In various cases, the cancer is head and neck cancer, squamous cell carcinoma, gastric carcinoma, or pancreatic cancer.

The compounds described herein are also contemplated to be used in the prevention and/or treatment of a multitude of diseases including, but not limited to, proliferative diseases, neurotoxic/degenerative diseases, ischemic conditions, autoimmune and autoinflammatory disorders, inflammation, immune-related diseases, HIV, cancers, organ graft rejection, septic shock, viral and parasitic infections, conditions associated with acidosis, macular degeneration, pulmonary conditions, muscle wasting diseases, fibrotic diseases, bone and hair growth diseases.

Examples of proliferative diseases or conditions include diabetic retinopathy, macular degeneration, diabetic nephropathy, glomerulosclerosis, IgA nephropathy, cirrhosis, biliary atresia, congestive heart failure, scleroderma, radiation-induced fibrosis, and lung fibrosis (idiopathic pulmonary fibrosis, collagen vascular disease, sarcoidosis, interstitial lung diseases and extrinsic lung disorders).

Inflammatory diseases include acute (e.g., bronchitis, conjunctivitis, myocarditis, pancreatitis) and chronic conditions (e.g., chronic cholecstitis, bronchiectasis, aortic valve stenosis, restenosis, psoriasis and arthritis), along with conditions associated with inflammation such as fibrosis, infection and ischemia.

Immunodeficiency disorders occur when a part of the immune system is not working properly or is not present. They can affect Blymophyctes, T lymphocytes, or phagocytes and be either inherited (e.g., IgA deficiency, severe combined immunodeficiency (SCID), thymic dysplasia and chronic granulomatous) or acquired (e.g., acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV) and drug-induced immunodeficiencies). Immune-related conditions include allergic disorders such as allergies, asthma and atopic dermatitis like eczema. Other examples of such immune-related conditions include lupus, rheumatoid arthritis, scleroderma, ankylosing spondylitis, dermatomyositis, psoriasis, multiple sclerosis and inflammatory bowel disease (such as ulcerative colitis and Crohn's disease).

Tissue/organ graft rejection occurs when the immune system mistakenly attacks the cells being introduced to the host's body. Graft versus host disease (GVHD), resulting from allogenic transplantation, arises when the T cells from the donor tissue go on the offensive and attack the host's tissues. In all three circumstances, autoimmune disease, transplant rejection and GVHD, modulating the immune system by treating the subject with a compound or composition of the disclosure could be beneficial.

Also provided herein is a method of treating an autoimmune disease in a patient comprising administering a therapeutically effective amount of the compound described herein. An “autoimmune disease” as used herein is a disease or disorder arising from and directed against an individual's own tissues. Examples of autoimmune diseases include, but are not limited to, inflammatory responses such as inflammatory skin diseases including psoriasis and dermatitis (e.g., atopic dermatitis); systemic scleroderma and sclerosis; responses associated with inflammatory bowel disease (such as Crohn's disease and ulcerative colitis); respiratory distress syndrome (including adult respiratory distress syndrome (ARDS)); dermatitis; meningitis; encephalitis; uveitis; colitis; glomerulonephritis; allergic conditions such as eczema and asthma and other conditions involving infiltration of T cells and chronic inflammatory responses; atherosclerosis; leukocyte adhesion deficiency; rheumatoid arthritis; systemic lupus erythematosus (SLE); diabetes mellitus (e.g., Type I diabetes mellitus or insulin dependent diabetes mellitus); multiple sclerosis; Reynaud's syndrome; autoimmune thyroiditis; allergic encephalomyelitis; Sjorgen's syndrome; juvenile onset diabetes; and immune responses associated with acute and delayed hypersensitivity mediated by cytokines and T-lymphocytes typically found in tuberculosis, sarcoidosis, polymyositis, granulomatosis and vasculitis; pernicious anemia (Addison's disease); diseases involving leukocyte diapedesis; central nervous system (CNS) inflammatory disorder; multiple organ injury syndrome; hemolytic anemia (including, but not limited to cryoglobinemia or Coombs positive anemia); myasthenia gravis; antigen-antibody complex mediated diseases; anti-glomerular basement membrane disease; antiphospholipid syndrome; allergic neuritis; Graves' disease; Lambert-Eaton myasthenic syndrome; pemphigoid bullous; pemphigus; autoimmune polyendocrinopathies; Reiter's disease; stiff-man syndrome; Behcet disease; giant cell arteritis; immune complex nephritis; IgA nephropathy; IgM polyneuropathies; immune thrombocytopenic purpura (ITP) or autoimmune thrombocytopenia. Compounds provided herein may be useful for the treatment of conditions associated with inflammation, including, but not limited to COPD, psoriasis, asthma, bronchitis, emphysema, and cystic fibrosis.

Also provided herein is the use of a compound as disclosed herein for the treatment of neurodegenerative diseases. Neurodegenerative diseases and conditions includes, but not limited to, stroke, ischemic damage to the nervous system, neural trauma (e.g., percussive brain damage, spinal cord injury, and traumatic damage to the nervous system), multiple sclerosis and other immune-mediated neuropathies (e.g., Guillain-Barre syndrome and its variants, acute motor axonal neuropathy, acute inflammatory demyelinating polyneuropathy, and Fisher Syndrome), HIV/AIDS dementia complex, axonomy, diabetic neuropathy, Parkinson's disease, Huntington's disease, multiple sclerosis, bacterial, parasitic, fungal, and viral meningitis, encephalitis, vascular dementia, multi-infarct dementia, Lewy body dementia, frontal lobe dementia such as Pick's disease, subcortical dementias (such as Huntington or progressive supranuclear palsy), focal cortical atrophy syndromes (such as primary aphasia), metabolic-toxic dementias (such as chronic hypothyroidism or B12 deficiency), and dementias caused by infections (such as syphilis or chronic meningitis).

Further guidance for using compounds and compositions described herein (e.g., a compound of Formula (I), a compound listed in Table A or B, or a pharmaceutically acceptable salt of the foregoing) for inhibiting protein secretion can be found in the Examples section, below.

Pharmaceutical Formulations and Administration

The methods provided herein include the manufacture and use of pharmaceutical compositions, which include one or more of the compounds provided herein. Also included are the pharmaceutical compositions themselves. Pharmaceutical compositions typically include a pharmaceutically acceptable carrier. Thus, provided herein are pharmaceutical formulations that include a compound described herein (e.g., a compound of Formula (I), a compound listed in Table A or B, or a pharmaceutically acceptable salt of the foregoing), as previously described herein, and one or more pharmaceutically acceptable carriers.

The phrase “pharmaceutically acceptable” is employed herein to refer to those ligands, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The phrase “pharmaceutically acceptable carrier” as used herein means a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. As used herein the language “pharmaceutically acceptable carrier” includes buffer, sterile water for injection, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch, potato starch, and substituted or unsubstituted β-cyclodextrin; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations. In certain embodiments, pharmaceutical compositions provided herein are non-pyrogenic, i.e., do not induce significant temperature elevations when administered to a patient.

The term “pharmaceutically acceptable salt” refers to the relatively non-toxic, inorganic and organic acid addition salts of a compound provided herein. These salts can be prepared in situ during the final isolation and purification of a compound provided herein, or by separately reacting the compound in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, laurylsulphonate salts, and amino acid salts, and the like. (See, for example, Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci. 66: 1-19.)

In some embodiments, a compound provided herein may contain one or more acidic functional groups and, thus, is capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. The term “pharmaceutically acceptable salts” in these instances refers to the relatively non-toxic inorganic and organic base addition salts of a compound provided herein. These salts can likewise be prepared in situ during the final isolation and purification of the compound, or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts, and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like (see, for example, Berge et al., supra).

Wetting agents, emulsifiers, and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring, and perfuming agents, preservatives and antioxidants can also be present in the compositions.

Compositions prepared as described herein can be administered in various forms, depending on the disorder to be treated and the age, condition, and body weight of the patient, as is well known in the art. For example, where the compositions are to be administered orally, they may be formulated as tablets, capsules, granules, powders, or syrups; or for parenteral administration, they may be formulated as injections (intravenous, intramuscular, or subcutaneous), drop infusion preparations, or suppositories. For application by the ophthalmic mucous membrane route, they may be formulated as eye drops or eye ointments. These formulations can be prepared by conventional means in conjunction with the methods described herein, and, if desired, the active ingredient may be mixed with any conventional additive or excipient, such as a binder, a disintegrating agent, a lubricant, a corrigent, a solubilizing agent, a suspension aid, an emulsifying agent, or a coating agent.

Actual dosage levels of the active ingredients in the pharmaceutical compositions provided herein may be varied so as to obtain “therapeutically effective amount,” which is an amount of the active ingredient effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

The concentration of a compound provided herein in a pharmaceutically acceptable mixture will vary depending on several factors, including the dosage of the compound to be administered, the pharmacokinetic characteristics of the compound(s) employed, and the route of administration. In some embodiments, the compositions provided herein can be provided in an aqueous solution containing about 0.1-10% w/v of a compound disclosed herein, among other substances, for parenteral administration. Typical dose ranges can include from about 0.01 to about 50 mg/kg of body weight per day, given in 1-4 divided doses. Each divided dose may contain the same or different compounds. The dosage will be a therapeutically effective amount depending on several factors including the overall health of a patient, and the formulation and route of administration of the selected compound(s).

Dosage forms or compositions containing a compound as described herein in the range of 0.005% to 100% with the balance made up from non-toxic carrier may be prepared. Methods for preparation of these compositions are known to those skilled in the art. The contemplated compositions may contain 0.001%-100% active ingredient, in one embodiment 0.1-95%, in another embodiment 75-85%. Although the dosage will vary depending on the symptoms, age and body weight of the patient, the nature and severity of the disorder to be treated or prevented, the route of administration and the form of the drug, in general, a daily dosage of from 0.01 to 2000 mg of the compound is recommended for an adult human patient, and this may be administered in a single dose or in divided doses. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect.

In jurisdictions that forbid the patenting of methods that are practiced on the human body, the meaning of “administering” of a composition to a human subject shall be restricted to prescribing a controlled substance that a human subject will self-administer by any technique (e.g., orally, inhalation, topical application, injection, insertion, etc.). The broadest reasonable interpretation that is consistent with laws or regulations defining patentable subject matter is intended. In jurisdictions that do not forbid the patenting of methods that are practiced on the human body, the “administering” of compositions includes both methods practiced on the human body and also the foregoing activities.

Other Embodiments

It is to be understood that while the disclosure is read in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the disclosure, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Examples

The following examples are provided for illustration and are not intended to limit the scope of the invention.

The starting material was synthesized using the method described in J. Med. Chem. 2016, 59, 2633-2647. To N-(3-((3-aminopropyl)(cyclohexylmethyl)amino)propyl)-4-methylbenzenesulfonamide (0.200 g, 0.523 mmol) in DCM (2.0 mL) was added DIEA (2 eq, 1.05 mmol, 179 uL) followed by piperidine-1-sulfonyl chloride (0.096 g, 0.523 mmol). After 16 h the reaction was quenched with sodium bicarbonate (sat.), extracted with DCM, dried with sodium sulfate, filtered, and concentrated.

To the crude N-(3-((cyclohexylmethyl)(3-((4-methylphenyl)sulfonamido)propyl)amino)propyl)piperidine-1-sulfonamide in DMF (10 mL) was added NaH (2.5 eq, 1.31 mmol, 0.052 g of a 60% dispersion in mineral oil). The mixture was stirred for 1 h then was heated to 85° C. and 3-chloro-2-chloromethyl-1-propene (0.9 eq, 0.471 mmol, 55 uL dissolved in 0.5 mL DMF) was added over 4 h. After heating for 16 h the mixture was cooled to ambient temp, diluted with brine and water, extracted with ethyl acetate (3×), washed with brine, dried with sodium sulfate, filtered, and concentrated. Flash column chromatography (0-60% hexanes/ethyl acetate+1% DEA) provided the freebase product.

To the freebase was added diethyl ether (1.0 mL) to dissolve and HCl (4 N in dioxane, 1.046 mmol, 262 uL). The HCl salt was filtered and dried under high vacuum to provide compound A5. MS(EI) for C₂₉H₄₈N₄O₄S₂, found 581 [M+H]⁺.

The following compounds were synthesized in a similar manner:

No. IUPAC [M + H]⁺ A6 9-(cyclohexylmethyl)-1-(ethanesulfonyl)-5-(4- 526 methylbenzenesulfonyl)-3-methylidene-1,5,9- triazacyclododecane A7 9-(cyclohexylmethyl)-1-(4- 540 methylbenzenesulfonyl)-3-methylidene-5- (propane-2-sulfonyl)-1,5,9-triazacyclododecane A8 1-(cyclohexanesulfonyl)-9-(cyclohexylmethyl)-5- 580 (4-methylbenzenesulfonyl)-3-methylidene-1,5,9- triazacyclododecane

To tert-butyl (3-aminobutyl)carbamate (2.5 g, 13.3 mmol) in DCM (12.5 mL), sat. Na₂CO₃ (12.5 mL), and sat. NaCl (12.5 mL) was added TsCl (13.3 mmol, 2.54 g). After 1 h the organic layer was washed with brine, dried with sodium sulfate, filtered, and concentrated to provide tert-butyl (3-((4-methylphenyl)sulfonamido)butyl)carbamate which was carried forward without further purification.

To the tosylate (13.3 mmol) was added TFA (66.5 mmol, 5.09 mL) and DCM (5.09 mL). After 2 h the reaction was concentrated, diluted with NaOH (1N, 30 mL), extracted with DCM (3×30 mL), dried with sodium sulfate, filtered, and concentrated to provide the amine.

To the amine (10.94 mmol) was added toluene (49 mL) and cyclohexanecarboxaldehyde (1.34 g, 12.0 mmol). The mixture was refluxed with a dean stark apparatus overnight (external temperature of 185° C.) then concentrated, diluted with ethanol (absolute, 19 mL) and NaBH₄ (0.827 g, 21.8 mmol) was added portion-wise while the internal temperature was maintained at <20° C. After stirring for 2 h the mixture was diluted with water (10 mL), stirred for 20 min, extracted with DCM (3×), washed with brine, dried with sodium sulfate, filtered, and concentrated to provide the amine. The amine was diluted with diethyl ether (20 mL) and HCl (conc., 0.3 mL) was added dropwise. The HCl salt crashed out within 5 min and was filtered using diethyl ether to wash. The product was dried under vacuum overnight to provide N-(4-((cyclohexylmethyl)amino)butan-2-yl)-4-methylbenzenesulfonamide hydrochloride.

To the HCl salt (3.5 mmol) was added acetonitrile (9 mL), sodium carbonate (0.99 g, 9.2 mmol), Lil (0.114 g), and 3-bromopropylphthalimide (2.30 g). The mixture was heated to 70° C. for 5 h at which time it was filtered and concentrated. The crude phthalimide was carried forward without further purification.

To the phthalimide (3.5 mmol) was added hydrazine monohydrate (4.2 mL) and ethanol (15 mL). After heating to 80° C. for 30 min the reaction was complete and the precipitate was filtered washing with ethanol. The filtrate was concentrated and diluted with HCl (2 N, 30 mL) then allowed to stand for 1 h. To the aqueous mixture was added NaOH (1 N) to basify to pH 10. The mixture was then extracted with DCM (3×), dried with sodium sulfate, filtered, and concentrated to provide crude N-(4-((3-aminopropyl)(cyclohexylmethyl)amino)butan-2-yl)-4-methylbenzenesulfonamide.

To the amine (695 mg, 1.76 mmol) was added DCM (9 mL), sat. Na₂CO₃ (9 mL), sat. NaCl (9 mL), TsCl (1.76 mmol, 336 mg). After stirring for 1 h the mixture was extracted with DCM (3×), dried with sodium sulfate, filtered, and concentrated to provide the freebase. The HCl salt was made by diluting the freebase in diethyl ether (50 mL) and adding HCl (conc., 300 uL). After placing under high vacuum for 2 h the HCl salt (1.02 g) was collected.

To the HCl salt (0.400 g, 0.683 mmol) in DMF (14 mL) was added NaH (3.5 eq, 2.39 mmol, 60% dispersion in mineral oil, 80.3 mg). After stirring for 1 h, 3-chloro-2-chloromethyl-1-propene (0.9 eq, 0.615 mmol, 71 uL in 7 mL DMF) was added dropwise over 3 h. After heating an additional 2 h the mixture was cooled to ambient temperature, diluted with brine, water, and ethyl acetate. The mixture was extracted with ethyl acetate (2×), washed with brine, dried with sodium sulfate, filtered, and concentrated. Flash column chromatography (0-90% hexanes/ethyl acetate+1% DEA) provided the product. The HCl salt was formed by diluting the freebase in diethyl ether (20 vol.) and adding HCl (4N in dioxane, 4 eq) to provide 5-(cyclohexylmethyl)-2-methyl-11-methylene-1,9-ditosyl-1,5,9-triazacyclododecane hydrochloride, compound B1. MS(EI) for C₃₂H₄₇N₃O₄S₂, found 602 [M+H]⁺.

The following compounds were synthesized in a similar manner:

No. IUPAC [M + H]⁺ B2 1-(cyclohexylmethyl)-3-methyl-5,9-bis(4- 602 methylbenzenesulfonyl)-7-methylidene-1,5,9- triazacyclododecane A9 N,N-dimethyl-4-{[5-(4-methylbenzenesulfonyl)- 619 3-methylidene-9-[(oxan-4-yl)methyl]-1,5,9- triazacyclododecan-1-yl]sulfonyl}aniline

To N-(3-((cyclohexylmethyl)(3-((4-methylphenyl)sulfonamido)butyl)amino)propyl)-4-methylbenzenesulfonamide (0.099 mmol) in DMF (10.0 mL) was added sodium hydride (0.350 mmol of a 60% dispersion in mineral oil). The mixture was stirred at ambient temperature for 30 min then heated to 80° C. before cyclopropane-1,1-diylbis(methylene) diethanesulfonate (0.099 mmol dissolved in 1.0 mL DMF) over the course of 2 h. After stirring an additional 4 h at 80° C. the mixture was cooled to ambient temperature, quenched with brine, extracted with ethyl acetate (3×). The combined organics were washed with brine (2×), dried with sodium sulfate, filtered, and concentrated. Flash column chromatography (0-60% hexanes (1% DEA)/ethyl acetate) provided the freebase product which was dissolved in diethyl ether (2 mL) and HCl (0.1 mL of a 4 N solution in 1,4-dioxane) was added. The mixture was concentrated to provide 4-{[9-(cyclohexylmethyl)-13-(4-methylbenzenesulfonyl)-5,9,13-triazaspiro[2.11]tetradecan-5-yl]sulfonyl}-N,N-dimethylaniline hydrochloride, compound A11. MS(EI) for C₃₃H₅₀N₄O₄S₂, found 631 [M+H]⁺.

The starting material was synthesized using the method described in J. Med. Chem. 2016, 59, 2633-2647. To the starting material (0.327 mmol) in methanol (2.0 mL) under argon was added Pd/C (20 mg). A hydrogen atmosphere was established and the mixture was stirred at ambient temp. After 3 h the reaction was filtered and purified by flash column chromatography (0-80% hexanes (1% DEA)/ethyl acetate) to provide the product.

To the starting material (0.028 mmol) was added toluene (5 mL) followed by the aldehyde (0.028 mmol). The mixture was stirred for 3 h at reflux then concentrated. To the imine was added ethanol followed by sodium borohydride. The mixture was stirred at ambient temp for 30 min then diluted with water (1 mL), extracted, with DCM (3×1 mL), dried with sodium sulfate, filtered, and concentrated. The product was purified by flash column chromatography (0-60% hexanes (1% DEA)/ethyl acetate). The freebase was diluted with ethyl ether (1 mL) and HCl (7 μL, 4 N in dioxane) was added. The mixture was filtered to provide 4-((9-((4,4-dimethylcyclohexyl)methyl)-3-methylene-5-tosyl-1,5,9-triazacyclododecan-1-yl)sulfonyl)-N,N-dimethylaniline hydrochloride (compound A10). MS(EI) for C₃₄H₅₂N₄O₄S₂, found 645 [M+H]⁺.

To triphosgene (0.0316 mmol, 9.4 mg) in DCM (100 uL) was added 1-propanol (0.190 mmol 14 uL). After stirring for 45 min this solution was added to the amine (0.0158 mmol, 8.2 mg), DIEA (0.126 mmol, 22 uL), and DCM (100 uL). The mixture was stirred at ambient temperature for 1 h then purified directly by flash column chromatography (0-70% hexanes/ethyl acetate) to provide propyl 5-((4-(dimethylamino)phenyl)sulfonyl)-7-methylene-9-tosyl-1,5,9-triazacyclododecane-1-carboxylate (compound A12). MS(EI) for C₂₉H₄₂N₄O₆S₂, found 607 [M+H]⁺.

The starting material, 4-((9-(cyclohexylmethyl)-3-methylene-5-((2-nitrophenyl)sulfonyl)-1,5,9-triazacyclododecan-1-yl)sulfonyl)-N,N-dimethylaniline, was synthesized using a similar method described in Route 2 substituting with the appropriate sulfonyl chlorides.

To the starting material (1.09 g, 1.68 mmol) in ACN (12.3 mL) was added DBU (0.780 mL, 5.22 mmol) followed by 2-mercaptoethanol (0.135 mL, 1.92 mmol). The mixture was stirred at ambient temperature for 2 h then an additional aliquot of 2-mercaptoethanol (1.14 eq) was added. After stirring an additional 2 h the mixture was concentrated and purified directly by FCC (0-100% hexanes (1% DEA)/ethyl acetate). 4-((9-(Cyclohexylmethyl)-3-methylene-1,5,9-triazacyclododecan-1-yl)sulfonyl)-N,N-dimethylaniline.

To the amine (70 mg, 0.152 mmol) in DCM (2 mL) was added DIEA (0.303 mmol, 52 uL) followed by piperidine-1-sulfonyl chloride (0.152 mmol, 28 mg). After allowing to stand overnight the reaction was purified directly by flash column chromatography (hexanes (1% DEA)/ethyl acetate 0-60%). The HCl salt of the product was made by dissolving the freebase in diethyl ether (1 mL) and adding HCl (4 N in dioxane, 38 uL). The filtrate was collected to provide 4-((9-(cyclohexylmethyl)-3-methylene-5-(piperidin-1-ylsulfonyl)-1,5,9-triazacyclododecan-1-yl)sulfonyl)-N,N-dimethylaniline hydrochloride (compound A15). MS(EI) for C₃₀H₅₁N₅O₄S₂, found 610 [M+H]⁺.

The following compounds were synthesized in a similar manner:

No. IUPAC [M + H]⁺ A16 9-(cyclohexylmethyl)-5-[4- 570 (dimethylamino)benzenesulfonyl]-N,N-dimethyl-3- methylidene-1,5,9-triazacyclododecane-1-sulfonamide A13 4-{[9-(cyclohexylmethyl)-3-methylidene-5-(piperidine- 610 1-sulfonyl)-1,5,9-triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline

The starting material, N-(3-((cyclohexylmethyl)(3-((4-(dimethylamino)phenyl)sulfonamido)propyl)amino)propyl)-4-methylbenzenesulfonamide, was synthesized using the same method described in Route 1 substituting with the appropriate sulfonyl chloride.

To the diamine (49 mg, 0.087 mmol) in DMF (2.5 mL) was added NaH (0.22 mmol, 9 mg). After stirring for 30 min at ambient temperature, 1,3-dichloropropane (0.087 mmol, 8.3 uL in 0.5 mL DMF) was slowly added over 1 h while heating at 80° C. After 3 h the mixture was cooled to ambient temp, diluted with brine (10 mL), water (5 mL), and ethyl acetate (10 mL). The aqueous layer was extracted with ethyl acetate (3×5 mL), the organics were combined and washed with brine (1×5 mL), dried with sodium sulfate, and concentrated. Flash column chromatography (0-50% hexanes (1% DEA/ethyl acetate) provided the freebase product that was converted to the HCl salt with the addition of ether (1 mL) then HCl (20 uL, 4 N in dioxane). The filtrate was collected and concentrated to provide 4-((5-(cyclohexylmethyl)-9-tosyl-1,5,9-triazacyclododecan-1-yl)sulfonyl)-N,N-dimethylaniline (compound A14). MS(EI) for C₃₁H₄₈N₄O₄S₂, found 605 [M+H]⁺.

The following compound was synthesized in a similar manner:

No. IUPAC [M + H]⁺ A17 4-{[10-(cyclohexylmethyl)-14-(piperidine-1-sulfonyl)- 640 2-oxa-6,10,14-triazaspiro[3.11]pentadecan-6- yl]sulfonyl}-N,N-dimethylaniline

The starting material was synthesized using the method described in J. Med. Chem. 2006, 49, 1291-1312. To N1-(3-aminopropyl)-N1-benzylpropane-1,3-diamine (363 mg, 1.64 mmol) in DCM (2 mL) was added DIEA (1.14 mL, 6.56 mL) then the sulfonyl chloride (345 μL, 2.46 mmol). The solution was allowed to stand overnight at ambient temp. Concentration and purification by flash column chromatography (0-80% hexanes (1% DEA)/ethyl acetate) provided the product.

To the starting material (260 mg, 504 μL) in DMF (20 mL) was added NaH (50 mg of a 60% dispersion in mineral oil, 1.26 mmol). The mixture was stirred at 80° C. for 20 min then the bis-sulfonate (144 mg, 504 μL) was added over the course of 1 h. After heating for 4 h the reaction was complete and was diluted with ethyl acetate (40 mL) and brine (40 mL), extracted with ethyl acetate (2×20 mL). The combined organics were washed with brine (20 mL), dried with sodium sulfate, filtered, and concentrated. Flash column chromatography (hexanes (1% DEA)/ethyl acetate 0-50%) provided the product which was diluted with ethyl ether (5 mL) and HCl (4 N in dioxane, 100 uL) was added. The mixture was concentrated, washed with diethyl ether, and dried to provide 9-benzyl-5,13-bis(piperidin-1-ylsulfonyl)-5,9,13-triazaspiro[2.11]tetradecane hydrochloride (compound A18). MS(EI) for C₂₈H₄₇N₅O₄S₂, found 581 [M+H]⁺.

The starting material, N-(3-((3-aminopropyl)(cyclohexylmethyl)amino)propyl)-4-(dimethylamino)benzenesulfonamide, was synthesized using a similar method as described in Route 2.

To N-(3-((3-aminopropyl)(cyclohexylmethyl)amino)propyl)-4-(dimethylamino)benzenesulfonamide (559 mg, 1.36 mmol) in DCM (2 mL) was added DIEA (0.71 mL, 4.08 mmol) then the sulfonyl chloride (250 mg, 1.36 mmol). The solution was allowed to stand overnight at ambient temp. Concentration and purification by flash column chromatography (0-80% hexanes (1% DEA)/ethyl acetate) provided the product.

The cyclization of N-(3-((cyclohexylmethyl)(3-((4-(dimethylamino)phenyl)sulfonamido)propyl)amino)propyl)piperidine-1-sulfonamide and salt formation was carried out in a similar manner to Route 8 to provide 4-((9-(cyclohexylmethyl)-13-(piperidin-1-ylsulfonyl)-5,9,13-triazaspiro[2.11]tetradecan-5-yl)sulfonyl)-N,N-dimethylaniline hydrochloride (compound A19). MS(EI) for C₃₁H₅₃N₅O₄S₂, found 624 [M+H]⁺.

The following compounds were synthesized in a similar manner. The cyclization of compounds A25, A26, A27, A28, and A29 was carried out using NMP as the solvent.

No. IUPAC [M + H]⁺ A20 4-{[9-(cyclohexylmethyl)-13-[(2-methylpiperidin-1- 638 yl)sulfonyl]-5,9,13-triazaspiro[2.11]tetradecan-5- yl]sulfonyl}-N,N-dimethylaniline A21 4-{[9-(cyclohexylmethyl)-13-[(3-methylpiperidin-1- 638 yl)sulfonyl]-5,9,13-triazaspiro[2.11]tetradecan-5- yl]sulfonyl}-N,N-dimethylaniline A22 4-{[9-(cyclohexylmethyl)-13-[(4-methylpiperidin-1- 638 yl)sulfonyl]-5,9,13-triazaspiro[2.11]tetradecan-5- yl]sulfonyl}-N,N-dimethylaniline A23 4-{[9-(cyclohexylmethyl)-13-(pyrrolidine-1-sulfonyl)- 610 5,9,13-triazaspiro[2.11]tetradecan-5-yl]sulfonyl}- N,N-dimethylaniline B3 4-{[8-(cyclohexylmethyl)-4-(piperidine-1-sulfonyl)- 584 1,4,8-triazacycloundecan-1-yl]sulfonyl}-N,N- dimethylaniline B4 4-{[7-(cyclohexylmethyl)-3-(piperidine-1-sulfonyl)- 570 1,3,7-triazecan-1-yl]sulfonyl}-N,N-dimethylaniline A25 4-{[13-(azepane-1-sulfonyl)-9-(cyclohexylmethyl)- 638 5,9,13-triazaspiro[2.11]tetradecan-5-yl]sulfonyl}- N,N-dimethylaniline A26 4-{[9-(cyclohexylmethyl)-13-[(4,4-dimethylpiperidin- 652 1-yl)sulfonyl]-5,9,13-thazaspiro[2.11]tetradecan-5- yl]sulfonyl}-N,N-dimethylaniline A27 4-{[9-(cyclohexylmethyl)-13-[(4-methoxypiperidin-1- 654 yl)sulfonyl]-5,9,13-triazaspiro[2.11]tetradecan-5- yl]sulfonyl}-N,N-dimethylaniline A28 1-{[9-(cyclohexylmethyl)-13-[4- 640 (dimethylamino)benzenesulfonyl]-5,9,13- triazaspiro[2.11]tetradecan-5-yl]sulfonyl}piperidin-4- ol A29 4-{[9-(cyclohexylmethyl)-13-[(4-phenylpiperidin-1- 700 yl)sulfonyl]-5,9,13-triazaspiro[2.11]tetradecan-5- yl]sulfonyl}-N,N-dimethylaniline

To the amine (67 mg, 0.14 mmol) in DCM (12 mL) was added DIEA (35 mg, 0.27 mmol) followed by 4-chlorobenzoyl chloride (24 mg, 0.14 mmol). After standing at ambient temperature for 30 min the reaction was quenched with sodium bicarbonate (sat.), extracted with DCM (3×), dried with sodium sulfate, and filtered. Flash column chromatography (0-60% hexanes (1% DEA)/ethyl acetate) provided (5,13-bis(piperidin-1-ylsulfonyl)-5,9,13-triazaspiro[2.11]tetradecan-9-yl)(4-chlorophenyl)methanone (compound A24). MS(EI) for C₂₈H₄₄ClN₅O₅S₂, found 630 [M+H]⁺.

To a solution of N,N-3-trimethylaniline (1.35 g, 10.0 mmol) in CHCl₃ (4 mL) was added chlorosulfonic acid (4 mL). The reaction mixture was heated at 80° C. for 18 h. The mixture was cooled to ambient temperature and diluted with DCM (20 mL). The resulting mixture was poured into ice-water (30 mL) and then adjusted to pH=7˜8 with saturated aqueous Na₂CO₃. The organic layer was separated, washed with saturated aqueous NaHCO₃, dried over anhydrous Na₂SO₄ and concentrated. The residue was recrystallized from petroleum ether/EtOAc (10:1, 10 mL) to provide 4-(dimethylamino)-2-methylbenzenesulfonyl chloride. ¹H NMR (400 MHz, CDCl₃): δ 7.88 (d, J=9.6 Hz, 1H), 6.53 (m, 2H), 3.09 (s, 6H), 2.70 (s, 3H).

4-{[9-(cyclohexylmethyl)-13-(piperidine-1-sulfonyl)-5,9,13-triazaspiro[2.11]tetradecan-5-yl]sulfonyl}-N,N,3-trimethylaniline was prepared following the procedure described in Route 12 to provide compound A30. ¹H NMR (400 MHz, DMSO-d₆): δ 9.57 (br s, 1H), 7.50 (d, J=8.8 Hz, 2H), 6.85 (m, 2H), 3.95 (br s, 1H), 2.89˜3.55 (m, 24H), 1.45˜1.90 (m, 15H), 1.28 (m, 4H), 0.95 (m, 2H), 0.66 (br s, 4H). MS(E) for C₃₂H₅₅N₅O₄S₂, found 638 [M+H]⁺.

The following compound was synthesized in a similar manner:

No. IUPAC [M + H^(]+) ¹H NMR A41 5-(cyclohexanesulfonyl)-9- 587 ¹H NMR (400 MHz, DMSO-d₆): δ (cyclohexylmethyl)-13- 9.46 (br s, 1H), 3.37-2.95 (m, 15H), (pipendine-1-sulfonyl)-5,9,13- 2.01-1.01 (m, 33H), 0.95 (m, 2H), triazaspiro[2.11]tetradecane 0.73 (m, 4H).

To a solution of piperidine-1-sulfonyl chloride (68.3 g, 0.37 mol) in toluene (350 mL) was added dropwise a solution of propane-1,3-diamine (83.4 g, 1.12 mol) in toluene (150 mL). The reaction mixture was stirred overnight at ambient temperature. The resulting slurry was filtered and the filtrate was concentrated. The residue was purified by column chromatography on silica gel (DCM/MeOH=50:1 to 20:1) to afford N-(3-aminopropyl)piperidine-1-sulfonamide. ¹H NMR (400 MHz, CDCl₃): δ 3.17 (m, 6H), 2.88 (t, J=6.0 Hz, 2H), 1.65 (m, 6H), 1.54 (m, 2H).

A mixture of N-(3-aminopropyl)piperidine-1-sulfonamide (22.62 mmol) and cyclohexanecarbaldehyde (2.8 g, 24.89 mmol) in toluene (90.0 mL) was heated under reflux overnight with removal of water by means of a Dean-Stark apparatus. The mixture was cooled to ambient temperature and concentrated under vacuum. The resulting product was dissolved in ethanol (35 mL) and NaBH₄ (1.66 g, 43.7 mmol) was added. The reaction mixture was stirred at ambient temperature overnight. The reaction was quenched with 2N aqueous HCl (30 mL) and then adjusted to pH=10 with aqueous NaOH. The resulting mixture was extracted with ethyl acetate (50 mL) and the organic layer was concentrated. The residue was purified by column chromatography on silica gel (DCM/MeOH=50:1 to 40:1) to provide N-(3-(cyclohexylmethylamino)propyl)piperidine-1-sulfonamide. ¹H NMR (400 MHz, CDCl₃): δ 3.17 (m, 6H), 2.78 (t, J=6.0 Hz, 2H), 2.45 (d, J=6.4 Hz, 2H), 1.75 (m, 12H), 1.44 (m, 1H), 1.23 (m, 3H), 0.96 (m, 2H). MS(EI) for C₁₅H₃₁N₃O₂S, found 318 [M+H]⁺.

To a solution of N-(3-(cyclohexylmethylamino)propyl)piperidine-1-sulfonamide (2.8 g, 8.83 mmol) in CH₃CN (50 mL) were added Na₂CO₃ (0.97 g, 9.19 mmol), Lil (0.28 g, 2.12 mmol) and 3-bromopropylphthalimide (5.66 g, 21.19 mmol). The reaction mixture was heated under reflux overnight. The mixture was cooled to ambient temperature and filtered. The filtrate was concentrated and the residue was purified by column chromatography on silica gel (EtOAc/Petroleum ether=1:3) to provide N-(3-((cyclohexylmethyl)(3-(1,3-dioxoisoindolin-2-yl)propyl)amino)propyl) piperidine-1-sulfonamide. ¹H NMR (400 MHz, CDCl₃): δ 7.85 (m, 2H), 7.73 (m, 2H), 5.82 (br s, 1H), 3.68 (t, J=7.2 Hz, 2H), 3.17 (m, 6H), 2.46 (m, 4H), 2.14 (m, 2H), 1.82 (m, 2H), 1.67 (m 12H), 1.45 (m, 3H), 1.18 (m, 2H), 0.87 (m, 2H).

To a solution of N-(3-((cyclohexylmethyl)(3-(1,3-dioxoisoindolin-2-yl)propyl)amino)propyl) piperidine-1-sulfonamide (500 mg, 0.10 mmol) in EtOH (5 mL) was added NH₂NH₂ (1.5 mL, 2.55 mmol). The reaction mixture was stirred at ambient temperature overnight. The solvent was removed under reduced pressure and the residue was diluted with ethyl acetate (20 mL). The resulting mixture was washed with water (2×10 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated to provide N-(3-((3-aminopropyl)(cyclohexylmethyl)amino)propyl)piperidine-1-sulfonamide (380 mg, quantitative). ¹H NMR (400 MHz, CDCl₃): δ 3.17 (m, 6H), 2.78 (t, J=6.8 Hz, 2H), 2.45 (m, 4H), 2.14 (d, J=7.2 Hz, 2H), 1.82 (m, 2H), 1.67 (m 12H), 1.45 (m, 3H), 1.18 (m, 2H), 0.87 (m, 2H). MS(EI) for C₁₈H₃₈N₄O₂S, found 375 [M+H]⁺.

To a solution of N-(3-((3-aminopropyl)(cyclohexylmethyl)amino)propyl)piperidine-1-sulfonamide (2.42 g, 6.49 mmol) and DIEA (1.31 g, 10.3 mmol) in DCM (50 mL) was added the sulfonyl chloride (1.69 g, 7.13 mmol). The reaction mixture was stirred at ambient temperature for 2 h. The mixture was washed with water (50 mL). The organic phase was dried over anhydrous Na₂SO₄ and concentrated. The residue was purified by column chromatography on silica gel (MeOH/DCM=1:80 to 1:30) to provide N-(3-((Cyclohexylmethyl)(3-(4-(dimethylamino)-2-fluorophenylsulfonamido) propyl)amino)propyl)piperidine-1-sulfonamide. ¹H NMR (400 MHz, CDCl₃): δ 7.66 (m, 1H), 6.43 (m, 2H), 5.58 (br s, 2H), 3.15 (m, 6H), 3.03 (s, 6H), 2.99 (br s, 2H) 2.46 (br s, 4H), 2.12 (br s, 2H), 1.30˜1.70 (m, 18H), 1.21 (m, 4H), 0.82 (m, 2H). MS(EI) for C₂₆H₄₆FN₅O₄S₂, found 575 [M+H]⁺.

To a solution of N-(3-((Cyclohexylmethyl)(3-(4-(dimethylamino)-2-fluorophenylsulfonamido) propyl)amino)propyl)piperidine-1-sulfonamide (2.28 g, 3.97 mmol) in DMF (20 mL) was added sodium hydride (400 mg, 3.97 mmol). The mixture was stirred for 30 min at ambient temperature. Cyclopropane-1,1-diylbis(methylene) diethanesulfonate (1.3 g, 3.97 mmol) was added and the reaction mixture was stirred at 80° C. for 2 h. The mixture was cooled to ambient temperature and poured into water (150 mL). The resulting mixture was extracted with ethyl acetate (100 mL). The organic layer was washed with water (50 mL×2), dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography on silica gel (EtOAc/Petroleum ether=1:15 to 1:8) to provide the freebase which was dissolved in ether (5 mL). Hydrochloric acid (1.5 mL or a 3 N solution in 1,4-dioxane) was added and the mixture was stirred for 0.5 h. The solvent was removed under vacuum and the residue was triturated with ether three times to provide compound A40. ¹H NMR (400 MHz, DMSO-d₆): δ 9.89 (br s, 1H), 7.54 (m, 1H), 6.63 (m, 2H), 3.67 (br s, 1H), 3.55-2.89 (m, 23H), 1.90-1.45 (m, 15H), 1.28 (m, 4H), 0.95 (m, 2H), 0.69 (m, 4H). MS(EI) for C₃₁H₅₂FN₅O₄S₂, found 643 [M+H]⁺.

The following compounds were synthesized in a similar manner:

No. IUPAC [M + H]⁺ ¹H NMR A31 9-(cyclohexylmethyl)-5-(4- 611 ¹H NMR (400 MHz, DMSO-d₆): δ 9.75 methoxybenzenesulfonyl)-13- (br s, 1H), 7.73 (d, J = 8.8 Hz, 2H), 7.16 (piperidine-1-sulfonyl)-5,9,13- (d, J = 8.8 Hz, 2H), 3.85 (s, 3H), 3.55- triazaspiro[2.11]tetradecane 2.89 (m, 18H), 1.90-1.45 (m, 15H), 1.28 (m, 4H), 0.95 (m, 2H), 0.66 (m, 4H). A32 9-(cyclohexylmethyl)-5-(3- 611 ¹H NMR (400 MHz, DMSO-d₆): δ 9.89 methoxybenzenesulfonyl)-13- (br s, 1H), 7.57 (m, 1H), 7.32 (m, 2H), (piperidine-1-sulfonyl)-5,9,13- 7.23 (s, 1H), 3.85 (s, 3H), 3.55-2.89 (m, triazaspiro[2.11]tetradecane 18H), 2.04-1.45 (m, 15H), 1.28 (m, 4H), 0.95 (m, 2H), 0.67 (m, 4H). A33 9-(cyclohexylmethyl)-5-(2- 611 ¹H NMR (400 MHz, DMSO-d₆): δ 9.35 methoxybenzenesulfonyl)-13- (br s, 1H), 7.80 (m, 1H), 7.68 (m, 1H), (piperidine-1-sulfonyl)-5,9,13- 7.28 (m, 1H), 7.13 (m, 1H), 3.89 (s, 3H), triazaspiro[2.11]tetradecane 3.55-2.89 (m, 18H), 1.90-1.45 (m, 15H), 1.28 (m, 4H), 0.95 (m, 2H), 0.66 (br s, 2H), 0.51 (br s, 2H). A34 5-(benzenesulfonyl)-9- 581 ¹H NMR (400 MHz, DMSO-d₆): δ 10.26 (cyclohexylmethyl)-13- (br s, 1H), 7.76 (m, 4H), 3.41-2.89 (m, (piperidine-1-sulfonyl)-5,9,13- 18H), 1.90-1.45 (m, 15H), 1.28 (m, 4H), triazaspiro[2.11]tetradecane 0.95 (m, 2H), 0.73 (br s, 4H).

To 1-((1H-imidazol-1-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium trifluorosulfonate (1.69 g, 4.65 mmol, reference: J. Org. Chem. 2002, 68, 115-119.) and 4-phenylpiperidine (750 mg, 4.65 mmol) was added ACN (16 mL) and the solution was allowed to stand for 2 h then concentrated and purified directly by flash column chromatography (0-80% hexanes/ethyl acetate) to provide the product.

To 1-((1H-imidazol-1-yl)sulfonyl)-4-phenylpiperidine (600 mg, 2.06 mmol) in DCM at 0° C. was added methyl triflate (0.23 mL, 2.06 mmol) over 5 min. After allowing to stand for 30 min the mixture was concentrated to provide 3-methyl-1-((4-phenylpiperidin-1-yl)sulfonyl)-1H-imidazol-3-ium trifluoromethanesulfonate which was carried forward without further purification. MS(EI) for C₁₅H₂₀N₃O₂S, found 307 [M]⁺.

The following compounds were synthesized in a similar manner:

-   1-((8-chloro-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A51). -   1-((7-chloro-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A52). -   1-((6-chloro-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A53). -   1-((5-chloro-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A54). -   1-((6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A59). -   1-((6-bromo-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A60). -   1-((4-isopropoxypiperidin-1-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate hydrochloride (Intermediate for compound     A66). -   1-((4-(cyclopent-1-en-1-yl)-3,6-dihydropyridin-1(2H)-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A67). -   1-((4-(cyclohex-1-en-1-yl)-3,6-dihydropyridin-1(2H)-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A68). -   1-((4-(3-chlorophenyl)-3,6-dihydropyridin-1(2H)-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A69). -   1-((4-(2-chlorophenyl)-3,6-dihydropyridin-1(2H)-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A73). -   1-((4-(4-chlorophenyl)-3,6-dihydropyridin-1(2H)-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A74). -   1-((4-(1H-pyrazol-1-yl)piperidin-1-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A79). -   1-((4-(benzo[d]oxazol-2-yl)piperidin-1-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A80). -   3-methyl-1-((4-(pyrimidin-2-yl)piperidin-1-yl)sulfonyl)-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A81). -   1-((2-chloro-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A82). -   1-((5-chloroisoindolin-2-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A89).

To 4-((9-(cyclohexylmethyl)-3-methylene-1,5,9-triazacyclododecan-1-yl)sulfonyl)-N,N-dimethylaniline (97 mg, 0.21 mmol) in ACN (0.8 mL) was added 3-methyl-1-((4-phenylpiperidin-1-yl)sulfonyl)-1H-imidazol-3-ium trifluoromethanesulfonate (95 mg, 0.21 mmol) and the mixture was heated to 80° C. for 8 h then concentrated and purified directly by flash column chromatography (0-70% hexanes (1% DEA)/ethyl acetate) to provide the freebase. To this was added diethyl ether (5 mL) and HCl (52 μL of a 4N HCl in 1,4-dioxane) and the mixture was allowed to stand for 10 min then concentrated to provide 4-{[9-(cyclohexylmethyl)-3-methylidene-5-[(4-phenylpiperidin-1-yl)sulfonyl]-1,5,9-triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline hydrochloride (compound A35). MS(EI) for C₃₆H₅₅N₅O₄S₂, found 686 [M+H]⁺.

The following compounds were synthesized in a similar manner:

No. IUPAC [M + H]⁺ A36 4-{[9-(cyclohexylmethyl)-3-methylidene-5-[(4- 687 phenylpiperazin-1-yl)sulfonyl]-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A37 4-{[9-(cyclohexylmethyl)-3-methylidene-5-[(4- 702 phenoxypiperidin-1-yl)sulfonyl]-1,5,9-triazacyclododecan- 1-yl]sulfonyl}-N,N-dimethylaniline A38 4-{[9-(cyclohexylmethyl)-3-methylidene-5-[(3- 686 phenylpiperidin-1-yl)sulfonyl]-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A39 1-{[9-(cyclohexylmethyl)-5-[4- 635 (dimethylamino)benzenesulfonyl]-3-methylidene-1,5,9- triazacyclododecan-1-yl]sulfonyl}piperidine-4-carbonitrile A42 4-{[5-(cyclohexylmethyl)-9-[(4-phenylpiperidin-1- 674 yl)sulfonyl]-1,5,9-triazacyclododecan-1-yl]sulfonyl}-N,N- dimethylaniline A43 4-{[9-(cyclohexylmethyl)-3-methylidene-5-{[(3S)-3- 686 phenylpiperidin-1-y]sulfonyl}-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A46 4-{[9-(cyclohexylmethyl)-5-{[(3 R)-3-methyl-4- 701 phenylpiperazin-1-yl]sulfonyl}-3-methylidene-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline A47 4-{[9-(cyclohexylmethyl)-5-{[(3S)-3-methyl-4- 701 phenylpiperazin-1-yl]sulfonyl}-3-methylidene-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline A48 4-{[9-(cyclohexylmethyl)-5-[4- 701 (dimethylamino)benzenesulfonyl]-3-methylidene-1,5,9- triazacyclododecan-1-yl]sulfonyl}-1-phenylpiperazin-2-one A49 4-{[9-(cyclohexylmethyl)-3-methylidene-5-{[(3 R)-3- 686 phenylpiperidin-1-yl]sulfonyl}-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A50 4-{[9-(cyclohexylmethyl)-3-methylidene-5-(1,2,3,4- 658 tetrahydroisoquinoline-2-sulfonyl)-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline

To N-(3-((3-aminopropyl)(cyclohexylmethyl)amino)propyl)-4-(dimethylamino)benzenesulfonamide (838 mg, 1.84 mmol) in ACN (5 mL) was added 3-methyl-1-((4-phenylpiperidin-1-yl)sulfonyl)-1H-imidazol-3-ium trifluoromethanesulfonate (838 mg, 1.84 mmol) and the mixture was heated to 80° C. for 8 h the concentrated and purified directly by flash column chromatography (0-70% hexanes (1% DEA)/ethyl acetate) to provide the product. ¹H NMR (400 MHz, CDCl₃): δ 7.68 (d, J=8.8 Hz, 2H), 7.33 (m, 5H), 6.68 (d, J=8.8 Hz, 2H), 5.75 (br s, 2H), 3.84 (m, 2H), 3.18 (m, 2H), 3.05 (s, 6H), 2.91 (m, 4H), 2.65 (m, 1H), 2.43 (m, 4H), 2.08 (m, 2H), 1.73 (m, 12H), 1.40 (m, 1H), 1.15 (m, 4H), 0.85 (m, 2H).

To 4-((9-(cyclohexylmethyl)-3-methyl-5-((4-phenylpiperidin-1-yl)sulfonyl)-1,5,9-triazacyclododecan-1-yl)sulfonyl)-N,N-dimethylaniline (123 mg, 0.194 mmol) in NMP (10 mL) was added sodium hydride (19 mg of a 60% dispersion in mineral oil, 0.485 mmol) over 20 min. The mixture was stirred at ambient temperature for 30 min then 80° C. for an additional 20 min. The bis-sulfonate was then added over the course of 1 h. After 8 h at 80° C. the mixture was cooled to ambient temp., diluted with brine and ethyl acetate, extracted with ethyl acetate (3×), the combined organics were washed with brine (3×), dried with sodium sulfate, filtered, and concentrated. Flash column chromatography (0-50% hexanes (1% DEA)/ethyl acetate) provided the freebase. The freebase was converted to the HCl salt with the addition of ethyl ether (5 mL) and HCl (4N in dioxane, 50 uL). Concentration after 10 min provided 4-{[9-(cyclohexylmethyl)-3-methyl-5-[(4-phenylpiperidin-1-yl)sulfonyl]-1,5,9-triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline hydrochloride (compound A44). MS(EI) for C₃₆H₅₇N₅O₄S₂, found 688 [M+H]⁺.

The following compound was synthesized in a similar manner:

No. IUPAC [M + H]⁺ B7 N-{3-[(cyclohexylmethyl)(3-{[(4-phenyl- 634 piperidin-1-yl)sulfonyl]amino}propyl)a- mino]propyl}-4-(dimethylamino)benzene- 1-sulfonamide

To 1,1-bis(hydroxymethyl)cyclopropane (5.00, 49.0 mmol) in acetone (20 mL) was added TEA (2.2 eq, 108 mmol) and the mixture was cooled to 0-5° C. Ethanesulfonyl chloride was added at a rate to maintain the internal temperature below 10° C. (1 h). After stirring an additional 2 h at ambient temperature the mixture was diluted with 150 mL of water, extracted with ethyl acetate (2×50 mL), washed with brine, dried with sodium sulfate, filtered, and concentrated to provide the product. ¹H NMR (400 MHz, CDCl₃): δ 4.16 (s, 4H), 3.20 (m, 4H), 1.46 (t, J=7.2 Hz, 6H), 0.83 (s, 4H). MS(EI) for C₉H₁₈O₆S₂, found 287 [M+H]⁺.

The following compound was synthesized in a similar manner 2-methylpropane-1,3-diyl diethanesulfonate (Intermediate for compound A44).

To N-(3-((cyclohexylmethyl) (3-((4-(dimethylamino)phenyl)sulfonamido)propyl)amino)propyl)-4-phenylpiperidine-1-sulfonamide (89 mg, 0.14 mmol) in NMP (7 mL) was added NaH (14 mg of a 60% dispersion in mineral oil, 0.35 mmol) portion-wise over 20 min. The mixture was stirred at ambient temperature for 30 min then 80° C. for 20 min. The dichloride was then added and the mixture was heated at 80° C. After 8 h at 80° C. the mixture was cooled to ambient temp, diluted with brine and ethyl acetate, extracted with ethyl acetate (3×), the combined organics were washed with brine (3×), dried with sodium sulfate, filtered, and concentrated. Flash column chromatography (0-50% hexanes (1% DEA)/ethyl acetate) provided the product. The product was converted to the HCl salt with the addition of ethyl ether (5 mL) and HCl (4N in dioxane, 35 uL). The mixture was concentrated to provide 4-{[5-(cyclohexylmethyl)-9-[(4-phenylpiperidin-1-yl)sulfonyl]-1,5,9-triazacyclotridecan-1-yl]sulfonyl}-N,N-dimethylaniline hydrochloride (compound B15). MS(EI) for C₃₆H₅₇N₅O₄S₂, found 688 [M+H]⁺.

The following compounds were synthesized in a similar manner:

No. IUPAC [M + H]⁺ B8 4-{[(11Z)-5-(cyclohexylmethyl)-9-[(4-phenylpiperidin-1 - 686 yl)sulfonyl]-1,5,9-triazacyclotridec-11-en-1-yl]sulfonyl}- N,N-dimethylaniline B9 4-{[(11E)-5-(cyclohexylmethyl)-9-[(4-phenylpiperidin-1- 686 yl)sulfonyl]-1,5,9-triazacyclotridec-11-en-1-yl]sulfonyl}- N,N-dimethylaniline

N-(4-((3-aminopropyl)(cyclohexylmethyl)amino)butan-2-yl)-4-(dimethylamino)benzenesulfonamide was synthesized following Route 2 with substitution of the appropriate sulfonyl chloride.

4-((5-(cyclohexylmethyl)-2-methyl-11-methylene-9-((4-phenylpiperidin-1-yl)sulfonyl)-1,5,9-triazacyclododecan-1-yl)sulfonyl)-N,N-dimethylaniline was synthesized following the procedure described in Route 15 substituting with 3-chloro-2-(chloromethyl)prop-1-ene to provide 4-((5-(cyclohexylmethyl)-2-methyl-11-methylene-9-((4-phenylpiperidin-1-yl)sulfonyl)-1,5,9-triazacyclododecan-1-yl)sulfonyl)-N,N-dimethylaniline (compound B6). MS(EI) for C₃₇H₅₇N₅O₄S₂, found 700 [M+H]⁺.

The following compounds were synthesized in a similar manner:

No. IUPAC [M + H]⁺ ¹H NMR B19 4-{[5-(cyclohexylmethyl)-2- 700 methyl-11-methylidene-9-[(4- phenylpiperidin-1-yl)sulfonyl]- 1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A51 4-({5-[(8-chloro-1,2,3,4- 692 tetrahydroisoquinolin-2- yl)sulfonyl]-9- (cyclohexylmethyl)-3- methylidene-1,5,9- triazacyclododecan-1- yl}sulfonyl)-N,N-dimethylaniline A52 4-({5-[(7-chloro-1,2,3,4- 692 tetrahydroisoquinolin-2- yl)sulfonyl]-9- (cyclohexylmethyl)-3- methylidene-1,5,9- triazacyclododecan-1- yl}sulfonyl)-N,N-dimethylaniline A53 4-({5-[(6-chloro-1,2,3,4- 692 ¹H NMR (400 MHz, CDCl₃): δ tetrahydroisoquinolin-2- 7.59 (d, J = 8.8 Hz, 2H), 7.15 yl)sulfonyl]-9- (m, 2H), 7.04 (m, 1H), 6.70 (cyclohexylmethyl)-3- (d, J = 8.8 Hz, 2H), 5.25 (s, 1H), methylidene-1,5,9- 5.13 (s, 1H), 4.34 (s, 2H), 4.12 triazacyclododecan-1- (s, 2H), 4.10 (s, 2H), 3.51 (m, yl}sulfonyl)-N,N-dimethylaniline 6H), 3.05 (s, 6H), 2.88 (m, 4H), 2.41 (m, 2H), 2.25 (m, 2H), 1.95 (m, 2H), 1.85 (m, 2H), 1.67 (m, 6H), 1.23 (m, 4H), 0.85 (m, 1H). A54 4-({5-[(5-chloro-1,2,3,4- 692 tetrahydroisoquinolin-2- yl)sulfonyl]-9- (cyclohexylmethyl)-3- methylidene-1,5,9- triazacyclododecan-1- yl}sulfonyl)-N,N-dimethylaniline A56 4-({5-[(6-chloro-1,2,3,4- 710 tetrahydroisoquinolin-2- yl)sulfonyl]-9- (cyclohexylmethyl)-3- methylidene-1,5,9- triazacyclododecan-1- yl}sulfonyl)-3-fluoro-N,N- dimethylaniline A57 4-[(5-{[4-(2- 720 chlorophenyl)piperidin-1- yl]sulfonyl}-9- (cyclohexylmethyl)-3- methylidene-1,5,9- triazacyclododecan-1- yl)sulfonyl]-N,N-dimethylaniline A58 4-[(5-{[4-(3- 720 chlorophenyl)piperidin-1- yl]sulfonyl}-9- (cyclohexylmethyl)-3- methylidene-1,5,9- triazacyclododecan-1- yl)sulfonyl]-N,N-dimethylaniline A59 4-{[9-(cyclohexylmethyl)-5-[(6- 676 fluoro-1,2,3,4- tetrahydroisoquinolin-2- yl)sulfonyl]-3-methylidene- 1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A60 4-({5-[(6-bromo-1,2,3,4- 736 tetrahydroisoquinolin-2- yl)sulfonyl]-9- (cyclohexylmethyl)-3- methylidene-1,5,9- triazacyclododecan-1- yl}sulfonyl)-N,N-dimethylaniline A64 4-{[9-(cyclohexylmethyl)-5-[(4- 678 cyclopentylpiperidin-1- yl)sulfonyl]-3-methylidene- 1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A65 4-{[9-(cyclohexylmethyl)-5-[(4- 692 cyclohexylpiperidin-1- yl)sulfonyl}-3-methylidene- 1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A66 4-{[9-(cyclohexylmethyl)-3- 668 methylidene-5-{[4-(propan-2- yloxy)piperidin-1-yl]sulfonyl}- 1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A67 4-{[9-(cyclohexylmethyl)-5-{[4- 674 (cyclopent-1-en-1-yl)-1,2,3,6- tetrahydropyridin-1-yl]sulfonyl}- 3-methylidene-1,5,9- triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A68 4-[(5-{[4-(cyclohex-1-en-1-yl)- 688 1,2,3,6-tetrahydropyridin-1- yl]sulfonyl}-9- (cyclohexylmethyl)-3- methylidene-1,5,9- triazacyclododecan-1- yl)sulfonyl}-N,N-dimethylaniline A69 4-[(5-{[4-(3-chlorophenyl)- 718 1,2,3,6-tetrahydropyridin-1- yl]sulfonyl}-9- (cyclohexylmethyl)-3- methylidene-1,5,9- triazacyclododecan-1- yl)sulfonyl]-N,N-dimethylaniline A70 2-{[9-(cyclohexylmethyl)-5-[4- 683 (dimethylamino)benzenesulfonyl]- 3-methylidene-1,5,9- triazacyclododecan-1- yl]sulfonyl}-1,2,3,4- tetrahydroisoquinoline-6- carbonitrile A71 4-{[9-(cyclohexylmethyl)-5-[(6- 688 methoxy-1,2,3,4- tetrahydroisoquinolin-2- yl)sulfonyl]-3-methylidene- 1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A72 4-[(5-{[4-(4- 720 chlorophenyl)piperidin-1- yl]sulfonyl}-9- (cyclohexylmethyl)-3- methylidene-1,5,9- triazacyclododecan-1- yl)sulfonyl]-N,N-dimethylaniline A73 4-[(5-{[4-(2-chlorophenyl)- 718 1,2,3,6-tetrahydropyridin-1- yl]sulfonyl}-9- (cyclohexylmethyl)-3- methylidene-1,5,9- triazacyclododecan-1- yl)sulfonyl]-N,N-dimethylaniline A74 4-[(5-{[4-(4-chlorophenyl)- 718 1,2,3,6-tetrahydropyridin-1- yl]sulfonyl}-9- (cyclohexylmethyl)-3- methylidene-1,5,9- triazacyclododecan-1- yl)sulfonyl]-N,N-dimethylaniline A78 4-{[9-(cyclohexylmethyl)-3- 694 methylidene-5-{[4-(oxan-4- yl)piperidin-1-yl]sulfonyl}-1,5,9- triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A79 4-{[9-(cyclohexylmethyl)-3- 676 methylidene-5-{[4-(1H-pyrazol- 1-yl)piperidin-1-yl]sulfonyl}- 1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A80 4-[(5-{[4-(1,3-benzoxazol-2- 727 yl)piperidin-1-yl]sulfonyl}-9- (cyclohexylmethyl)-3- methylidene-1,5,9- triazacyclododecan-1- yl)sulfonyl]-N,N-dimethylaniline A81 4-{[9-(cyclohexylmethyl)-3- 688 methylidene-5-{[4-(pyrimidin-2- yl)piperidin-1-yl]sulfonyl}-1,5,9- triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A82 4-({5-[(2-chloro-5,6,7,8- 693 tetrahydro-1,6-naphthyridin-6- yl)sulfonyl]-9- (cyclohexylmethyl)-3- methylidene-1,5,9- triazacyclododecan-1- yl}sulfonyl)-N,N-dimethylaniline A88 (3Z)-9-(cyclohexylmethyl)-1-[4- 717 (dimethylamino)benzenesulfonyl]- N-methoxy-5-[(4- phenylpiperidin-1-yl)sulfonyl]- 1,5,9-triazacyclododecan-3- imine A83 4-[(5-{[4-(2- 721 ¹H NMR (400 MHz, CDCl₃): δ 7.61 chlorophenyl)piperazin-1- (d, J = 8.8 Hz, 2H), 7.39 (m, 2H), yl]sulfonyl}-9- 7.05 (m, 2H), 6.82 (d, J = 8.8 Hz, (cyclohexylmethyl)-3- 2H), 5.35 (m, 2H), 4.10 (m, 2H), methylidene-1,5,9- 3.41 (m, 6H), 3.10 (m, 4H), 3.05 triazacyclododecan-1- (s, 6H), 2.88 (m, 2H), 2.41 (m, 3H), yl)sulfonyl]-N,N-dimethylaniline 2.21 (m, 4H), 2.01 (m, 3H), 1.85 (m, 6H), 1.55 (m, 11H), 1.15 (m, 9H), 0.82 (m, 3H). A84 4-[(5-{[4-(3- 721 ¹H NMR (400 MHz, CDCl₃): δ 7.59 chlorophenyl)piperazin-1- (d, J = 8.8 Hz, 2H), 7.18 (m, 1H), yl]sulfonyl}-9- 6.85 (m, 3H), 6.78 (d, J = 8.8 Hz, (cyclohexylmethyl)-3- 2H), 5.25 (m, 2H), 4.10 (m, 2H), methylidene-1,5,9- 3.51 (m, 2H), 3.20 (m, 10H), 3.05 triazacyclododecan-1- (s, 6H), 2.88 (m, 2H), 2.41 (m, 2H), yl)sulfonyl]-N,N-dimethylaniline 2.01 (m,2H), 1.85 (m, 4H), 1.65 (m, 6H), 1.25 (m, 5H), 0.82 (m, 1H). A85 4-[(5-{[4-(4- 721 ¹H NMR (400 MHz, CDCl₃): δ 7.59 chlorophenyl)piperazin-1- (d, J = 8.8 Hz, 2H), 7.26 (d, J = 8.0 yl]sulfonyl}-9- Hz, 2H), 6.87 (d, J = 8.0 Hz, 2H), (cyclohexylmethyl)-3- 6.70 (d, J = 8.8 Hz, 2H), 5.25 (m, methylidene-1,5,9- 2H), 4.10 (m, 2H), 3.51 (m, 2H), triazacyclododecan-1- 3.20 (m, 10H), 3.05 (s, 6H), 2.88 yl)sulfonyl]-N,N-dimethylaniline (m, 2H), 2.41 (m, 2H), 2.01 (m,2H), 1.85 (m, 4H), 1.65 (m, 6H), 1.27 (m, 5H), 0.85 (m, 1H). A89 4-({5-[(5-chloro-2,3-dihydro-1H- 678 ¹H NMR (400 MHz, CDCl₃): δ 7.59 isoindo1-2-yl)sulfonyl]-9- (d, J = 8.8 Hz, 2H), 7.25 (m, 4H), (cyclohexylmethyl)-3- 6.68 (d, J = 8.8 Hz, 2H), 5.28 (s, 1H), methylidene-1,5,9- 5.12 (s, 1H), 4.64 (m, 4H), 4.12 (s, triazacyclododecan-1- 2H), 3.45 (m, 4H), 3.05 (s, 6H), 2.88 yl}sulfonyl)-N,N-dimethylaniline (m, 2H), 2.25 (m, 2H), 1.95 (m, 2H), 1.65 (m, 8H), 1.23 (m, 8H), 0.85 (m, 1H).

To N-(3-((cyclohexylmethyl) (3-((4-(dimethylamino)phenyl)sulfonamido)propyl)amino)propyl)-4-phenylpiperidine-1-sulfonamide (33 mg, 0.052 mmol) in NMP (3 mL) was added sodium hydride (4.6 mg of a 60% dispersion in mineral oil, 0.11 mmol). The mixture was stirred at ambient temperature for 30 min then 80° C. for an additional 20 min. The dichloride (19 mg, 0.052 mmol) was then added. After 2 h at 80° C. the mixture was cooled to ambient temp, diluted with brine and ethyl acetate, extracted with ethyl acetate (3×), the combined organics were washed with brine (3×), dried with sodium sulfate, filtered, and concentrated. Flash column chromatography (0-50% hexanes (1% DEA)/ethyl acetate) provided 9-(cyclohexylmethyl)-1-[4-(dimethylamino)benzenesulfonyl]-5-[(4-phenylpiperidin-1-yl)sulfonyl]-1,5,9-triazacyclododecan-3-ol (compound A55). MS(EI) for C₃₅H₅₅N₅O₅S₂, found 690 [M+H]⁺.

To a solution of 3-fluoro-4-iodoaniline (1.11 g, 4.68 mmol) in acetonitrile (15.00 mL) were added 37% aqueous formaldehyde (8.0 mL, 99.9 mmol) and sodium cyanoborohydride (1.88 g, 29.97 mmol). Then acetic acid (1 mL) was added dropwise over 10 min and the reaction mixture was stirred at ambient temperature overnight. Aqueous NaOH (1N, 30 mL) was added and the resulting mixture was extracted with ethyl acetate (50 mL). The organics were washed with brine, dried over anhydrous sodium sulfate and concentrated to provide 3-fluoro-4-iodo-N,N-dimethylaniline. ¹H NMR (400 MHz, CDCl₃): δ 7.47 (m, 1H), 6.43 (m, 1H), 6.28 (m, 1H), 2.94 (s, 6H).

To a solution of 3-fluoro-4-iodo-N,N-dimethylaniline (500 mg, 1.89 mmol) in ether (5 mL) was added n-BuLi (0.8 mL, 1.89 mmol) at −78° C. The mixture was stirred for 0.5 h at this temperature. Sulfuryl dichloride (405 mg, 3 mmol) was added and the reaction mixture was stirred for 1 h. The reaction was quenched with water (10 mL) and then adjusted to pH=8 with saturated aqueous NaHCO₃. The resulting mixture was extracted with ethyl acetate (10 mL). The organic phase was separated and concentrated. The residue was purified by column chromatography on silica gel to provide 4-(dimethylamino)-2-fluorobenzene-1-sulfonyl chloride. ¹H NMR (400 MHz, CDCl₃): δ 7.73 (m, 1H), 6.43 (m, 2H), 3.15 (s, 3H).

To 9-(cyclohexylmethyl)-1-((4-(dimethylamino)phenyl)sulfonyl)-5-((4-phenylpiperidin-1-yl)sulfonyl)-1,5,9-triazacyclododecan-3-ol (30 mg, 0.043 mmol) in toluene (0.5 mL) was added NaH (1.6 mg of a 60% dispersion in mineral oil, 0.065 mmol) followed by iodomethane (14 μL, 0.22 mmol). After stirring for 1 h the mixture was quenched with water, extracted with DCM (2×), the organics were combined and dried with sodium sulfate, filtered, and concentrated. Flash column chromatography (0-50% hexanes/ethyl acetate+1% DEA) provided 4-{[9-(cyclohexylmethyl)-3-methoxy-5-[(4-phenylpiperidin-1-yl)sulfonyl]-1,5,9-triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline (compound A61). MS(EI) for C₃₆H₅₇N₅O₅S₂, found 704 [M+H]⁺.

To 9-(cyclohexylmethyl)-1-((4-(dimethylamino)phenyl)sulfonyl)-5-((4-phenylpiperidin-1-yl)sulfonyl)-1,5,9-triazacyclododecan-3-ol (171 mg, 0.248 mmol) was added DCM (10 mL) followed by Dess-Martin periodinane (126 mg, 0.297 mmol). The mixture was allowed to stand for 2 h at rt then it was concentrated and purified directly by FCC (0-60% hexanes (1% DEA)/ethyl acetate) to provide 9-(cyclohexylmethyl)-1-((4-(dimethylamino)phenyl)sulfonyl)-5-((4-phenylpiperidin-1-yl)sulfonyl)-1,5,9-triazacyclododecan-3-one (compound B20). MS(EI) for C₃₅H₅₃N₅O₅S₂, found 688 [M+H]⁺.

To 4-((5-((6-bromo-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-9-(cyclohexylmethyl)-3-methylene-1,5,9-triazacyclododecan-1-yl)sulfonyl)-N,N-dimethylaniline (70 mg, 0.095 mmol) in DMF (0.7 mL) was added water (0.1 mL), phenylboronic acid (13 mg, 0.10 mmol), Pd(dppf)Cl₂-DCM (7.8 mg, 0.001 mmol), and sodium carbonate (30 mg, 0.29 mmol). The mixture was heated to 80° C. for 1 h then diluted with brine, extracted with ethyl acetate (2×), dried with sodium sulfate, filtered, and concentrated. Flash column chromatography (0-50% hexanes (1% DEA)/ethyl acetate) provided 4-((9-(cyclohexylmethyl)-3-methylene-5-((6-phenyl-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-1,5,9-triazacyclododecan-1-yl)sulfonyl)-N,N-dimethylaniline (compound A63). MS(EI) for C₄₀H₅₃N₅O₄S₂, found 734 [M+H]⁺.

To a mixture of cyclopentanone (5.50 g, 65.5 mmol) and Na₂CO₃ (10.4 g, 98.2 mmol) in DCM (130 mL) was added Tf₂O (18.6 g, 72.0 mmol) at −20° C. The reaction mixture was allowed to warm to ambient temperature and stirred overnight. The solid was filtered off and the filtrate was concentrated to provide cyclopentenyl trifluoromethanesulfonate.

A solution of cyclopentenyl trifluoromethanesulfonate (7.7 g, 35.6 mmol) in 1,4-dioxane (105 mL) and water (50 mL) was degassed and then filled with argon. tert-Butyl 4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (6.0 g, 19.4 mmol), Pd(PPh₃)₄ (1.02 g, 0.88 mmol) and sodium carbonate (10.3 g, 97.1 mmol) were added. The reaction mixture was stirred overnight at 90° C. and then cooled to ambient temperature. The mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. Purification by flash column chromatography on silica gel (ethyl acetate/hexanes=1:99 to 5:95) provided tert-Butyl 4-cyclopentenyl-5,6-dihydropyridine-1(2H)-carboxylate. ¹H NMR (400 MHz, CDCl₃): δ 5.73 (br s, 1H), 5.56 (br s, 1H), 4.00 (br s, 2H), 3.45 (br s, 2H), 2.47 (m, 4H), 2.33 (br s, 2H), 1.94 (m, 2H), 1.48 (s, 9H).

To a solution of tert-Butyl 4-cyclopentenyl-5,6-dihydropyridine-1(2H)-carboxylate (3.3 g, 15.3 mmol) in methanol (30 mL) was added Pd/C (0.6 g). The mixture was hydrogenated under 15 psi pressure for 5 h. The mixture was filtered and the filtrate was concentrated under reduced pressure to provide tert-Butyl 4-cyclopentylpiperidine-1-carboxylate.

To a solution of tert-Butyl 4-cyclopentylpiperidine-1-carboxylate (2.9 g, 11.5 mmol) in ethyl acetate (15 mL) was added EtOAc/HCl (4N, 20 mL). The mixture was stirred for 2 h and the solvent was removed. The resulting product was washed with ether to provide 4-cyclopentylpiperidine hydrochloride. 1H NMR (400 MHz, D₂O): δ 3.25 (m, 2H), 2.75 (m, 2H), 1.84 (m, 2H), 1.61 (m, 2H), 1.45 (m, 8H), 0.96 (m, 2H).

4-Cyclopentylpiperidine hydrochloride (1.4 g, 9.5 mmol) and 1-(1H-imidazol-1-ylsulfonyl)-3-methyl-1H-imidazol-3-ium trifluoromethanesulfonate (3.45 g, 9.5 mmol) were mixed in CH₃CN (20 mL). The mixture was stirred at ambient temperature overnight. The solvent was removed. The residue was purified by column chromatography on silica gel (EtOAc/petroleum ether=1:9 to 1:3) to provide 1-(1H-Imidazol-1-ylsulfonyl)-4-cyclopentylpiperidine. 1H NMR (400 MHz, CDCl₃): δ 7.91 (s, 1H), 7.24 (s, 1H), 7.14 (s, 1H), 3.87 (m, 2H), 2.51 (m, 2H), 1.83 (m, 4H), 1.54 (m, 5H), 1.33 (m, 2H), 1.08 (m, 3H).

To a solution of 1-(1H-Imidazol-1-ylsulfonyl)-4-cyclopentylpiperidine (500 mg, 1.8 mmol) in DCM (5 mL) was added MeOTf (0.3 g, 1.8 mmol). The reaction mixture was stirred at ambient temperature overnight. The solvent was removed and the resulting product was washed with ether to provide 1-((4-cyclopentylpiperidin-1-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium trilfluoromethanesulfonate. ¹H NMR (400 MHz, CD₃OD): δ 9.59 (s, 1H), 8.02 (s, 1H), 7.78 (s, 1H), 4.00 (s, 3H), 3.95 (m, 2H), 2.87 (m, 2H), 1.81 (m, 4H), 1.54 (m, 6H), 1.23 (m, 4H).

The following compounds were synthesized in a similar manner:

-   1-((4-cyclohexylpiperidin-1-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A65). -   3-methyl-1-((4-(tetrahydro-2H-pyran-4-yl)piperidin-1-yl)sulfonyl)-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A78).

To 9-(cyclohexylmethyl)-1-((4-(dimethylamino)phenyl)sulfonyl)-5-((4-phenylpiperidin-1-yl)sulfonyl)-1,5,9-triazacyclododecan-3-one (19 mg, 0.028 mmol) in DCM (0.5 mL) and methanol (0.05 mL) was added hydroxylamine hydrochloride (5.8 mg, 0.083 mmol) and sodium acetate (6.8 mg, 0.083 mmol). The mixture was stirred for 6 h at ambient temperature then concentrated and purified by flash column chromatography (0-60% hexanes (1% DEA)/ethyl acetate) to provide 9-(cyclohexylmethyl)-1-((4-(dimethylamino)phenyl)sulfonyl)-5-((4-phenylpiperidin-1-yl)sulfonyl)-1,5,9-triazacyclododecan-3-one oxime (compound A75). MS(EI) for C₃₅H₅₄N₆O₅S₂, found 703 [M+H]⁺.

A solution of 1-chloro-2-iodobenzene (5.0 g, 21.1 mmol) in DMF (150 mL) was degassed and then filled with argon. tert-Butyl 4-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (7.13 g, 23.0 mmol), Pd(dppf)Cl₂ (1.7 g, 2.1 mmol) and potassium carbonate (8.69 g, 63.0 mmol) were added. The reaction mixture was stirred overnight at 110° C. and then cooled to ambient temperature. The mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. Purification by flash column chromatography on silica gel (ethyl acetate/hexanes=1:9 to 1:4) provided tert-Butyl 4-(2-chlorophenyl)-5,6-dihydropyridine-1(2H)-carboxylate. ¹H NMR (400 MHz, CDCl₃): δ 7.37 (m, 1H), 7.18 (m, 3H), 5.67 (m, 1H), 4.06 (m, 2H), 3.64 (m, 2H), 2.46 (br s, 2H), 1.51 (s, 9H).

To a solution of tert-Butyl 4-(2-chlorophenyl)-5,6-dihydropyridine-1(2H-carboxylate (2.0 g, 6.8 mmol) in MeOH (20 mL) was added HCl/MeOH (3M, 20 mL). The mixture was stirred at ambient temperature for 2 h. The resulting solution of 4-(2-chlorophenyl)-1,2,3,6-tetrahydropyridine hydrochloride was used directly in the next step.

To the solution of 4-(2-chlorophenyl)piperidine hydrochloride in MeOH/HCl was added PtO₂ (0.1 g). The mixture was hydrogenated at ambient temperature under 15 psi for 3 h. The catalyst was filtered off and the filtrate was concentrated to provide the product. ¹H NMR (400 MHz, DMSO-d₆): δ 9.19 (br s, 2H), 7.37 (m, 1H), 7.36 (m, 4H), 3.44 (m, 1H), 3.33 (m, 2H), 3.08 (m, 2H), 1.95 (m, 4H).

The free base (0.95 g, 4.8 mmol) and 1-(1H-imidazol-1-ylsulfonyl)-3-methyl-1H-imidazol-3-ium trifluoromethanesulfonate (1.76 g, 4.8 mmol) were mixed in CH₃CN (10 mL). The mixture was stirred at ambient temperature overnight. The solvent was removed, and the residue was purified by column chromatography on silica gel to provide 1-(1H-imidazol-1-ylsulfonyl)-4-(2-chlorophenyl)piperidine. ¹H NMR (400 MHz, CDCl₃): δ 8.01 (s, 1H), 7.36 (m, 2H), 7.18 (m, 4H), 4.07 (m, 2H), 3.06 (m, 1H), 2.74 (m, 2H), 1.99 (m, 2H), 1.81 (m, 2H).

To a solution of 1-(1H-imidazol-1-ylsulfonyl)-4-(2-chlorophenyl)piperidine (501 mg, 1.5 mmol) in DCM (5 mL) was added MeOTf (0.27 g, 1.63 mmol). The mixture was stirred at ambient temperature overnight. The solvent was removed. The resulting product was washed with ether to provide 1-((4-(2-chlorophenyl)piperidin-1-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium trifluoromethanesulfonate (Intermediate for compound A57). 1H NMR (400 MHz, CD₃OD): δ 9.65 (s, 1H), 8.08 (s, 1H), 7.82 (s, 1H), 7.39 (m, 4H), 4.16 (m, 2H), 4.02 (s, 3H), 3.31 (m, 3H), 2.03 (m, 2H), 1.85 (m, 2H).

The following compounds were synthesized in a similar manner:

-   1-((4-(3-chlorophenyl)piperidin-1-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A58). -   1-((4-(4-chlorophenyl)piperidin-1-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium     trifluoromethanesulfonate (Intermediate for compound A72).

To a solution of 2-(3-chlorophenyl)ethanamine (149 g, 0.95 mol) and TEA (144 g, 1.42 mol) in DCM (1.5 L) was added dropwise ethyl carbonochloridate (107 g, 1.14 mol) at 0° C. The reaction mixture was stirred for 3 h and then washed with 1 N aqueous HCl (1 L) and saturated aqueous NaHCO₃ (600 mL). The DCM layer was dried over anhydrous sodium sulfate and concentrated to provide methyl 3-chlorophenethylcarbamate. ¹H NMR (400 MHz, CDCl₃): δ 7.27 (m, 3H), 7.08 (m, 1H), 4.77 (m, 1H), 3.78 (s, 3H), 3.44 (m, 2H), 2.80 (m, 2H).

Methyl 3-chlorophenethylcarbamate (193 g, 0.9 mol) was dissolved in CF₃SO₃H (1.36 kg). The mixture was heated at 120° C. overnight. The mixture was cooled to ambient temperature and then poured into ice-water (4 L). The resulting product was collected by filtration and washed with ether to provide 6-chloro-3,4-dihydroisoquinolin-1(2H)-one. ¹H NMR (400 MHz, CDCl₃): δ 8.01 (m, 1H), 7.35 (m, 1H), 7.25 (m, 2H), 6.21 (br s, 1H), 3.60 (m, 2H), 3.01 (m, 2H).

To a solution of 6-chloro-3,4-dihydroisoquinolin-1(2H)-one (33 g, 182 mmol) in THF (330 mL) was added dropwise BH₃-Me₂S (73 mL, 729 mmol). The reaction mixture was refluxed overnight. The mixture was cooled to ambient temperature and then quenched with 6N aqueous HCl (300 mL). THF was removed under reduced pressure and the remaining solution was refluxed overnight. The mixture was concentrated to a certain volume and then basified with 2N aqueous NaOH. The resulting mixture was extracted with DCM. The DCM layer was dried over anhydrous sodium sulfate and concentrated to provide 6-chloro-1,2,3,4-tetrahydroisoquinoline.

To a solution of 6-chloro-1,2,3,4-tetrahydroisoquinoline (18.5 g, 0.11 mol) in CH₃CN (180 mL) was added compound 2,3-dimethyl-1-((2-methyl-1H-imidazol-1-yl)sulfonyl)-1H-imidazol-3-ium trifluoromethanesulfonate (43.5 g, 0.11 mol, Reference: J. Org. Chem. 2002, 68, 115-119.). The reaction mixture was stirred overnight at 30° C. The solvent was removed and the residue was purified by column chromatography on silica gel (EtOAc/Petroleum ether=1:1) to provide 6-chloro-2-(2-methyl-1H-imidazol-1-ylsulfonyl)-1,2,3,4-tetrahydroisoquinoline. ¹H NMR (400 MHz, CDCl₃): δ 7.21 (m, 1H), 7.18 (s, 1H), 7.02 (m, 1H), 6.94 (m, 1H), 4.45 (s, 2H), 3.62 (m, 2H), 2.92 (m, 2H), 2.67 (s, 3H).

To a solution of 6-chloro-2-(2-methyl-1H-imidazol-1-ylsulfonyl)-1,2,3,4-tetrahydroisoquinoline (25.5 g, 82 mmol) in DCM (260 mL) was added CF₃SO₃Me (13.45 g, 82 mmol). The reaction mixture was stirred at ambient temperature overnight. The solvent was removed and the residue was washed with ether to provide 1-(6-chloro-3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)-2,3-dimethyl-1H-imidazol-3-ium trifluoromethanesulfonate.

To a solution of 1-(6-Chloro-3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)-2,3-dimethyl-1H-imidazol-3-ium trifluoromethanesulfonate (8.7 g, 18.4 mmol) in CH₃CN (100 mL) was added (R)—N-(3-amino-2-methylpropyl)-4-(dimethylamino)benzenesulfonamide (5.0 g, 18.4 mmol). The reaction mixture was stirred overnight at 30° C. The solvent was removed and the residue was purified by column chromatography on silica gel (EtOAc/Petroleum ether=1:3 to 1:1) to provide (S)-6-chloro-N-(3-((4-(dimethylamino)phenyl)sulfonamido)-2-methylpropyl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide (compound B10). ¹H NMR (400 MHz, CDCl₃): δ 7.85 (m, 2H), 7.43 (m, 2H), 7.18 (m, 2H), 7.03 (m, 1H), 4.35 (s, 2H), 3.48 (m, 2H), 3.18 (s, 6H), 3.15 (m, 1H), 2.95 (m, 6H), 2.85 (m, 1H), 1.89 (m, 1H), 0.89 (m, 3H).

(S)-6-Chloro-N-(3-((4-(dimethylamino)phenyl)sulfonamido)-2-methylpropyl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide (300 mg, 0.6 mmol) was dissolved in NMP (3 mL) and NaH (60%, 96 mg, 2.4 mmol) was added. The mixture was stirred for 30 min at ambient temperature and then heated at 80° C. for 20 min. The mixture was cooled to ambient temperature. A solution of ((cyclohexylmethyl)azanediyl)bis(propane-3,1-diyl) dimethanesulfonate (231 mg, 0.6 mmol) in NMP (1 mL) was added. The reaction mixture was heated at 80° C. for 1 h then cooled to ambient temperature and quenched with water (10 mL). The resulting mixture was extracted with ethyl acetate (15 mL). The extract was washed with brine and concentrated. The residue was purified by column chromatography on silica gel (EtOAc/petroleum ether=1:8 to 1:3) to provide compound A87. MS(EI) for C₃₄H₅₂ClN₅O₄S₂, found 695[M+H]⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, J=8.8 Hz, 2H), 7.15 (m, 2H), 7.00 (m, 1H), 6.68 (d, J=8.8 Hz, 2H), 4.34 (m, 2H), 3.71 (m, 2H), 3.45 (m, 2H), 3.17 (m, 3H), 3.05 (s, 6H), 2.88 (m, 4H), 2.25 (m, 2H), 2.15 (m, 6H), 1.95 (m, 2H), 1.65 (1, 8H), 1.23 (m, 6H), 0.95 (m, 5H).

The following compounds were synthesized in a similar manner:

No. IUPAC [M + H]⁺ ¹H NMR B11 N-[(2 R)-3-{[(6-chloro-1,2,3,4- 501 tetrahydroisoquinolin-2- yl)sulfonyl]amino}-2-methylpropyl]- 4-(dimethylamino)benzene-1- sulfonamide A90 4-{[(3S)-9-(cyclohexylmethyl)-3- 674 methyl-5-{[(3S)-3-phenylpyrrolidin- 1-yl]sulfonyl}-1,5,9- triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline A91 4-{[(3S)-9-(cyclohexylmethyl)-3- 674 methyl-5-{[(3 R)-3-phenylpyrrolidin- 1-yl]sulfonyl}-1,5,9- triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline A92 4-{[(3S)-9-(cyclohexylmethyl)-3- 704 methyl-5-[(4-phenoxypiperidin-1- yl)sulfonyl]-1,5,9- triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline A93 4-{[(3S)-9-(cyclohexylmethyl)-3- 691 methyl-5-{[4-(pyrimidin-2- yl)piperazin-1-yl]sulfonyl}-1,5,9- triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline A94 4-{[(3S)-9-(cyclohexylmethyl)-5- 707 {[4-(2-fluorophenyl)piperazin-1- yl]sulfonyl}-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline A95 4-{[(3S)-9-(cyclohexylmethyl)-5- 707 {[4-(3-fluorophenyl)piperazin-1- yl]sulfonyl}-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline A96 4-{[(3S)-9-(cyclohexylmethyl)-5- 707 {[4-(4-fluorophenyl)piperazin-1- yl]sulfonyl}-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline A97 4-{[(3S)-9-(cyclohexylmethyl)-3- 703 methyl-5-{[4-(2- methylphenyl)piperazin-1- yl]sulfonyl}-1,5,9- triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline A98 4-{[(3S)-9-(cyclohexylmethyl)-3- 703 methyl-5-{[4-(3- methylphenyl)piperazin-1- yl]sulfonyl}-1,5,9- triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline A99 4-{[(3S)-9-(cyclohexylmethyl)-3- 703 methyl-5-{[4-(4- methylphenyl)piperazin-1- yl]sulfonyl}-1,5,9- triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline A100 4-{[(3S)-5-[(4-benzoylpiperazin-1- 717 yl)sulfonyl]-9-(cyclohexylmethyl)-3- methyl-1,5,9-triazacyclododecan- 1-yl]sulfonyl}-N,N-dimethylaniline A101 4-{[(3S)-9-(cyclohexylmethyl)-3- 660 methyl-5-[(3-phenylazetidin-1- yl)sulfonyl]-1,5,9- triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline A102 4-{[(3S)-9-(cyclohexylmethyl)-5- 721 {[4-(4-fluoro-2- methylphenyl)piperazin-1- yl]sulfonyl}-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline A76 4-{[(3 R)-9-(cyclohexylmethyl)-3- 688 ¹H NMR (400 MHz, CDCl₃): δ methyl-5-[(4-phenylpiperidin-1- 7.60 (d, J = 8.8 Hz, 2H), 7.33 (m, yl)sulfonyl]-1,5,9- 5H), 6.82 (d, J = 8.8 Hz, 2H), triazacyclododecan-1-yl]sulfonyl}- 3.77 (m, 4H), 3.28 (m, 1H), 3.18 N,N-dimethylaniline (m, 3H), 3.05 (s, 6H), 2.88 (m, 4H), 2.61 (m, 1H), 2.41 (m, 1H), 2.21 (m, 4H), 2.01 (m, 3H), 1.85 (m, 8H), 1.25 (m, 6H), 0.93 (m, 3H), 0.82 (m, 4H). A77 4-{[(3S)-9-(cyclohexylmethyl)-3- 688 ¹H NMR (400 MHz, CDCl₃): δ methyl-5-[(4-phenylpiperidin-1- 7.60 (d, J = 8.8 Hz, 2H), 7.33 yl)sulfonyl]-1,5,9- (m, 5H), 6.82 (d, J = 8.8 Hz, 2H), triazacyclododecan-1-yl]sulfonyl}- 3.77 (m, 4H), 3.28 (m, 1H), 3.18 N,N-dimethylaniline (m, 3H), 3.05 (s, 6H), 2.88 (m, 4H), 2.61 (m, 1H), 2.41 (m, 1H), 2.21 (m, 4H), 2.01 (m, 3H), 1.85 (m, 8H), 1.25 (m, 6H), 0.93 (m, 3H), 0.82 (m, 4H).

To a solution of benzylamine (37.7 g, 0.350 mol) in CH₃CN (1 L) were added 3-chloropropan-1-ol (100 g, 1.06 mol) and Na₂CO₃ (131 g, 1.24 mol). The reaction mixture was refluxed for 50 h and then cooled to ambient temperature. The mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (MeOH/DCM=1:99 to 3:97) to provide 3,3′-(benzylazanediyl)dipropan-1-ol. ¹H NMR (400 MHz, CDCl₃): δ 7.34 (m, 5H), 3.70 (m, 4H), 3.61 (s, 2H), 3.48 (s, 2H), 2.68 (m, 4H), 1.78 (m, 4H).

To a solution of 3,3′-(benzylazanediyl)dipropan-1-ol (55 g) in MeOH (500 mL) was added Pd/C (10 g). The mixture was hydrogenated at ambient temperature under 15 kg pressure for 6 h. The mixture was filtered and the filtrate was concentrated to provide 3,3′-azanediyldipropan-1-ol. ¹H NMR (400 MHz, CDCl₃): δ 3.78 (m, 4H), 3.46 (s, 2H), 2.84 (m, 4H), 1.75 (m, 4H).

To a solution of 3,3′-azanediyldipropan-1-ol (15 g, 113 mmol) in DCM (300 mL) were added cyclohexanecarbaldehyde (18.8 g, 141 mmol) and NaBH(OAc)₃ (72.5 g, 0.34 mol). The mixture was stirred for 0.5 h and HOAc (20.4 g, 0.34 mol) was added. The reaction mixture was stirred at ambient temperature overnight. The mixture was quenched with water (150 mL) and then adjusted to pH=12 with NaOH. The organic layer was separated, dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography on silica gel (MeOH/DCM=3:97 to 1:9) to provide 3,3′-((cyclohexylmethyl)azanediyl)bis(propan-1-ol). ¹H NMR (400 MHz, CDCl₃): δ 3.75 (m, 4H), 2.64 (m, 4H), 2.18 (m, 2H), 1.75 (m, 9H), 1.55 (m, 1H), 1.21 (m, 3H), 0.89 (m, 1H).

To a solution of compound 3,3′-((cyclohexylmethyl)azanediyl)bis(propan-1-ol) (1.2 g, 5.2 mmol) and TEA (1.0 g, 10.4 mmol) in DCM (15 mL) was added MsCl (1.18 g, 10.4 mmol) at 0° C. The reaction mixture was stirred for 4 h and then quenched with water (15 mL). The DCM layer was separated, dried over anhydrous sodium sulfate and concentrated to provide compound ((cyclohexylmethyl)azanediyl)bis(propane-3,1-diyl) dimethanesulfonate. The dimesylate was used immediately without further purification.

To a solution of propane-1,3-diamine (100 g, 1.35 mol) in THF (800 mL) was added a solution of Boc₂O (73.6 g, 0.34 mol) in THF (200 mL) at 0˜10° C. The reaction mixture was stirred for 3 h and water (1 L) was added. The resulting mixture was extracted with ethyl acetate (500 mL×2). The organic layers were combined and concentrated to a volume of 400 mL. Hexane (300 mL) was added and to the resulting solution was added 15% aqueous oxalic acid (1 L). The mixture was stirred for 0.5 h. The organic layer was decanted and the aqueous layer was adjusted to pH=10 with 3N aqueous NaOH. The resulting mixture was extracted with DCM (600 mL×2). The combined extracts were dried over anhydrous sodium sulfate and concentrated to provide tert-Butyl 3-aminopropylcarbamate. ¹H NMR (400 MHz, CDCl₃): δ 5.03 (br s, 1H), 3.23 (br s, 2H), 2.69 (m, 2H), 1.71 (m, 2H), 1.44 (s, 9H).

Triethylamine (4.70 g, 46.5 mmol) was added dropwise to a stirred mixture of benzyl 3-bromopropylcarbamate (4.2 g, 15.5 mmol) to provide tert-Butyl 3-aminopropylcarbamate (2.7 g, 15.5 mmol) in DMF (50 mL) at ambient temperature. The reaction mixture was heated at 70° C. for 1 h. The majority of DMF was removed under vacuum and the remaining mixture was diluted with water (120 mL) and washed with ether (150 mL×4) to remove most of the dialkylated by-product. The aqueous layer was adjusted to pH=11 with 1N aqueous NaOH and extracted with ether (200 mL). The extract was washed with water (150 mL×3) to remove unreacted tert-Butyl 3-aminopropylcarbamate, dried with anhydrous sodium sulfate and concentrated to provide tert-butyl (3-((3-(((benzyloxy)carbonyl)amino)propyl)amino)propyl)carbamate. ¹H NMR (400 MHz, CDCl₃): δ 7.36 (m, 5H), 5.60 (br s, 1H), 5.11 (m, 3H), 3.30 (m, 2H), 3.20 (m, 2H), 2.68 (m, 4H), 1.70 (m, 5H), 1.44 (s, 9H).

To a solution of tert-butyl (3-((3-(((benzyloxy)carbonyl)amino)propyl)amino)propyl)carbamate (100 mg, 0.27 mmol) in DCM (5 mL) was added cyclohexanecarbaldehyde (31 mg, 0.27 mmol) and HOAc (30 mg, 1.1 mmol). The mixture was stirred for 0.5 h and NaBH(OAc)₃ (235 g, 1.1 mmol) was added in one portion. The reaction mixture was stirred for 4 h. TLC analysis showed 50% conversion and another portion of cyclohexane carbaldehyde (15 mg, 0.13 mmol) was added. The reaction mixture was stirred overnight at ambient temperature. Water (10 mL) was added to quench the reaction and the mixture was adjusted to pH=2 by addition of HOAc. The mixture was stirred for another 0.5 h and then adjusted to pH=12 with aqueous NaOH (1N). The organic layer was separated and concentrated to provide tert-butyl (3-((3 (((benzyloxy)carbonyl)amino)propyl)(cyclohexylmethyl)amino)propyl)carbamate. ¹H NMR (400 MHz, CDCl₃): δ 7.27 (m, 5H), 6.12 (br s, 1H), 5.55 (br s, 1H), 5.01 (s, 3H), 3.34 (m, 2H), 3.18 (m, 2H), 3.08 (m, 2H), 2.80 (m, 4H), 1.65 (m, 9H), 1.44 (s, 9H), 1.12 (m, 6H).

To a solution of tert-butyl (3-((3-(((benzyloxy)carbonyl)amino)propyl) (cyclohexylmethyl)amino)propyl)carbamate (0.50 g, 1.1 mmol) in MeOH (5 mL) was added Pd/C (0.1 g). The mixture was hydrogenated under 15 psi pressure for 3 h. The mixture was filtered and the filtrate was concentrated to provide tert-butyl (3-((3-aminopropyl)(cyclohexylmethyl)amino)propyl)carbamate. ¹H NMR (400 MHz, CDCl₃): δ 5.78 (br s, 1H), 3.19 (br s, 2H), 2.78 (m, 2H), 2.40 (m, 4H), 2.13 (m, 2H), 1.98 (br s, 2H), 1.67 (m, 9H), 1.44 (s, 9H), 1.12 (m, 4H), 0.89 (m, 2H).

To a solution of tert-butyl (3-((3-aminopropyl)(cyclohexylmethyl)amino)propyl) carbamate (1.2 g, 3.7 mmol) in CH₃CN (10 mL) was added 3-methyl-1-(4-phenylpiperidin-1-ylsulfonyl)-1H-imidazol-3-ium (1.47 g, 3.7 mmol). The reaction mixture was stirred at ambient temperature overnight. The solvent was removed and the residue was purified by column chromatography on silica gel to provide tert-butyl 3-((cyclohexylmethyl)(3-(4-phenylpiperidine-1-sulfonamido)propyl) amino)propylcarbamate.

To a solution of tert-butyl 3-((cyclohexylmethyl)(3-(4-phenylpiperidine-1-sulfonamido)propyl) amino)propylcarbamate (0.85 g, 1.5 mmol) in DCM (15 mL) was added TFA (10 mL). The reaction mixture was stirred at ambient temperature for 3 h. The solvent was removed and the residue was dissolved in DCM (50 mL). The solution was basified with 1N aqueous NaOH. The DCM layer was dried over anhydrous Na₂SO₄ and concentrated to provide N-(3-((3-aminopropyl)(cyclohexylmethyl)amino)propyl)-4-phenylpiperidine-1-sulfonamide.

To a solution of N-(3-((3-aminopropyl)(cyclohexylmethyl)amino)propyl)-4-phenylpiperidine-1-sulfonamide (90 mg, 0.20 mmol) in DCM (5 mL) was added TEA (40 mg, 0.4 mmol). The mixture was cooled 0° C. and a solution of 4-(dimethylamino)-2,6-difluorobenzene-1-sulfonyl chloride (60 mg, 0.24 mmol) in DCM (1 mL) was added. The reaction mixture was stirred at ambient temperature for 2 h. The mixture was diluted with DCM (30 mL) and then washed with water (20 mL). The organic layer was dried over anhydrous Na₂SO₄ and concentrated. The residue was purified by column chromatography on silica gel to provide N-(3-((cyclohexylmethyl)(3-(4-(dimethylamino)phenylsulfonamido)propyl) amino)propyl)-4-phenylpiperidine-1-sulfonamide.

To a solution of N-(3-((cyclohexylmethyl)(3-(4-(dimethylamino)phenylsulfonamido)propyl) amino)propyl)-4-phenylpiperidine-1-sulfonamide (80 mg, 0.123 mmol) in NMP (2 mL) was added NaH (12 mg, 0.29 mmoL). The mixture was heated at 80° C. for 0.5 h. The mixture was cooled to ambient temperature and a solution of 3-chloro-2-(chloromethyl)prop-1-ene (15 mg, 0.12 mmol) in NMP (0.1 mL) was added. The reaction mixture was heated at 80° C. for 2 h. The mixture was cooled to ambient temperature and water (20 mL) was added. The resulting mixture was extracted with ethyl acetate (15 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography on silica gel (ethyl acetate/hexane=10:30 to 20:10) to provide compound A86. MS(EI) for C₃₆H₅₃F₂N₅O₄S₂, found 733 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.31 (m, 5H), 6.18 (m, 2H), 5.25 (m, 2H), 4.05 (s, 2H), 3.87 (m, 4H), 3.20 (m, 4H), 3.05 (s, 6H), 2.88 (m, 2H), 2.41 (m, 4H), 2.05 (m, 5H), 1.75 (m, 9H), 1.27 (m, 6H), 0.85 (m, 2H).

To a solution of 3,5-difluoro-4-iodo-N,N-dimethylaniline (500 mg, 1.77 mmol) in ether (5 mL) was added dropwise n-BuLi (0.71 mL, 1.77 mmol) at −78° C. The mixture was stirred for 0.5 h at −78° C. Sulfuryl dichloride (358 mg, 1.5 mmol) was added. The reaction mixture was stirred for another 0.5 h. The mixture was quenched with water (10 mL) and then extracted with ethyl acetate (15 mL). The organic layer was dried over anhydrous Na₂SO₄ and concentrated. The residue was purified by column chromatography on silica gel to provide the crude product, which was further recrystallized from hexane/EtOAc (10:1) to provide 4-(dimethylamino)-2,6-difluorobenzene-1-sulfonyl chloride. ¹H NMR (400 MHz, CDCl₃): δ 6.21 (s, 1H), 6.18 (s, 1H), 3.09 (s, 6H).

To a suspension of 1, 3-dichloropropan-2-one (5.0 g, 39.5 mmol) in H₂O (50 mL) was added O-methylhydroxylamine hydrochloride (3.5 g, 41.5 mmol) and the reaction mixture was stirred at ambient temperature for 1 h. The organic layer was separated, diluted with ether and concentrated under vacuum (<30° C.) to provide 1,3-dichloropropan-2-one O-methyl oxime. H NMR (400 MHz, CDCl₃): δ 4.33 (s, 2H), 4.27 (s, 2H), 3.94 (s, 3H).

To (S)-6-chloro-N-(3-((4-(dimethylamino)phenyl)sulfonamido)-2-methylpropyl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide (100.0 mg, 0.200 mmol) in dry NMP (3 mL) at 0° C. was added NaH (24.0 mg, 0.600 mmol) and the mixture was stirred at ambient temp for 20 min and turned from a cloudy mixture to nearly transparent during this time. Iodomethane (27 μL, 0.440 mmol) was added and the mixture was allowed to stir at ambient temp for 1 h and did not progress past 50% completion, so the same amount of NaH and methyl iodide was added again and the reaction was complete after an additional hour at ambient temp. Brine (10 mL) and EA (10 mL) was added. The aqueous layer was extracted with EA (1×5 mL) and the organics were combined, washed with brine (3×10 mL), dried with sodium sulfate, filtered and concentrated. FCC (hexanes/EA 0-70%) provided compound B12. MS(EI) for C₂₃H₃₃ClN₄O₄S₂, found 529 [M+H]⁺.

To a solution of methyl methacrylate (300 g, 3.0 mol) in MeOH (1.5 L) was added (S)-1-phenylethanamine (363 g, 3 mol). The reaction mixture was refluxed for 5 days. The mixture was concentrated and the residue was purified by column chromatography on silica gel (EtOAc/Petroleum ether=1:9 to 1:1) to provide methyl 2-methyl-3-((S)-1-phenylethylamino)propanoate. ¹H NMR (400 MHz, CDCl₃): δ 7.25 (m, 5H), 3.75 (m, 1H), 3.69 (s, 3H), 2.75 (m, 3H), 1.39 (m, 1H), 1.28 (m, 3H), 1.09 (m, 3H).

To a solution of 2-methyl-3-((S)-1-phenylethylamino)propanoate (440 g, 1.99 mol) in acetone (6 L) was added TsOH—H₂O (378 g, 1.99 mol). The mixture was stirred at ambient temperature for 1 h. The precipitated solid was collected by filtration and dried to provide a salt (300 g) which was suspended in acetone (2 L) and refluxed for 1 h. The mixture was cooled to ambient temperature and the resulting precipitate was collected by filtration to provide a salt which was suspended in DCM (2 L) and saturated aqueous K₂CO₃ (1.5 L). The mixture was stirred for 0.5 h and the solid was dissolved. The DCM layer was separated, dried over anhydrous Na₂SO₄ and concentrated to provide (R)-methyl 2-methyl-3-((S)-1-phenylethylamino)propanoate.

To a solution of (R)-methyl 2-methyl-3-((S)-1-phenylethylamino)propanoate (140 g, 0.630 mol) in MeOH (1.4 L) were added HOAc (30 mL) and Pd/C (15 g). The mixture was hydrogenated under 20 kg pressure at 60° C. for 6 h. The catalyst was removed by filtration and the filtrate was concentrated to provide (R)-methyl 3-amino-2-methylpropanoate. ¹H NMR (400 MHz, CDCl₃): δ 5.09 (br, 3H), 3.72 (s, 3H), 3.05 (m, 1H), 2.93 (m, 1H), 2.75 (m, 1H), 1.23 (d, J=7.2 Hz, 3H).

To a solution of (R)-methyl 3-amino-2-methylpropanoate (112 g, 0.63 mol) in dichloromethane (1 L) were added TEA (160 g, 1.58 mol) and Boc₂O (152 g, 0.69 mol) at 0˜5° C. The reaction mixture was allowed to warm to ambient temperature and stirred overnight. The mixture was washed with water (1 L), 2N aqueous HCl (1 L) and saturated aqueous NaHCO₃ (1 L), respectively. The organic layer was dried over anhydrous Na₂SO₄ and concentrated. The residue was purified by column chromatography on silica gel to provide (R)-methyl 3-(tert-butoxycarbonylamino)-2-methylpropanoate. ¹H NMR (400 MHz, CDCl₃): δ 4.94 (br s, 1H), 3.70 (s, 3H), 3.31 (m, 2H), 2.70 (m, 1H), 1.52 (s, 9H), 1.18 (d, J=7.2 Hz, 3H).

To a solution of (R)-methyl 3-(tert-butoxycarbonylamino)-2-methylpropanoate (6 g, 51.3 mmol) in THF (60 mL) was added LiBH₄ (1.12 g, 102 mmol). The reaction mixture was stirred overnight at ambient temperature. The mixture was quenched with water (30 mL) followed by addition of 1N aqueous HCl to adjust pH=2˜3. The resulting mixture was extracted with ethyl acetate and the extract was washed with saturated aqueous NaHCO₃, dried over anhydrous Na₂SO₄ and concentrated to provide (R)-tert-Butyl 3-hydroxy-2-methylpropylcarbamate. ¹H NMR (400 MHz, CDCl₃): δ 3.57 (m, 1H), 3.37 (m, 2H), 3.05 (m, 1H), 1.77 (m, 1H), 1.48 (s, 9H), 0.88 (d, J=7.2 Hz, 3H).

To a solution of (R)-tert-Butyl 3-hydroxy-2-methylpropylcarbamate (2.5 g, 13.2 mmol) in toluene (25 mL) were added PPh₃ (4.15 g, 15.8 mmol) and isoindoline-1,3-dione (2.72 g, 18.5 mmol). The mixture was cooled to 0˜5° C. and DIAD (3.2 g, 15.8 mmol) was added dropwise. The reaction mixture was stirred at ambient temperature for 3 h. The precipitated solid was filtered off and the filtrate was concentrated. The residue was purified by column chromatography on silica gel (EtOAc/Petroleum ether=1:9 to 1:1) to provide (R)-tert-Butyl 3-(1,3-dioxoisoindolin-2-yl)-2-methylpropylcarbamate. ¹H NMR (400 MHz, CDCl₃): δ 7.85 (m, 2H), 7.47 (m, 2H), 5.23 (br s, 1H), 3.64 (m, 2H), 3.03 (br s, 2H), 2.13 (m, 1H), 1.43 (s, 9H), 0.96 (d, J=6.4 Hz, 3H).

To a solution of (R)-tert-Butyl 3-(1,3-dioxoisoindolin-2-yl)-2-methylpropylcarbamate (40 g, 8.83 mmol) in MeOH (200 mL) was added methylamine solution (7.8 g, 30% in MeOH). The reaction mixture was heated at 60° C. for 6 h. The solvent was removed under reduced pressure. The residue was suspended in ether (300 mL) and then stirred for 0.5 h. The solid was filtered off and the filtrate was concentrated under reduced pressure to provide (S)-tert-Butyl 3-amino-2-methylpropylcarbamate.

To a solution of (S)-tert-Butyl 3-amino-2-methylpropylcarbamate (12.5 g, 66.5 mmol) in DCM (250 mL) was added TEA (10.3 g, 101.7 mmol). The mixture was cooled to 0˜5° C. and 4-(dimethylamino) benzene-1-sulfonyl chloride (16 g, 72 mmol) was added. The reaction mixture was stirred at ambient temperature for 3 h. The mixture was washed with water and the organic phase was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (EtOAc/Petroleum ether=1:9 to 3:7) to provide (R)-tert-Butyl 3-(4-(dimethylamino)phenylsulfonamido)-2-methylpropylcarbamate. ¹H NMR (400 MHz, CDCl₃): δ 7.70 (d, J=8.8 Hz, 2H), 6.71 (d, J=8.8 Hz, 2H), 5.45 (m, 1H), 4.72 (m, 1H), 3.18 (m, 1H), 3.04 (s, 6H), 2.98 (m, 2H), 2.75 (m, 1H), 1.78 (m, 1H), 1.41 (s, 9H), 0.87 (m, J=6.8 Hz, 3H).

To a solution of (R)-tert-Butyl 3-(4-(dimethylamino)phenylsulfonamido)-2-methylpropylcarbamate (21 g, 59.3 mmol) in MeOH (150 mL) was added 4N HCl/MeOH (150 mL). The mixture was stirred for 3 h at ambient temperature. The solvent was removed under reduced pressure. The resulting solid was suspended in DCM (200 mL) and saturated aqueous K₂CO₃ (150 mL) was added. The mixture was stirred for 5 min and the organic layer was separated, dried over anhydrous Na₂SO₄, and concentrated to provide compound (R)—N-(3-amino-2-methylpropyl)-4-(dimethylamino)benzenesulfonamide. ¹H NMR (400 MHz, CDCl₃): δ 7.70 (d, J=8.8 Hz, 2H), 6.68 (d, J=8.8 Hz, 2H), 3.04 (s, 6H), 2.98 (m, 1H), 2.75 (m, 2H), 2.58 (m, 1H), 1.78 (m, 2H), 0.87 (m, J=7.2 Hz, 3H).

Using a similar method (S)—N-(3-amino-2-methylpropyl)-4-(dimethylamino)benzenesulfonamide was synthesized (Intermediate for compound A76).

To 6-chloro-N-((R)-3-((4-(dimethylamino)phenyl)sulfonamido)-2-methylpropyl)-1,2,3,4-tetrahydronaphthalene-2-sulfonamide (100 mg, 200 μM) in dry NMP (4 mL) at 0° C. was added NaH (24 mg, 600 μmol) and the mixture was stirred at ambient temp for 20 min over which time it turned from a cloudy mixture to nearly transparent. The dichloride (21.3 μL, 200 μmol) was added and the mixture was heated to 80° C. After 40 min the reaction was quenched with brine and the aqueous layer was extracted with ethyl acetate (2×), the combined organics were washed with brine (3×), dried with sodium sulfate, filtered, and concentrated. Column chromatography (0-50% hexanes+1% diethylamine)/ethyl acetate) provided the product (compound B21). MS(EI) for C₂₅H₃₅ClN₄O₄S₂, found 555 [M+H]⁺.

To a solution of 1-(4-fluoro-2-methoxyphenyl)piperazine (1.4 g, 6.8 mmol) in CH₃CN (15 mL) was added 1-(1H-imidazol-1-ylsulfonyl)-3-methyl-1H-imidazol-3-ium trifluoromethanesulfonate (2.7 g, 6.8 mmol). The reaction mixture was stirred at ambient temperature overnight. The mixture was then concentrated and the residue was purified by column chromatography to provide 1-((1H-imidazol-1-yl)sulfonyl)-4-(4-fluoro-2-methoxyphenyl)piperazine.

To a solution of 1-((1H-imidazol-1-yl)sulfonyl)-4-(4-fluoro-2-methoxyphenyl)piperazin (0.92 g, 2.7 mmol) in DCM (10 mL) was added CF₃SO₃Me (0.45 g, 2.7 mmol) at 0° C. The reaction mixture was stirred at ambient temperature for 5 h then concentrated and the resulting product was washed with ether to provide 1-((4-(4-fluoro-2-methoxyphenyl)piperazin-1-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium trifluoromethanesulfonate.

To a solution of (R)—N-(3-amino-2-methylpropyl)-4-(dimethylamino)benzenesulfonamide (0.6 g, 2.2 mmol) in CH₃CN (6 mL) was added 1-((4-(4-fluoro-2-methoxyphenyl)piperazin-1-yl)sulfonyl)-3-methyl-1H-imidazol-3-ium trifluoromethanesulfonate (1.1 g, 2.2 mmol). The reaction mixture was stirred at ambient temperature overnight. The mixture was concentrated and the residue was purified by column chromatography to provide (S)—N-(3-((4-(dimethylamino)phenyl)sulfonamido)-2-methylpropyl)-4-(4-fluoro-2-methoxyphenyl)piperazine-1-sulfonamide.

To a solution of (S)—N-(3-((4-(dimethylamino)phenyl)sulfonamido)-2-methylpropyl)-4-(4-fluoro-2-methoxyphenyl)piperazine-1-sulfonamide (771 mg, 1.42 mmol) in NMP (7 mL) was added NaH (140 mg, 3.48 mmol, 60%). The mixture was stirred for 0.5 h at 80° C. The mixture was cooled to 70° C. and ((cyclohexylmethyl)azanediyl)bis(propane-3,1-diyl) dimethanesulfonate (820 mg, 2.1 mmol) was added. The reaction mixture was stirred for 2 h at 70° C. then cooled and poured into water. The resulting mixture was extracted with ethyl acetate. The extract was concentrated and the residue was purified by column chromatography (petroleum ether/EtOAc=10:1) to provide compound A137. MS (EI) for C₃₆H₅₇FN₆O₅S₂, found 737 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.62 (d, J=8.8 Hz, 2H), 7.16 (m, 2H), 7.05 (m, 1H), 6.86 (d, J=8.8 Hz, 2H), 4.35 (m, 2H), 3.62 (m, 4H), 3.19 (m, 2H), 3.04 (s, 6H), 2.87 (m 4H), 2.46 (m, 5H), 1.92 (m, 1H), 1.79 (m, 2H), 1.66 (m, 4H).

The following compounds were synthesized in a similar manner:

No. IUPAC [M + H]⁺ A153 tert-butyl 4-{[(3S)-9-(cyclohexylmethyl)-5-[4- 714 (dimethylamino)benzenesulfonyl]-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}piperazine-1-carboxylate A118 2-(4-{[(3S)-9-(cyclohexylmethyl)-5-[4- 715 (dimethylamino)benzenesulfonyl]-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}piperazin-1-yl)benzonitrile A154 4-{[(3S)-9-(cyclohexylmethyl)-5-{[4-(2-methoxyphenyl)piperazin- 720 1-yl]sulfonyl}-3-methyl-1,5,9-triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline A155 4-{[(3S)-9-(cyclohexylmethyl)-3-methyl-5-(piperazine-1-sulfonyl)- 613 1,5,9-triazacyclododecan-1-yl]sulfonyl}-N, N-dimethylaniline A119 4-{[(3S)-9-(cyclohexylmethyl)-5-{[4-(2,6- 717 dimethylphenyl)piperazin-1-yl]sulfonyl}-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline A136 4-{[(3S)-9-(cyclohexylmethyl)-5-[(6-ethyl-1,2,3,4- 688 tetrahydroisoquinolin-2-yl)sulfonyl]-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline A161 4-{[(3S)-9-(cyclohexylmethyl)-5-{[6-(4-fluoro-2-methylphenyl)- 733 2,6-diazaspiro[3.3]heptan-2-yl]sulfonyl}-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline A162 4-{[(3S)-9-(cyclohexylmethyl)-5-{[(2 S)-4-(4-fluoro-2- 735 methylphenyl)-2-methylpiperazin-1-yl]sulfonyl}-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline A163 4-{[(3S)-9-(cyclohexylmethyl)-5-{[(2 R)-4-(4-fluoro-2- 735 methylphenyl)-2-methylpiperazin-1-yl]sulfonyl}-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline A166 4-{[(3S)-9-(cyclohexylmethyl)-3-methyl-5-[(5-methyl-1,2,3,4- 674 tetrahydroisoquinolin-2-yl)sulfonyl]-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A138 4-{[(3S)-9-(cyclohexylmethyl)-5-[(5-methoxy-1,2,3,4- 690 tetrahydroisoquinolin-2-yl)sulfonyl]-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline A151 2-{[(3S)-9-(cyclohexylmethyl)-5-[4- 685 (dimethylamino)benzenesulfonyl]-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}-1,2,3,4-tetrahydroisoquinoline- 5-carbonitrile A170 4-{[(3S)-9-(cyclohexylmethyl)-3-methyl-5-[(1-methyl-1,2,3,4- 674 tetrahydroisoquinolin-2-yl]sulfonyl]-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A172 4-{[(3S)-9-(cyclohexylmethyl)-3-methyl-5-[(3-methyl-1,2,3,4- 674 tetrahydroisoquinolin-2-yl]sulfonyl]-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A173 4-{[(3S)-9-(cyclohexylmethyl)-3-methyl-5-({4-[2- 773 (trifluoromethoxy)phenyl]piperazin-1-yl}sulfonyl)-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline A174 4-{[(3S)-9-(cyclohexylmethyl)-5-{[4-(3,4-difluoro-2- 755 methoxyphenyl)piperazin-1-yl]sulfonyl}-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline A175 4-{[(3S)-9-(cyclohexylmethyl)-5-{[4-(3-fluoro-2- 737 methoxyphenyl)piperazin-1-yl]sulfonyl}-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline A176 4-{[(3S)-9-(cyclohexylmethyl)-5-{[4-(5-fluoro-2- 737 methoxyphenyl)piperazin-1-yl]sulfonyl}-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline A177 4-{[(3S)-9-(cyclohexylmethyl)-5-{[(3 R)-4-(4-fluoro-2- 751 methoxyphenyl)-3-methylpiperazin-1-yl]sulfonyl}-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline A178 4-{[(3S)-9-(cyclohexylmethyl)-5-{[3-(4-fluoro-2- 708 methoxyphenyl)azetidin-1-yl]sulfonyl}-3-methyl-1,5,9 - triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline A181 4-{[(3S)-5-[(5-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]- 694 9-(cyclohexylmethyl)-3-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A187 (3S)-N-benzyl-9-(cyclohexylmethyl)-5-[4- 634 (dimethylamino)benzenesulfonyl]-3-methyl-1,5,9- triazacyclododecane-1-sulfonamide A198 4-{[(3S)-5-{[4-(2-chlorophenyl)piperazin-1-yl]sulfonyl}-9- 723 (cyclohexylmethyl)-3-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A199 4-{[(3S)-9-(cyclohexylmethyl)-5-{[4-(4-methoxyphenyl)piperazin- 719 1-yl]sulfonyl}-3-methyl-1,5,9-triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline A201 4-{[(3S)-9-(cyclohexylmethyl)-5-{[4-(3-methoxyphenyl)piperazin- 719 1-yl]sulfonyl}-3-methyl-1,5,9-triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline A202 4-{[(3S)-9-(cyclohexylmethyl)-5-{[4-(3-fluoro-4- 737 methoxyphenyl)piperazin-1-yl]sulfonyl}-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline A206 4-{[(3S)-5-{[4-(2-chloro-4-fluorophenyl)piperazin-1-yl]sulfonyl}-9- 741 (cyclohexylmethyl)-3-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A147 4-{[(4 S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]- 694 9-(cyclohexylmethyl)-4-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A148 4-{[(4 R)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]- 694 9-(cyclohexylmethyl)-4-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A150 4-{[(2 S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]- 694 9-(cyclohexylmethyl)-2-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A149 4-{[(2 R)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]- 694 9-(cyclohexylmethyl)-2-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A190 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]- 708 9-[(1 S)-1-cyclohexylethyl]-3-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A191 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]- 708 9-[(1 R)-1-cyclohexylethyl]-3-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A207 4-{[(3S)-9-[(1 S)-1-cyclohexylethyl]-5-{[(3 R)-4-(4-fluoro-2- 765 methoxyphenyl)-3-methylpiperazin-1-yl]sulfonyl}-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline A205 N,N-dimethyl-4-{[(3S)-3-methyl-9-[(1 S)-1-phenylethyl]-5-(1,2,3,4- 668 tetrahydroisoquinoline-2-sulfonyl)-1,5,9-triazacyclododecan-1- yl]sulfonyl}aniline

To a solution of (R)-methyl 2-((tert-butoxycarbonylamino)methyl)butanoate (4.8 g, 20.8 mmol) in THF (50 mL) was added LiBH₄ (0.7 g, 33 mmol). The reaction mixture was stirred overnight at ambient temperature. The mixture was quenched with water (30 mL) followed by addition of 1N aqueous HCl dropwise to adjust to pH=2˜3. The resulting mixture was extracted with ethyl acetate and the extract was washed with saturated aqueous NaHCO₃, dried over anhydrous sodium sulfate, and concentrated to provide (R)-tert-butyl 2-(hydroxymethyl)butylcarbamate.

To a solution of (R)-tert-butyl 2-(hydroxymethyl)butylcarbamate (3.4 g, 16.7 mmol) in toluene (40 mL) was added PPh₃ (6.2 g, 17.4 mmol) and isoindoline-1,3-dione (3.7 g, 25 mmol). The mixture was cooled to 0˜5° C. and DIAD (4.3 g, 22 mmol) was added dropwise. The reaction mixture was stirred at ambient temperature for 3 h. The resulting precipitate was filtered and the filtrate was concentrated. The residue was purified by column chromatography (petroleum ether/EtOAc=9:1 to 1:1) to provide 1-(4-fluoro-2-methoxyphenyl)-4-(2-methyl-1H-imidazol-1-ylsulfonyl)piperazine.

To a solution of 1-(4-fluoro-2-methoxyphenyl)-4-(2-methyl-1H-imidazol-1-ylsulfonyl)piperazine (3.8 g, 11.4 mmol) in EtOH (70 mL) was added hydrazine hydrate (1.1 g, 80%). The reaction mixture was refluxed for 6 h. The resulting product was filtered and the filtrate was concentrated under reduced pressure. The residue was dissolved in 1N aqueous NaOH (20 mL) then extracted with DCM (50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated to provide (S)-tert-butyl 2-(aminomethyl)butylcarbamate.

To a solution of (S)-tert-butyl 2-(aminomethyl)butylcarbamate (1.87 g, 9.2 mmol) in DCM (20 mL) was added TEA (1.01 g, 10.1 mol). The mixture was cooled to 0˜5° C. and 4-(dimethylamino)benzene-1-sulfonyl chloride (2.0 g, 9.2 mmol) was added. The reaction mixture was stirred at ambient temperature for 3 h. The mixture was washed with water then concentrated. The residue was purified by column chromatography (petroleum ether/EtOAc=9:1 to 7:3) to provide (R)-tert-butyl 2-((4-(dimethylamino)phenylsulfonamido)methyl) butylcarbamate.

To a solution of (R)-tert-butyl 2-((4-(dimethylamino)phenylsulfonamido)methyl) butylcarbamate (2.9 g, 7.5 mmol) in MeOH (10 mL) was added 4N HCl/MeOH (15 mL). The mixture was stirred for 3 h at ambient temperature. The solvent was removed under reduced pressure. The resulting product was suspended in DCM (100 mL) and saturated aqueous K₂CO₃ (450 mL) was added. The mixture was stirred for 5 min. The DCM layer was separated, dried over anhydrous sodium sulfate, and concentrated to provide (R)—N-(2-(aminomethyl)butyl)-4-(dimethylamino)benzenesulfonamide.

To a solution of (R)—N-(2-(aminomethyl)butyl)-4-(dimethylamino) benzenesulfonamide (0.9 g, 3.2 mmol) in CH₃CN (9 mL) was added 1-((6-chloro-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-2,3-dimethyl-1H-imidazol-3-ium trifluoromethanesulfonate (0.59 g, 3.2 mmol). The reaction mixture was stirred overnight at ambient temperature. The mixture was concentrated and the residue was purified by column chromatography (petroleum ether/EtOAc=8:1 to 2:1) to provide (S)-6-chloro-N-(2-((4-(dimethylamino)phenylsulfonamido)methyl)butyl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide.

To a solution of (S)-6-chloro-N-(2-((4-(dimethylamino)phenylsulfonamido)methyl)butyl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide (0.8 g, 1.5 mmol) in NMP (3 mL) was added NaH (159 mg, 3.9 mmol, 60%). The mixture was stirred for 0.5 h at 80° C. The mixture was cooled to 70° C. and cyclopropane-1,1-diylbis(methylene) dimethanesulfonate (510 mg, 2.0 mmol) was added. The reaction mixture was stirred for 2 h at 70° C. The solvent was removed and the residue was purified by column chromatography (petroleum ether/EtOAc=15:1) to provide compound A182. LC-MS: m/z 708.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.59 (m, 2H), 7.15 (m, 2H), 7.05 (m, 1H), 6.68 (m, 2H), 4.34 (m, 2H), 3.55 (m, 4H), 3.19 (m, 6H), 3.04 (s, 6H), 2.87 (m, 4H), 2.15 (m, 4H), 1.89 (m, 10H), 1.32 (m, 8H), 0.88 (m, 3H).

To benzyl(S)-5-((6-chloro-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-9-((4-(dimethylamino)phenyl)sulfonyl)-7-methyl-1,5,9-triazacyclododecane-1-carboxylate (25 mg) was added HBr (33% in acetic acid, 0.5 mL). After 30 min at ambient temperature the mixture was diluted with diethyl ether and water (1:1 mix, 10 mL) and the organic layer was removed. The aqueous layer was washed with diethyl ether (1×5 mL), basified with NaOH (4 N) to pH 12, then extracted with DCM (3×2 mL). The organics were dried with sodium sulfate, filtered, and concentrated. Addition of hexanes (2 mL) followed by concentration was used to facilitate precipitation of the product. Drying under vacuum provided compound A183. MS(EI) for C₂₇H₄₀ClN₅O₄S₂, found 598 [M+H]⁺.

To a solution of 3,3′-azanediyldipropan-1-ol (1.0 g, 7.5 mmol) in DCM (20 mL) was added isobutyraldehyde (1.22 g, 11.3 mmol). The mixture was stirred for 30 min at ambient temperature. Acetic acid (1.8 g, 30.1 mmol) was added and the mixture was stirred for another 30 min. Sodium triacetoxyborohydride (6.40 g, 30.1 mmol) was then added and the reaction mixture was stirred overnight at ambient temperature. The mixture was adjusted to pH=1-2 with 3N aqueous HCl and then stirred for 1 h. To the mixture was added 20% aqueous NaOH (to adjust pH to 10-11) then it was extracted with DCM (50 mL). The extract was washed with brine, dried over anhydrous sodium sulfate, and concentrated to provide 3,3′-(isobutylazanediyl)bis(propan-1-ol).

To a solution of 3,3′-(isobutylazanediyl)bis(propan-1-ol) (780 mg, 4.1 mmol) in DCM (10 mL) was added NEt₃ (820 mg, 8.2 mmol). MsCl (935 mg, 8.2 mmol) was then added slowly at 0° C. The reaction mixture was stirred for 3 h at ambient temperature. The mixture was diluted with DCM (20 mL) and then washed with water (25 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated to provide 3,3′-(Isobutylazanediyl)bis(propane-3,1-diyl) dimethanesulfonate.

To a solution of (S)-6-chloro-N-(3-((4-(dimethylamino)phenyl)sulfonamido)-2-methylpropyl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide (0.515 g, 1.03 mmol) in dry N-methyl pyrrolidone was added NaH (0.25 g, 2.26 mmol) at ambient temperature. The mixture was heated at 80° C. with stirring for 30 min and then cooled to ambient temperature. 3,3′-(Isobutylazanediyl)bis(propane-3,1-diyl) dimethanesulfonate (0.5 g, 1.5 mmol) was added and the reaction mixture was heated at 80° C. for 2 h. The reaction was quenched with water then extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate and concentrated. The residue was purified by flash column chromatography to afford compound A152. MS (EI) for C₃₁H₄₈ClN₅O₄S₂, found 654.4 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.59 (d, 2H), 7.16 (m, 2H), 7.04 (m, 1H), 6.69 (d, 2H), 4.32 (m, 2H), 3.60 (m, 4H), 3.31 (m, 3H), 3.04 (s, 6H), 2.90 (m, 4H), 2.27 (m, 4H), 1.93 (m, 2H), 1.79 (m, 1H), 0.87 (m, 9H).

The following compounds were synthesized in a similar manner:

No. IUPAC [M + H]⁺ A123 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-3- 668 methyl-9-(3-methylbutyl)-1,5,9-triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline A156 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-3- 702 methyl-9-[(3-methylphenyl)methyl]-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A131 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-3- 702 methyl-9-[(4-methylphenyl)methyl]-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A157 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-9- 680 (cyclopentylmethyl)-3-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A106 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-3- 668 methyl-9-(2-methylbutyl)-1,5,9-triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline A108 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-9- 666 (cyclobutylmethyl)-3-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A134 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-9- 708 (2-cyclohexylethyl)-3-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A122 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-9- 666 (2-cyclopropylethyl)-3-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A120 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-9- 694 (2-cyclopentylethyl)-3-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A165 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-3- 694 methyl-9-(3,3,3-trifluoropropyl)-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A141 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-3- 640 methyl-9-(propan-2-yl)-1,5,9-triazacyclododecan-1-yl]sulfonyl}- N,N-dimethylaniline A176 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-9- 678 [(cyclopent-1-en-1-yl)methyl]-3-methyl-1,5,9-triazacyclododecan- 1-yl]sulfonyl}-N,N-dimethylaniline A135 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-9- 692 [(cyclohex-1-en-1-yl)methyl]-3-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A167 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-3- 680 methyl-9-(2,2,2-trifluoroethyl)-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A169 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-9- 702 [(3,3-difluorocyclobutyl)methyl]-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline A133 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-3- 702 methyl-9-[(2-methylphenyl)methyl]-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A140 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-9- 656 (2-methoxyethyl)-3-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A125 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-3- 679 methyl-9-[(1,3-oxazol-2-yl)methyl]-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A124 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-3- 679 methyl-9-[(1,2-oxazol-3-yl)methyl]-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A183 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-3- 598 methyl-1,5,9-triazacyclododecan-1-yl]sulfonyl}-N,N- dimethylaniline A185 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-9- 730 [(4,4-difluorocyclohexyl)methyl]-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline A107 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-9- 668 (2,2-dimethylpropyl)-3-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A204 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-9- 712 [(4-fluorocyclohexyl)methyl]-3-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline

To a mixture of 4-fluoro-2-methoxyaniline (25.0 g, 177 mmol), K₂CO₃ (36.7 g, 266 mmol) and NaI (10.6 g, 0.07 mmol) in i-PrOH (250 mL) was added bis(2-chloroethyl)amine hydrochloride (47 g, 177 mmol). The reaction mixture was refluxed overnight. The solvent was removed and the residue was purified by column chromatography (petroleum ether/EtOAc=10:1) to provide 1-(4-fluoro-2-methoxyphenyl)piperazine. MS: m/z 212.36 [M+H]⁺.

A solution of 1-(4-fluoro-2-methoxyphenyl)piperazine (4.0 g, 19 mmol) in MeCN (40 mL) was added 2,3-dimethyl-1-(2-methyl-1H-imidazol-1-ylsulfonyl)-1H-imidazol-3-ium (7.5 g, 19 mmol). The reaction mixture was stirred overnight at ambient temperature. The solvent was removed and the residue was purified by column chromatography (petroleum ether/EtOAc=20:1) to provide 1-(4-fluoro-2-methoxyphenyl)-4-(2-methyl-1H-imidazol-1-ylsulfonyl)piperazine. MS: m/z 355.36 [M+H]⁺.

To a solution of 1-(4-fluoro-2-methoxyphenyl)-4-(2-methyl-1H-imidazol-1-ylsulfonyl)piperazine (6.0 g, 17 mmol) in DCM (60 mL) was added CF₃SO₃Me (2.78 g, 17 mmol). The reaction mixture was stirred for 2 h at ambient temperature. The solvent was removed and the residue was washed with ether to provide 1-(4-(4-fluoro-2-methoxyphenyl)piperazin-1-ylsulfonyl)-2,3-dimethyl-1H-imidazol-3-ium trifluoromethanesulfonate.

To a solution of 1-(4-(4-fluoro-2-methoxyphenyl)piperazin-1-ylsulfonyl)-2,3-dimethyl-1H-imidazol-3-ium trifluoromethanesulfonate (740 mg, 2.3 mmol) in CH₃CN (8 mL) was added tert-butyl 3-((3-aminopropyl)(cyclohexylmethyl)amino)propylcarbamate (1.17 g, 2.3 mmol). The reaction mixture was stirred overnight at ambient temperature. The mixture was concentrated and the residue was purified by column chromatography (petroleum ether/EtOAc=8:1 to 2:1) to provide tert-butyl-3-((cyclohexylmethyl)(3-(4-(4-fluoro-2-methoxyphenyl)piperazine-1-sulfonamido)propyl)amino)propylcarbamate.

To a solution of tert-butyl-3-((cyclohexylmethyl)(3-(4-(4-fluoro-2-methoxyphenyl)piperazine-1-sulfonamido)propyl)amino)propylcarbamate (600 mg, 1 mmol) in DCM (30 mL) was added TFA (30 mL). The mixture was stirred for 2 h at ambient temperature. The solvent was removed and the residue was dissolved in ethyl acetate then washed with saturated aqueous NaHCO₃. The organic phase was dried over anhydrous sodium sulfate and concentrated to provide N-(3-((3-aminopropyl)(cyclohexylmethyl)amino)propyl)-4-(4-fluoro-2-methoxy phenyl)piperazine-1-sulfonamide.

To a solution of N-(3-((3-aminopropyl)(cyclohexylmethyl)amino)propyl)-4-(4-fluoro-2-methoxy phenyl)piperazine-1-sulfonamide (416 mg, 0.83 mmol) in DCM (5 mL) was added Et₃N (170 mg, 1.66 mmol) and 4-(dimethylamino)benzenesulfonyl chloride (365 mg, 1.66 mmol). The reaction mixture was stirred overnight at ambient temperature. The mixture was concentrated and purified by column chromatography (petroleum ether/EtOAc=8:1 to 2:1) to provide N-(3-((cyclohexylmethyl)(3-(4-(dimethylamino)phenylsulfonamido)propyl) amino)propyl)-4-(4-fluoro-2-methoxyphenyl)piperazine-1-sulfonamide.

To a solution of N-(3-((cyclohexylmethyl)(3-(4-(dimethylamino)phenylsulfonamido)propyl) amino)propyl)-4-(4-fluoro-2-methoxyphenyl)piperazine-1-sulfonamide (320 mg, 0.45 mmol) in NMP (3 mL) was added NaH (53 mg, 1.32 mmol, 60% dispersion). The mixture was stirred for 0.5 h at 80° C. then cooled to 70° C. and cyclopropane-1,1-diylbis(methylene) dimethanesulfonate (170 mg, 0.66 mmol) was added. The reaction mixture was stirred for 2 h at 70° C. The solvent was removed and the residue was purified by column chromatography (petroleum ether/EtOAc=15:1) to provide compound A193. MS (EI) for C₃₇H₅₇FN₆O₅S₂, found 745.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.57 (t, 2H), 6.64 (t, 1H), 6.63 (br s, 4H), 3.86 (s, 3H), 3.19 (m, 4H), 3.04 (m, 8H), 2.87 (m, 12H), 2.36 (m, 2H), 1.56 (m, 15H), 0.43 (m, 4H).

To a solution of (S)-tert-butyl 3-amino-2-methylpropylcarbamate (4.0 g, 21.3 mmol) in THF (20 mL) and water (20 mL) was added CbzOSu (5.83 g, 23.5 mmol). Aqueous NaOH (4N) was added to adjust to pH=11. The reaction mixture was stirred at ambient temperature for 2 h. The mixture was diluted with water (15 mL) and then extracted with ethyl acetate (50 mL). The organic phase was washed with 1N aqueous HCl, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by column chromatography to provide benzyl tert-butyl (2-methylpropane-1,3-diyl)(S)-dicarbamate.

To a solution of benzyl tert-butyl (2-methylpropane-1,3-diyl)(S)-dicarbamate (4.5 g, 14.0 mmol) in DCM (25 mL) was added TFA (20 mL). The reaction mixture was stirred at ambient temperature for 3 h. The mixture was concentrated and the residue was dissolved in DCM (50 mL). The resulting solution was washed with saturated aqueous K₂CO₃ and the DCM layer was dried over anhydrous sodium sulfate and concentrated to provide (R)-benzyl 3-amino-2-methylpropylcarbamate.

To a solution of (R)-benzyl 3-amino-2-methylpropylcarbamate (2.7 g, 12.2 mmol) in CH₃CN (25 mL) was added 1-(6-chloro-3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)-2,3-dimethyl-1H-imidazol-3-ium (5.7 g, 12.2 mmol). The reaction mixture was stirred at ambient temperature overnight. The mixture was concentrated and the residue was purified by column chromatography to provide (S)-benzyl 3-(6-chloro-1,2,3,4-tetrahydroisoquinoline-2-sulfonamido)-2-methyl propylcarbamate.

(S)-Benzyl 3-(6-chloro-1,2,3,4-tetrahydroisoquinoline-2-sulfonamido)-2-methyl propylcarbamate (2.7 g, 6.0 mmol) was dissolved in HBr (48%)/HOAc (20 mL). The mixture was stirred at ambient temperature for 1 h. The mixture was diluted with water (100 mL) and then washed with ether (50 mL). The aqueous layer was basified with NaOH to pH=10. The resulting mixture was extracted with DCM (100 mL). The DCM layer was dried over anhydrous sodium sulfate and concentrated to provide (S)—N-(3-amino-2-methylpropyl)-6-chloro-3,4-dihydroisoquinoline-2(1H)-sulfonamide.

To a solution of (S)—N-(3-amino-2-methylpropyl)-6-chloro-3,4-dihydroisoquinoline-2(1H)-sulfonamide (0.6 g, 1.9 mmol) and TEA (270 mg, 2.7 mmol) in DCM (6 mL) was added benzo[d]isoxazole-5-sulfonyl chloride (420 mg, 1.9 mmol) at 0° C. The reaction mixture was stirred at ambient temperature for 2 h. The mixture was washed with water and then concentrated. The residue was purified by column chromatography to provide (S)—N-(3-(6-chloro-1,2,3,4-tetrahydroisoquinoline-2-sulfonamido)-2-methylpropyl)benzo[d]isoxazole-5-sulfonamide.

To a solution of (S)—N-(3-(6-chloro-1,2,3,4-tetrahydroisoquinoline-2-sulfonamido)-2-methylpropyl)benzo[d]isoxazole-5-sulfonamide (0.61 g, 1.22 mmol) in NMP (6 mL) was added NaH (122 mg, 3.05 mmol, 60%). The mixture was stirred for 0.5 h at 80° C. The mixture was cooled to 70° C. and 3,3′-(cyclohexylmethylazanediyl)bis(propane-3,1-diyl) dimethanesulfonate (0.74 g, 1.83 mmol) was added. The reaction mixture was stirred for 2 h at 70° C. The mixture was cooled and poured into water. The resulting mixture was extracted with ethyl acetate. The organic phase was concentrated and the residue was purified by column chromatography (petroleum ether/EtOAc=12:1) to provide compound A180. LC-MS (ESI): m/z 692.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.84 (S, 1H), 7.61 (m, 1H), 7.13 (m, 3H), 6.69 (m, 2H), 4.32 (m, 2H), 3.66 (m, 5H), 3.21 (m, 5H), 2.91 (m, 4H), 2.77 (m, 4H), 1.91 (m, 4H), 1.57 (m, 6H), 1.13 (m, 6H), 0.89 (m, 3H).

The following compounds were synthesized in a similar manner:

No. IUPAC [M + H]⁺ A168 3-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-9- 694 (cyclohexylmethyl)-3-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylaniline A171 6-chloro-2-{[(3S)-9-(cyclohexylmethyl)-3-methyl-5- 665 phenylmethanesulfonyl-1,5,9-triazacyclododecan-1-yl]sulfonyl}- 1,2,3,4-tetrahydroisoquinoline A179 4-{[(3S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2-yl)sulfonyl]-9- 722 (cyclohexylmethyl)-3-methyl-1,5,9-triazacyclododecan-1- yl]sulfonyl}-N,N-dimethylbenzamide A184 (3S)-N-benzyl-9-(cyclohexylmethyl)-5-[4- 648 (dimethylamino)benzenesulfonyl]-N,3-dimethyl-1,5,9- triazacyclododecane-1-sulfonamide A188 6-chloro-2-{[(3S)-9-(cyclohexylmethyl)-3-methyl-5-[(1-methyl-1 H- 704 indol-5-yl)sulfonyl]-1,5,9-triazacyclododecan-1-yl]sulfonyl}-1,2,3,4- tetrahydroisoquinoline A189 (3S)-9-(cyclohexylmethyl)-5-[4-(dimethylamino)benzenesulfonyl]- 662 N-[(4-ethylpheny)methyl]-3-methyl-1,5,9-triazacyclododecane-1 - sulfonamide A192 N-{4-[({[(3S)-9-(cyclohexylmethyl)-5-[4- 705 (dimethylamino)benzenesulfonyl]-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}amino)methyl]phenyl}-N- methylacetamide

To a suspension of Mg (4.4 g, 181 mmol) in THF (200 mL) was added 1-bromo-2-methoxybenzene (40 g, 214 mmol). The mixture was stirred at 80° C. for 0.5 h. The mixture was cooled to 0° C. and a solution of tert-butyl 3-oxopiperidine-1-carboxylate (35.5 g, 181 mmol) in THF was added. The reaction mixture was stirred at ambient temperature for 2 h. The residue was purified by column chromatography to provide tert-butyl 3-hydroxy-3-(2-methoxyphenyl)piperidine-1-carboxylate. ¹H NMR (400 MHz, CDCl₃): δ 7.48 (m, 1H), 7.32 (m, 1H), 6.98 (m, 2H), 4.08 (m, 1H), 3.96 (s, 3H), 3.82 (m, 1H), 3.31 (s, 1H), 2.98 (m, 1H), 2.25 (m, 1H), 1.99 (m, 2H), 1.62 (m, 2H), 1.63 (m, 9H).

A solution of tert-butyl 3-hydroxy-3-(2-methoxyphenyl)piperidine-1-carboxylate (23.0 g, 75 mmol) and triethylsilane (44 ml) in DCM (230 mL) was cooled to −30° C. and TFA (27 mL) was added. The reaction mixture was stirred at −30° C. for 2.5 h and then allowed to warm to ambient temperature and stirred for another 3.5 h. The mixture was poured into ice-water and the solution was adjusted to pH=9 with saturated aqueous sodium hydroxide. The resulting mixture was extracted three times with DCM. The combined organic phases were dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography to provide 3-(2-methoxyphenyl)piperidine.

A solution of 3-(2-methoxyphenyl)piperidine (6.5 g, 34 mmol) and D-tartaric acid (5.1 g, 34 mmol) in MeOH (25 mL) was refluxed for 2 h. The mixture was cooled to ambient temperature and filtered to provide the tartrate salt. This tartrate salt was recrystallized twice from MeOH and then treated with aqueous NaOH. The resulting mixture was extracted with DCM. The DCM layer was dried over anhydrous sodium sulfate and concentrated to provide (S)-3-(2-methoxyphenyl)piperidine.

A solution of (S)-3-(2-methoxyphenyl)piperidine (500 mg, 2.6 mmol) and 2,3-dimethyl-1-((2-methyl-1H-imidazol-1-yl)sulfonyl)-1H-imidazol-3-ium trifluromethanesulfonate (1.1 g, 2.7 mmol) in MeCN (15 ml) was stirred overnight at ambient temperature. The solvent was removed. The residue was purified by column chromatography (petroleum ether/EtOAc=20:1) to provide (S)-3-(2-methoxyphenyl)-1-((2-methyl-1H-imidazol-1-yl)sulfonyl)piperidine. LC-MS (ESI): m/z 336.06 [M+H]⁺.

To a solution of (S)-3-(2-methoxyphenyl)-1-((2-methyl-1H-imidazol-1-yl)sulfonyl)piperidine (800 g, 2.4 mmol) in DCM (10 ml) was added CF₃SO₃Me (398 mg, 2.4 mmol). The reaction mixture was stirred for 2 h at ambient temperature. The solvent was removed and the residue was washed with ether to provide (S)-1-(3-(2-methoxyphenyl)piperidin-1-yl)-2,3-dimethyl-1H-imidazol-3-ium trifluoromethanesulfonate.

To a solution of (S)-1-(3-(2-methoxyphenyl)piperidin-1-yl)-2,3-dimethyl-1H-imidazol-3-ium trifluoromethanesulfonate (1 g, 2 mmol) in CH₃CN (24 ml) was added (R)—N-(3-amino-2-methylpropyl)-4-(dimethylamino)benzenesulfonamide (0.55 g, 2 mmol). The reaction mixture was stirred overnight at ambient temperature. The mixture was concentrated. The residue was purified by column chromatography (petroleum ether/EtOAc=8:1 to 2:1) to provide (S)—N-((S)-3-((4-(dimethylamino)phenyl)sulfonamido)-2-methylpropyl)-3-(2-methoxyphenyl)piperidine-1-sulfonamide.

To a solution of (S)—N-((S)-3-((4-(dimethylamino)phenyl)sulfonamido)-2-methylpropyl)-3-(2-methoxyphenyl)piperidine-1-sulfonamide (454 mg, 0.86 mmol) in NMP (14 mL) was added NaH (104 mg, 2.6 mmol, 60%). The mixture was stirred for 0.5 h at 80° C. The mixture was cooled to 70° C. and ((cyclohexylmethyl)azanediyl)bis(propane-3,1-diyl) dimethanesulfonate (500 mg, 1.3 mmol) was added. The reaction mixture was stirred for 2 h at 70° C. The mixture was cooled to 0-5° C. and poured into water. The resulting mixture was extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate and concentrated. The residue was purified by prep-HPLC to provide compound A210. LC-MS (ESI): m/z 718.17 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.60 (m, 2H), 7.23 (m, 2H), 6.95 (m, 2H), 6.68 (m, 2H), 3.82 (s, 3H), 3.73 (m, 5H), 3.26 (m, 4H), 3.12 (s, 6H), 2.76 (m, 5H), 2.36 (m, 4H), 1.76 (m, 9H), 1.33 (m, 10H), 0.86 (m, 6H).

The following compound was synthesized in a similar manner:

No. IUPAC [M + H]⁺ A208 4-{[(3S)-9-(cyclohexylmethyl)-5-{[(3S)-3-(4- 718 methoxyphenyl)piperidin-1-yl]sulfonyl]-3-methyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline

To a solution of tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaboroan-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (10.92 g, 35 mmol), 1-bromo-3-methoxybenzene (6.6 g, 35 mmol) and Cs₂CO₃ (3.44 g, 106 mmol) in 1,4-dioxane (50 mL) and H₂O (10 mL) was added Pd(dppf)Cl₂ (1.32 g, 1.75 mmol). The reaction mixture was stirred overnight at 80° C. The solvent was removed. The residue was purified by column chromatography (petroleum ether/EtOAc=10:1) to provide tert-butyl 3-(3-methoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylate. LC-MS (ESI): m/z 290.12 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.26 (m, 1H), 6.96 (m, 1H), 6.89 (s, 1H), 6.81 (m, 1H), 6.19 (s, 1H), 4.25 (s, 2H), 3.81 (s, 3H), 3.54 (m, 2H), 2.30 (s, 2H), 1.49 (s, 9H).

To a solution of tert-butyl 3-(3-methoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylate (9.46 g, 32 mmol) in MeOH (75 mL) and EtOAc (25 mL) was added Pd/C (2 g). The mixture was stirred at ambient temperature for 4 h under H₂ atmosphere. The mixture was filtered and the filtrate was concentrated to provide tert-butyl 3-(3-methoxyphenyl)piperidine-1-carboxylate. ¹H NMR (400 MHz, CDCl₃): δ 7.25 (m, 1H), 6.81 (m, 3H), 3.99 (m, 2H), 3.73 (s, 3H), 2.65 (m, 1H), 2.55 (m, 1H), 2.50 (m, 2H), 1.98 (m, 1H), 1.65 (m, 2H), 1.44 (s, 9H).

A solution of tert-butyl 3-(3-methoxyphenyl)piperidine-1-carboxylate (7.85 g, 27 mmol) in HCl/MeOH (80 mL) was stirred at ambient temperature for 4 h. The mixture was treated with water and then adjusted to pH=12 with 3N aqueous NaOH. The resulting mixture was extracted with EtOAc (100 mL×2). The combined extracts were dried over anhydrous sodium sulfate and concentrated to provide 3-(3-methoxyphenyl). LC-MS (ESI): m/z 192.09 [M+H]⁺.

To a solution of D-(−)-tartaric acid (2.5 g, 16.7 mmol) in MeOH (12.5 mL) was added 3-(3-methoxyphenyl)piperidine (3.2 g, 16.7 mmol). The mixture was stirred at 80° C. for 24 h then cooled to ambient temperature. The resulting precipitate was collected by filtration and then recrystallized three times from MeOH to provide (S)-3-(3-methoxyphenyl)piperidine.

To a solution of (S)-3-(3-methoxyphenyl)piperidine (1.28 g, 6.7 mmol) in CH₃CN (10 mL) was added 1-(1H-imidazol-1-ylsulfonyl)-3-methyl-1H-imidazol-3-ium trifluoromethanesulfonate (2.87 g, 7.3 mmol). The reaction mixture was stirred at ambient temperature overnight. The solvent was removed. The residue was purified by column chromatography (petroleum ether/EtOAc=9:1 to 8:2) to provide (S)-3-(3-methoxyphenyl)-1-(2-methyl-1H-imidazol-1-ylsulfonyl)piperidine. ¹H NMR (400 MHz, CDCl₃): δ 7.27 (m, 1H), 7.21 (s, 1H), 6.93 (s, 1H), 6.79 (m, 2H), 6.72 (s, 1H), 3.93 (m, 2H), 3.82 (s, 3H), 2.68 (m, 1H), 2.65 (m, 2H), 2.62 (s, 3H), 2.06 (m, 1H), 1.95 (m, 1H), 1.82 (m, 1H), 1.62 (m, 1H).

To a solution of (S)-3-(3-methoxyphenyl)-1-(2-methyl-1H-imidazol-1-ylsulfonyl)piperidine (1.6 mg, 4.7 mmol) in DCM (20 mL) was added CF₃CO₂Me (782 mg, 4.7 mmol). The reaction mixture was stirred at ambient temperature for 2 h. The solvent was removed. The resulting product was washed with ether to provide (S)-1-(3-(3-methoxyphenyl)piperidin-1-ylsulfonyl)-2,3-dimethyl-1H-imidazol-3-ium trifluoromethanesulfonate.

To a solution of (S)-1-(3-(3-methoxyphenyl)piperidin-1-ylsulfonyl)-2,3-dimethyl-1H-imidazol-3-ium trifluoromethanesulfonate (1.1 g, 2.2 mmol) in CH₃CN (11 mL) was added (R)—N-(3-amino-2-methylpropyl)-4-(dimethylamino)benzenesulfonamide (896 mg, 33 mmol). The mixture was stirred at ambient temperature overnight. The solvent was removed. The residue was purified by column chromatography to provide (S)—N-((S)-3-(4-(dimethylamino)phenylsulfonamido)-2-methylpropyl)-3-(3-methoxyphenyl)piperidine-1-sulfonamide. ¹H NMR (400 MHz, CDCl₃): δ 7.68 (m, 2H), 7.28 (m, 1H), 6.85 (m, 1H), 6.80 (m, 2H), 6.68 (m, 2H), 4.81 (m, 2H), 3.82 (s, 3H), 3.76 (m, 2H), 3.12 (m, 1H), 3.07 (s, 6H), 2.82 (m, 4H), 2.11 (m, 1H), 1.93 (m, 2H), 1.77 (m, 1H), 1.29 (m, 3H), 0.91 (m, 3H).

To a solution of (S)—N-((S)-3-(4-(dimethylamino)phenylsulfonamido)-2-methylpropyl)-3-(3-methoxyphenyl)piperidine-1-sulfonamide (550 mg, 1.05 mmol) in NMP (6 mL) was added sodium hydride (75.6 mg, 3.15 mmol). The mixture was stirred for 30 min at 80° C. The mixture was cooled to 70° C. and a solution of ((cyclohexylmethyl)azanediyl)bis(propane-3,1-diyl) dimethanesulfonate (606 mg, 1.57 mmol) in NMP (3 mL) was added. The reaction mixture was stirred at 70° C. for 1 h. The mixture was cooled to ambient temperature and poured into water (10 mL). The resulting mixture was extracted with ethyl acetate (20 mL). The organic layer was washed with water (15 mL×2), dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography (EtOAc/Petroleum ether=1:15 to 1:5) to provide compound A209. LC-MS (ESI): m/z 719.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.61 (m, 2H), 7.28 (m, 2H), 6.84 (m, 3H), 6.70 (m, 2H), 3.83 (s, 3H), 3.70 (m, 2H), 3.55 (m, 2H), 3.30 (m, 1H), 3.11 (s, 9H), 2.79 (m, 5H), 2.41 (m, 1H), 2.33 (m, 3H), 2.05 (m, 8H), 1.67 (m, 4H), 1.27 (m, 7H), 0.94 (m, 3H), 0.85 (m, 2H).

To a solution of (S)—N-(3-((4-(dimethylamino)phenyl)sulfonamido)-2-methylpropyl)-4-(4-fluoro-2-methoxyphenyl)piperazine-1-sulfonamide (900 mg, 1.65 mmol) in NMP (5 mL) was added NaH (198 mg, 4.92 mmol, 60%). The mixture was stirred for 0.5 h at 80° C. The mixture was cooled to 70° C. and (S)-3,3′-(1-cyclohexylethylazanediyl)bis(propane-3,1-diyl) dimethanesulfonate (844 mg, 2.49 mmol) was added. The reaction mixture was stirred for 2 h at 70° C. then cooled to 0-5° C. and poured into water. The resulting mixture was extracted with ethyl acetate. The extract was concentrated. The residue was purified by column chromatography (petroleum ether/EtOAc=15:1) to provide compound A203. LC-MS (ESI): m/z 751.33 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.68 (m, 2H), 6.92 (m, 1H), 6.78 (m, 4H), 3.92 (s, 4H), 3.86 (m, 1H), 3.62 (m, 1H), 3.40 (m, 2H), 3.19 (m, 3H), 3.04 (s, 9H), 2.87 (m 2H), 2.26 (m, 3H), 1.92 (m, 3H), 1.79 (m, 4H), 1.66 (m, 2H), 1.54 (m, 2H), 1.38 (m, 4H), 1.26 (m, 5H), 0.98 (m, 3H), 0.83 (m, 4H).

The following compounds were synthesized in a similar manner:

No. IUPAC [M + H]⁺ B22 4-{[(1S,12R)-10-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2- 706 yl]sulfonyl]-6-(cyclohexylmethyl)-2,6,10- triazabicyclo[10.2.0]tetradecan-2-yl]sulfonyl}-N,N-dimethylaniline A160 4-{[(3S,7S,11S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2- 722 yl]sulfonyl]-9-(cyclohexylmethyl)-3,7,11-trimethyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline B16 4-{[(3S,7R,11S)-5-[(6-chloro-1,2,3,4-tetrahydroisoquinolin-2- 722 yl]sulfonyl]-9-(cyclohexylmethyl)-3,7,11-trimethyl-1,5,9- triazacyclododecan-1-yl]sulfonyl}-N,N-dimethylaniline

To a solution of 1-bromo-4-fluoro-2-methoxybenzene (910 mg, 4.4 mmol) and 1M KHMDS (18 mL, 18 mmol) in 1,4-dioxane (9 mL) was added tert-butyl (3R,5R)-3,5-dimethylpiperazine-1-carboxylate (950 mg, 4.4 mmol). The reaction mixture was stirred at 100° C. for 3 h. The solvent was removed and the residue was purified by column chromatography (petroleum ether/EtOAc=20:1) to provide tert-butyl (3R,5R)-4-(3-fluoro-5-methoxyphenyl)-3,5-dimethylpiperazine-1-carboxylate. LC-MS (ESI): m/z 339.0 [M+H]⁺.

To a solution of tert-butyl (3R,5R)-4-(3-fluoro-5-methoxyphenyl)-3,5-dimethylpiperazine-1-carboxylate (800 mg, 2.4 mmol) in DCM (4 mL) was added TFA (4 mL). The mixture was stirred at ambient temperature for 1 h. The solvent was removed. The residue was dissolved in DCM (50 mL) and then washed with saturated aqueous K₂CO₃. The organic layer was dried over anhydrous sodium sulfate and concentrated to provide (2R,6R)-1-(3-methoxy-5-methylphenyl)-2,6-dimethylpiperazine.

To a solution of (2R,6R)-1-(3-methoxy-5-methylphenyl)-2,6-dimethylpiperazine (500 mg, 2.1 mmol) in MeCN (5 mL) was added 2,3-dimethyl-1-((2-methyl-1H-imidazol-1-yl)sulfonyl)-1H-imidazol-3-ium trifluoromethanesulfonate (825 mg, 2.1 mmol). The reaction mixture was stirred overnight at ambient temperature. The solvent was removed. The residue was purified by column chromatography (petroleum ether/EtOAc=20:1) to provide (2R,6R)-1-(3-fluoro-5-methoxyphenyl)-2,6-dimethyl-4-((2-methyl-1H-imidazol-1-yl)sulfonyl)piperazine. LC-MS (ESI): m/z 383.53 [M+H]⁺.

To a solution of (2R,6R)-1-(3-methoxy-5-methylphenyl)-2,6-dimethylpiperazine (450 mg, 1.2 mmol) in DCM (5 mL) was added CF₃SO₃Me (193 mg, 1.2 mmol). The reaction mixture was stirred for 2 h at ambient temperature. The solvent was removed and the residue was washed with ether to provide 1-(((3R,5R)-4-(3-fluoro-5-methoxyphenyl)-3,5-dimethylpiperazin-1-yl)sulfonyl)-2,3-dimethyl-1H-imidazol-3-ium trifluoromethanesulfonate.

To a solution of 1-(((3R,5R)-4-(3-fluoro-5-methoxyphenyl)-3,5-dimethylpiperazin-1-yl)sulfonyl)-2,3-dimethyl-1H-imidazol-3-ium trifluoromethanesulfonate (500 mg, 0.91 mmol) in CH₃CN (5 mL) was added (R)—N-(3-amino-2-methylpropyl)-4-(dimethylamino)benzenesulfonamide (248 mg, 0.91 mmol). The reaction mixture was stirred overnight at ambient temperature. The mixture was concentrated. The residue was purified by column chromatography (petroleum ether/EtOAc=8:1 to 2:1) to provide (2S,6S)—N-((S)-3-((4-(dimethylamino)phenyl)sulfonamido)-2-methylpropyl)-4-(3-fluoro-5-methoxyphenyl)-2,6-dimethylpiperazine-1-sulfonamide. LC-MS (ESI): m/z 572.4 [M+H]⁺.

To a solution of (2S,6S)—N-((S)-3-((4-(dimethylamino)phenyl)sulfonamido)-2-methylpropyl)-4-(3-fluoro-5-methoxyphenyl)-2,6-dimethylpiperazine-1-sulfonamide (430 mg, 0.75 mmol) in NMP (4 mL) was added NaH (91 mg, 2.3 mmol, 60%). The mixture was stirred for 0.5 h at 80° C. The mixture was cooled to 70° C. and ((cyclohexylmethyl)azanediyl)bis(propane-3,1-diyl) dimethanesulfonate (435 mg, 1.1 mmol) was added. The reaction mixture was stirred for 2 h at 70° C. The solvent was removed and the residue was purified by column chromatography (petroleum ether/EtOAc=15:1) to provide compound A200. LC-MS (ESI): m/z 764.3 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃): δ 7.60 (d, 2H), 6.69 (d, 2H), 6.32 (d, 3H), 3.78 (s, 3H), 3.06 (q, 2H), 3.04 (s, 8H), 3.00 (s, 2H), 2.87 (d, 2H), 2.76 (s, 2H), 2.34 (br s, 4H), 2.09 (br s, 2H), 1.33 (s, 17H), 1.04 (d, 7H), 0.93 (d, 3H).

(S)-3,3′-(1-Cyclohexylethylazanediyl)dipropan-1-ol (Intermediate for Compounds A203, A190, A207)

To a solution of (S)-1-cyclohexylethanamine (4.0 g, 31.46 mmol) in methanol (50 mL) was added methyl acrylate (8.1 g, 94.38 mmol). The reaction mixture was stirred for 72 h at 45° C. The mixture was concentrated and the residue was purified by column chromatography (EtOAc/petroleum ether=30:1) to provide (S)-dimethyl 3,3′-(1-cyclohexylethylazanediyl)dipropanoate.

To a solution of (S)-dimethyl 3,3′-(1-cyclohexylethylazanediyl)dipropanoate (4.0 g, 13.37 mmol) in THF (50 mL) was added LiBH₄ (1.45 g, 66.84 mmol). The reaction mixture was stirred at 60° C. for 2 h. The mixture was cooled to 0-5° C. and quenched with water (30 mL). The mixture was adjusted to pH=3 with 1N aqueous hydrochloric acid and stirred for 30 minutes. The resulting mixture was washed with dichloromethane. The aqueous layer was adjusted to pH=9-10 with saturated aqueous sodium carbonate and then extracted with DCM (3×). The combined organic layers were dried over anhydrous sodium sulfate and concentrated to provide (S)-3,3′-(1-cyclohexylethylazanediyl)dipropan-1-ol. ¹H NMR (400 MHz, CDCl₃): δ 3.66 (s, 1H), 2.82 (m, 2H), 2.42 (m, 2H), 2.21 (m, 1H), 1.96 (m, 2H), 1.67 (m, 4H), 1.22 (m, 4H), 0.91 (m, 3H), 0.81 (m, 1H), 0.72 (m, 1H).

The following compounds were synthesized in a similar manner: (R)-3,3′-(1-Cyclohexylethylazanediyl)dipropan-1-ol (Intermediate for compound A191) and (S)-3,3′-((1-phenylethyl)azanediyl)bis(propan-1-ol) (Intermediate for compound A205)

6-Chloro-N-(((1R,2S)-2-(4-(dimethylamino)phenylsulfonamido)cyclobutyl) methyl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide (Intermediate for Compound B22)

To a suspension of cis-3-oxabicyclo[3.2.0]heptane-2,4-dione (32.8 g, 200 mmol) and quinine (71.4 g, 220 mmol) in toluene (1 L) was added benzyl alcohol (64.9 g, 600 mmol) dropwise over a period of 0.5 h at −55° C. The reaction mixture was stirred at −55° C. for 96 h. The resulting clear solution was concentrated to dryness and the residue was dissolved in diethyl ether (1.2 L). The solution was washed with 2N aqueous HCl (1 L), the organic layer was extracted with saturated aqueous sodium bicarbonate (500×5 mL), and the resulting combined aqueous phases were washed with diethyl ether (500 mL) to remove the traces of benzyl alcohol. The aqueous phase was acidified with 8N aqueous HCl then extracted with DCM (1.0 L×2). The combined organic layers were dried over anhydrous sodium sulfate and concentrated to provide (1S,2R)-2 (benzyloxycarbonyl)cyclobutanecarboxylic acid.

To a solution of (1S,2R)-2-(benzyloxycarbonyl)cyclobutanecarboxylic acid (40.1 g, 171.4 mmol) and triethylamine (26.0 g, 257 mmol) in dichloroethane (400 mL) was added dropwise DPPA (51.8 g, 188.5 mmol) at 0° C. The mixture was stirred for 2 h at ambient temperature then washed with water and dried over anhydrous NaSO₄. To the organic solution was added BnOH (18.5 g, 171 mmol) and triethylamine (34.6 g, 342 mmol). The reaction mixture was refluxed overnight and then diluted with DCM (500 mL). The mixture was washed with 1N aqueous HCl (1 L) and saturated aqueous NaHCO₃. The organic phase was dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to provide (1R,2S)-benzyl 2-(benzyloxycarbonylamino) cyclobutanecarboxylate.

To a solution of (1R,2S)-benzyl 2-(benzyloxycarbonylamino)cyclobutanecarboxylate (20 g, 59 mmol) in THF (100 mL) was added 4N aqueous NaOH (50 mL) at 0° C. The reaction mixture was stirred overnight at ambient temperature. The mixture was diluted with water (30 mL) then washed with ether (50 mL×2). The aqueous layer was acidified with 3N aqueous HCl and extracted with ethyl acetate. The extracts were dried over anhydrous sodium sulfate and concentrated to provide (1R,2S)-2-(benzyloxycarbonylamino)cyclobutanecarboxylic acid. ¹H NMR (400 MHz, CDCl₃): δ 7.34 (m, 5H), 5.12 (m, 2H), 4.62 (m, 1H), 3.58 (m, 1H), 2.28 (m, 2H), 1.89 (m, 2H).

To a solution of (1R,2S)-2-(benzyloxycarbonylamino)cyclobutanecarboxylic acid (4.0 g, 16.1 mmol) and K₂CO₃ (4.4 g, 32 mmol) in DMF (40 mL) was added MeI (2.96 g, 20.8 mmol). The reaction mixture was stirred at ambient temperature overnight. The mixture was poured into water (150 mL) then extracted with ether (200 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography to provide (1R,2S)-methyl 2-(benzyloxycarbonylamino)cyclobutanecarboxylate. ¹H NMR (400 MHz, CDCl₃): δ 7.34 (m, 5H), 5.69 (m, 1H), 5.08 (s, 2H), 4.62 (m, 1H), 3.66 (s, 3H), 3.38 (m, 1H), 2.32 (m, 2H), 1.99 (m, 2H).

To a solution of (1R,2S)-methyl 2-(benzyloxycarbonylamino) cyclobutanecarboxylate (8.9 g, 33.8 mmol) in MeOH (250 mL) was added NaOMe (9.1 g, 169 mmol). The mixture was heated at 45° C. for 4 h then cooled to 0° C. and HOAc (10.2 g, 169 mmol) was added dropwise. The mixture was then poured into water (500 mL) and extracted with ethyl acetate (300 mL). The extract was washed with saturated aqueous NaHCO₃ and dried over anhydrous sodium sulfate. The organic solution was concentrated and the residue was purified by column chromatography to provide (1S,2S)-methyl 2-(benzyloxycarbonylamino)cyclobutanecarboxylate. ¹H NMR (400 MHz, CDCl₃): δ 7.34 (m, 5H), 5.08 (m, 3H), 4.38 (m, 1H), 3.72 (s, 3H), 3.38 (m, 1H), 2.32 (m, 2H), 1.89 (m, 2H).

To a solution of (1S,2S)-methyl 2-(benzyloxycarbonylamino) cyclobutanecarboxylate (1.3 g, 4.9 mmol) in THF (10 mL) was added LiBH₄ (0.38 g, 9.8 mmol). The reaction mixture was stirred for 3 h at ambient temperature then poured into water (15 mL) and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate and concentrated to provide benzyl (1S,2S)-2-(hydroxymethyl)cyclobutylcarbamate. ¹H NMR (400 MHz, CDCl₃): δ 7.34 (m, 5H), 5.08 (m, 3H), 3.72 (m, 1H), 3.57 (m, 2H), 2.32 (m, 2H), 1.89 (m, 2H), 1.45 (m, 1H).

To a solution of benzyl (1S,2S)-2-(hydroxymethyl)cyclobutylcarbamate (1.1 g, 4.94 mmol), PPh₃ (1.5 g, 5.9 mmol) and isoindoline-1,3-dione (1.0 g, 6.9 mmol) in toluene (10 mL) was added DIAD (1.2 g, 5.9 mmol) at 0° C. The reaction mixture was stirred for 3 h. The precipitate was filtered off and the filtrate was concentrated and purified by column chromatography to provide benzyl (1S,2R)-2-((1,3-dioxoisoindolin-2-yl)methyl)cyclobutylcarbamate.

To a solution of benzyl (1S,2R)-2-((1,3-dioxoisoindolin-2-yl)methyl) cyclobutylcarbamate (2.0 g, 5.5 mmol) in EtOH (40 mL) was added hydrazine hydrate (0.64 g). The reaction mixture was refluxed for 3 h. The mixture was cooled, filtered, and the filtrate was concentrated. The residue was dissolved in 1N aqueous HCl (30 mL) and then washed with ether (20 mL). The aqueous layer was adjusted to pH=10. The resulting mixture was extracted with DCM (50 mL×2). The combined organics were dried over anhydrous sodium sulfate and concentrated to provide benzyl (1S,2R)-2-(aminomethyl)cyclobutylcarbamate.

To a solution of benzyl (1S,2R)-2-(aminomethyl)cyclobutylcarbamate (0.8 g, 3.4 mmol) in CH₃CN (10 mL) was added 1-((6-chloro-3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-2,3-dimethyl-1H-imidazol-3-ium trifluoromethanesulfonate (2.4 g, 5.12 mmol). The reaction mixture was stirred at ambient temperature overnight. The mixture was concentrated and the residue was purified by column chromatography to provide benzyl (1S,2R)-2-((6-chloro-1,2,3,4-tetrahydroisoquinoline-2-sulfonamido)methyl) cyclobutylcarbamate.

To 40% HBr solution in HOAc (10 mL) was added benzyl (1S,2R)-2-((6-chloro-1,2,3,4-tetrahydroisoquinoline-2-sulfonamido)methyl) cyclobutylcarbamate (1.2 g, 2.6 mmol). The mixture was stirred for 3 h then poured into water (50 mL) and washed with ether. The aqueous layer was adjusted to pH=10 with 8N aqueous NaOH. The mixture was extracted with DCM (50 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated to provide N-(((1R,2S)-2-aminocyclobutyl)methyl)-6-chloro-3,4-dihydroisoquinoline-2(1)-sulfonamide.

To a solution of N-(((1R,2S)-2-aminocyclobutyl)methyl)-6-chloro-3,4-dihydroisoquinoline-2(1H)-sulfonamide (0.66 g, 2.0 mmol) and NEt₃ (350 mg, 3.5 mmol) in DCM (5 mL) was added 4-(dimethylamino)benzenesulfonyl chloride (426 mg, 2.0 mmol) at 0° C. The reaction mixture was stirred at ambient temperature for 2 h then concentrated. The residue was dissolved in DCM and washed with water. The organic phase was dried over anhydrous sodium sulfate and concentrated to provide 6-chloro-N-(((1R,2S)-2-(4-(dimethylamino)phenylsulfonamido)cyclobutyl) methyl)-3,4-dihydroisoquinoline-2(1H-sulfonamide. ¹H NMR (400 MHz, CDCl₃): δ 7.77 (m, 2H), 7.18 (m, 2H), 7.05 (m, 1H), 6.75 (m, 2H), 5.28 (m, 1H), 5.05 (m, 1H), 4.36 (s, 2H), 3.50 (m, 2H), 3.35 (m, 1H), 3.15 (m, 1H), 3.09 (s, 6H), 2.92 (m, 3H), 2.42 (m, 1H), 2.03 (m, 1H), 1.65 (m, 2H), 1.25 (m, 1H).

(S)-3-((Cyclohexylmethyl)((R)-2-methyl-3-(methylsulfonyloxy)propyl)amino)-2-methylpropyl methanesulfonate (Intermediate for Compound A178)

To a solution of (S)-methyl 3-hydroxy-2-methylpropanoate (4.0 g, 25.42 mmol) and triethylamine (5.3 g, 50.84 mmol) in DCM (60 mL) was added slowly methanesulfonyl chloride (5.6 g, 10.20 mmol) at 0-5° C. The reaction mixture was stirred for 1 h at ambient temperature. The mixture was then diluted with DCM (100 mL) and washed with water (50 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated to provide (S)-methyl 2-methyl-3-(methylsulfonyloxy)propanoate.

To a solution of (R)-methyl 2-aminopropanoate hydrochloride (1.60 g, 10.20 mmol) in acetonitrile (200 mL) was added (S)-methyl 2-methyl-3-(methylsulfonyloxy)propanoate (4.2 g, 21.43 mmol) and potassium carbonate (4.20 g, 30.60 mmol). The reaction mixture was refluxed for 16 h then filtered and the filtrate was concentrated to provide (2R,2′S)-dimethyl 2,2′-azanediylbis(methylene)dipropanoate.

To a solution of (2R,2′S)-dimethyl 2,2′-azanediylbis(methylene)dipropanoate (650 mg, 3.0 mmol) in DCM (10 mL) was added cyclohexanecarbaldehyde (336 mg, 3.0 mmol) and sodium triacetoxyborohydride (954 mg, 4.50 mmol). The reaction mixture was stirred overnight at ambient temperature. The mixture was quenched with water and adjusted to pH=10. The resulting mixture was extracted with DCM. The extract was concentrated and the residue was purified by column chromatography to provide (2R,2′S)-dimethyl 2,2′-(cyclohexylmethylazanediyl)bis(methylene)dipropanoate.

To a solution of (2R,2′S)-dimethyl 2,2′-(cyclohexylmethylazanediyl)bis(methylene) dipropanoate (350 mg, 1.28 mmol) in THF (10 mL) was added LiBH₄ (486 mg, 12.80 mmol). The reaction mixture was stirred at 80° C. overnight. The mixture was cooled and quenched with water. The resulting mixture was adjusted to pH=5 with 1N aqueous hydrochloric acid and stirred for 0.5 h then adjusted to pH=10 and extracted with ethyl acetate three times. The combined organics were dried over anhydrous sodium sulfate and concentrated to provide (2R,2′S)-2,2′-(cyclohexylmethylazanediyl)bis(methylene)dipropan-1-01.

To a solution of (2R,2′S)-2,2′-(cyclohexylmethylazanediyl)bis(methylene) dipropan-1-ol (153 mg, 0.59 mmol) and triethylamine (0.12 g, 1.2 mmol) in DCM (5 mL) was added MsCl (135 mg, 1.18 mmol) at 0° C. The reaction mixture was stirred for 3 h at ambient temperature. The mixture was diluted with DCM (15 mL) and then washed with water (20 mL×2). The organics were dried over anhydrous sodium sulfate and concentrated to provide (S)-3-((cyclohexylmethyl)((R)-2-methyl-3-(methylsulfonyloxy)propyl)amino)-2-methylpropyl methanesulfonate. MS (EI) C₁₇H₃₅NO₆S₂, found 414 [M+H]⁺.

The following compound was synthesized in a similar manner: (2S,2′S)-((cyclohexylmethyl)azanediyl)bis(2-methylpropane-3,1-diyl) dimethanesulfonate (Intermediate for compound A160)

(R)-6-Chloro-N-(4-(4-(dimethylamino)phenylsulfonamido)butan-2-yl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide (Intermediate for Compound A148)

A solution of (R)-tert-butyl 1-cyanopropan-2-ylcarbamate (13.0 g, 71 mmol) in ethanol (250 mL) saturated with anhydrous ammonia was treated with Raney-Ni (24 g) under 55 psi of H₂ overnight. The mixture was filtered through a pad of celite and the filtrate was concentrated. The residue was purified by column chromatography to provide (R)-tert-Butyl 4-aminobutan-2-ylcarbamate.

To a solution of (R)-tert-butyl 4-aminobutan-2-ylcarbamate (2.5 g, 13.3 mmol) and triethylamine (1.33 g, 13.3 mmol) in DCM (25 mL) was added slowly a solution of 4-(dimethylamino)benzene-1-sulfonyl chloride (2.93 g, 13.3 mmol) in DCM (15 mL) at 0-5° C. The reaction mixture was stirred for 1 h at ambient temperature. The mixture was diluted with DCM (50 mL) and washed with water (30 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography to provide (R)-tert-butyl 4-(4-(dimethylamino)phenylsulfonamido)butan-2-ylcarbamate.

To a solution of (R)-tert-butyl 4-(4-(dimethylamino)phenylsulfonamido)butan-2-ylcarbamate (1.2 g, 3.2 mmol) in DCM (15 mL) was added TFA (7 mL). The mixture was stirred for 2 h and the solvent was removed. The residue was dissolved in DCM (30 mL) and then washed with saturated aqueous NaHCO₃. The organic phase was dried over anhydrous sodium sulfate and concentrated to provide (R)—N-(3-aminobutyl)-4-(dimethylamino)benzenesulfonamide (0.88 g, quantitative).

To a solution of (R)—N-(3-aminobutyl)-4-(dimethylamino)benzenesulfonamide (0.88 g, 4.0 mmol) in CH₃CN (10 mL) was added 6-chloro-1,2,3,4-tetrahydroisoquinoline (1.98 g, 4.0 mmol). The reaction mixture was stirred at ambient temperature overnight. The mixture was concentrated and the residue was purified by column chromatography to provide (R)-6-chloro-N-(4-(4-(dimethylamino)phenylsulfonamido)butan-2-yl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide.

The following compounds were synthesized in a similar manner: (S)-6-chloro-N-(4-((4-(dimethylamino)phenyl)sulfonamido)butan-2-yl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide (Intermediate for compound A147); (S)-6-chloro-N-(3-((4-(dimethylamino)phenyl)sulfonamido)butyl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide (Intermediate for compound A150); and (R)-6-chloro-N-(3-((4-(dimethylamino)phenyl)sulfonamido)butyl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide (Intermediate for compound A149)

(R)-1-(4-fluoro-2-methoxyphenyl)-2-methylpiperazine (Intermediate for Compound A177)

To tert-butyl (R)-3-methylpiperazine-1-carboxylate (5.37 g, 26.8 mmol) and 1-bromo-4-fluoro-2-methoxybenzene (5.00 g, 24.4 mmol) in toluene (50 mL) was added sodium tert-butoxide (4.69 g, 48.8 mmol) followed by BrettPhos palladacycle G3 (66.4 mg, 0.0732 mmol). The mixture was sealed under nitrogen and stirred at 100° C. and after 1 h the mixture was cooled to ambient temp, diluted with ethyl acetate and water. The organic layer was dried with sodium sulfate, filtered, and concentrated. Crude product was purified by column chromatography (0-40%, ethyl acetate/hexanes) to provide the product. MS(EI) for C₁₇H₂₅FN₂O₃, found 325 [M+H]⁺.

To tert-butyl (R)-4-(4-fluoro-2-methoxyphenyl)-3-methylpiperazine-1-carboxylate (0.51 g, 1.6 mmol) was added HCl (1.6 mL, 4 N in dioxane) and the mixture was allowed to stand at ambient temp for 16 h then diluted with water (5 mL) and ethyl acetate (5 mL). The organic layer was removed and washed with water (1×5 mL). The combined aqueous layers were washed with ethyl acetate (1×5 mL), basified with NaOH (5 N to pH 12), extracted with DCM (3×5 mL), dried with sodium sulfate, filtered, and concentrated to provide (R)-1-(4-fluoro-2-methoxyphenyl)-2-methylpiperazine which was carried forward without further purification. MS(EI) for C₁₂H₁₇FN₂O, found 225 [M+H]⁺.

The following compounds were synthesized in a similar manner:

-   1-(4-fluoro-2-methoxyphenyl)piperazine (Intermediate for A137) -   1-(2-methoxyphenyl)piperazine (Intermediate A154) -   2-(piperazin-1-yl)benzonitrile (Intermediate for A118) -   1-(2,6-dimethylphenyl)piperazine (Intermediate for A119) -   2-(4-fluoro-2-methyl)-2,6-diazaspiro[3.3]heptane (Intermediate for     A161) -   (S)-1-(4-fluoro-2-methylphenyl)-3-methylpiperazine (Intermediate for     A162) -   (R)-1-(4-fluoro-2-methylphenyl)-3-methylpiperazine (Intermediate for     A163) -   1-(2-(trifluoromethoxy)phenyl)piperazine (Intermediate for A173) -   1-(3,4-difluoro-2-methoxyphenyl)piperazine (Intermediate for A174) -   1-(3-fluoro-2-methoxyphenyl)piperazine (Intermediate for A175) -   1-(5-fluoro-2-methoxyphenyl)piperazine (Intermediate for A176) -   1-(2-chlorophenyl)piperazine (Intermediate for A198) -   1-(4-methoxyphenyl)piperazine (Intermediate for A199) -   1-(3-methoxyphenyl)piperazine (Intermediate for A201) -   1-(3-fluoro-4-methoxyphenyl)piperazine (Intermediate for A202) -   1-(2-chloro-4-fluorophenyl)piperazine (Intermediate for A206) -   (S)-1-(3-fluoro-5-methoxyphenyl)-2-methylpiperazine (Intermediate     for A194) -   (R)-1-(3-fluoro-5-methoxyphenyl)-2-methylpiperazine (Intermediate     for A195) -   (2S,6R)-1-(3-fluoro-5-methoxyphenyl)-2,6-dimethylpiperazine     (Intermediate for A197) -   (2R,6R)-1-(3-fluoro-5-methoxyphenyl)-2,6-dimethylpiperazine     (Intermediate for A200)     Assays     Dox Induced PD1-ss-Gluc Assay

FIp-In 293 T-REx™ cells were transfected with pcDNA™5/FRT/TO plasmid inserted with cDNA encoding Gaussia Luciferase fused to the 3′ end of cDNA encoding PD1 signal sequence plus 10 amino acids (N-MQIPQAPWPVVWAVLQLGWRPGWFLDSPDR-C) (SEQ ID NO: 1). Transfected cells were selected for resistance to the selectable markers Hygromycin and Blasticidin to create a stable cell line that contained the PD1-ss+10aa/Gaussia Luciferase cDNA insert whose expression was regulated under the T-REx™ system. The day before assay, cells were trypsinized and plated in 384-well tissue culture plates. The next day, compound dilutions in DMSO/media containing doxycycline were added to the wells and incubated at 37° C., 5% CO₂. 24 hours later, coelenterazine substrate was added to each well and luciferase signal was quantified using Tecan Infinite M1000 Pro for potency determination.

Results for select compounds provided herein are shown in Table 1, below. For chemical structures that include one or more stereoisomers, but are illustrated without indicating stereochemistry, the assay data refers to a mixture of stereoisomers.

Dox Induced PD1-FL-Gluc Assay

FIp-In 293 T-REx™ cells were transfected with pcDNA™5/FRT/TO plasmid inserted with cDNA encoding Firefly Luciferase fused to the 3′ end of cDNA encoding full length PD1 (amino acids 1-288). Transfected cells were selected for resistance to the selectable markers Hygromycin and Blasticidin to create a stable cell line that contained the PD1-FL/Firefly Luciferase cDNA insert whose expression was regulated under the T-REx™ system. The day before assay, cells were trypsinized and plated in 384-well tissue culture plates. The next day, compound dilutions in DMSO/media containing doxycycline were added to the wells and incubated at 37° C., 5% CO₂. 24 hours later, coelenterazine substrate was added to each well and luciferase signal was quantified using Tecan Infinite M1000 Pro for potency determination.

Results for select compounds provided herein are shown in Table 1, below. For chemical structures that include one or more stereoisomers, but are illustrated without indicating stereochemistry, the assay data refers to a mixture of stereoisomers.

Dox Induced TNFα-FL-Gluc Assay

FIp-In 293 T-REx™ cells were transfected with pcDNA™5/FRT/TO plasmid inserted with cDNA encoding Gaussia Luciferase fused to the 3′ end of cDNA encoding full length TNFα (amino acids 1-233). Transfected cells were selected for resistance to the selectable markers Hygromycin and Blasticidin to create a stable cell line that contained the TNFα-FL/Gaussia Luciferase cDNA insert whose expression was regulated under the T-REx™ system. The day before assay, cells were trypsinized and plated in 384-well tissue culture plates. The next day, compound dilutions in DMSO/media containing doxycycline were added to the wells and incubated at 37° C., 5% CO₂. 24 hours later, coelenterazine substrate was added to each well and luciferase signal was quantified using Tecan Infinite M1000 Pro for potency determination.

Results for select compounds provided herein are shown in Table 1, below. For chemical structures that include one or more stereoisomers, but are illustrated without indicating stereochemistry, the assay data refers to a mixture of stereoisomers.

Dox Induced IL2-FL-Gluc Assay

FIp-In 293 T-REx™ cells were transfected with pcDNA™5/FRT/TO plasmid inserted with cDNA encoding Gaussia Luciferase fused to the 3′ end of cDNA encoding full length IL-2 (amino acids 1-153). Transfected cells were selected for resistance to the selectable markers Hygromycin and Blasticidin to create a stable cell line that contained the IL-2-FL/Gaussia Luciferase cDNA insert whose expression was regulated under the T-REx™ system. The day before assay, cells were trypsinized and plated in 384-well tissue culture plates. The next day, compound dilutions in DMSO/media containing doxycycline were added to the wells and incubated at 37° C., 5% CO₂. 24 hours later, coelenterazine substrate was added to each well and luciferase signal was quantified using Tecan Infinite M1000 Pro for potency determination.

Results for select compounds provided herein are shown in Table 1, below. For chemical structures that include one or more stereoisomers, but are illustrated without indicating stereochemistry, the assay data refers to a mixture of stereoisomers.

Dox Induced HER3-ss-Gluc Assay

FIp-In 293 T-REx™ cells were transfected with pcDNA™5/FRT/TO plasmid inserted with cDNA encoding Gaussia Luciferase fused to the 3′ end of cDNA encoding HER3 signal sequence plus 4 amino acids (N-MRANDALQVLGLLFSLARGSEVG-C) (SEQ ID NO: 2). Transfected cells were selected for resistance to the selectable markers Hygromycin and Blasticidin to create a stable cell line that contained the HER3-ss+4aa/Gaussia Luciferase cDNA insert whose expression was regulated under the T-REx™ system. The day before assay, cells were trypsinized and plated in 384-well tissue culture plates. The next day, compound dilutions in DMSO/media containing doxycycline were added to the wells and incubated at 37° C., 5% CO₂. 24 hours later, coelenterazine substrate was added to each well and luciferase signal was quantified using Tecan Infinite M1000 Pro for potency determination.

Results for select compounds provided herein are shown in the below table. For chemical structures that include one or more stereoisomers, but are illustrated without indicating stereochemistry, the assay data refers to a mixture of stereoisomers.

Table for HER3 activity 24 hr Dox Inducible Her3(ss + 4) Gluc 293FRT/TO: No. Mean 1050 (nM) A122 110.63 A120 31.42 A137 10.85 A151 276.03 A177 10.86 A179 399.69 A124 912.67 A182 203.11 A183 2145.26 A184 155.56 A185 85.5 A107 44.21 A187 802.1 A188 88.04 A189 959.52 A190 35.6 A191 116.79 A192 1709.12 A193 50.85 A194 303.25 A195 381.8 A196 78.19 A197 77.48 A198 44.08 A199 131.52 A200 29.08 A201 211.04 A202 129.54 A203 34.13 A204 134.41 A205 230.38 A206 38.19 A207 17.98 A208 427.53 A209 497.91 A210 342.58 B22 57.77 H929 Cell Viability Assay

The human multiple myeloma cell line NCl-H929 was cultured in Advanced RPMI 1640 media (Gibco®) supplemented with 6% fetal bovine serum, 2 mM Glutamine, and 1× Penicillin/Streptomycin. On the day of assay, cells were resuspended in RPMI 1640 media supplemented with 10% fetal bovine serum, 2 mM Glutamine, and 1× Penicillin/Streptmycin and plated in 384-well tissue culture plates and treated with compound dilutions in DMSO/media. Plates were incubated at 37° C., 5% CO₂ for 48 hours. After 48 hours, Celltiter-Glo® (Promega) was added to each well and luciferase signal was quantified using Tecan Infinite M1000 Pro for cell viability determination.

Results for select compounds provided herein are shown in Table 1, below. For chemical structures that include one or more stereoisomers, but are illustrated without indicating stereochemistry, the assay data refers to a mixture of stereoisomers.

U266 Cell Viability Assay

The human multiple myeloma cell line U266B1 was cultured in RPMI 1640 media supplemented with 10% fetal bovine serum, 2 mM Glutamine, and 1× Penicillin/Streptomycin. Cells were plated in 384-well tissue culture plates and treated with compound dilutions in DMSO/media. Plates were incubated at 37° C., 5% CO₂ for 48 hours. After 48 hours, Celltiter-Glo® (Promega) was added to each well and luciferase signal was quantified using Tecan Infinite M1000 Pro for cell viability determination.

Results for select compounds provided herein are shown in Table 1, below. For chemical structures that include one or more stereoisomers, but are illustrated without indicating stereochemistry, the assay data refers to a mixture of stereoisomers

In Vitro Microsome Stability Assays

Potassium phosphate (423 μL of a 0.1 M solution) was added to 8-strip deep well tubes followed by human, mouse, rat, or monkey microsomes (25 μL of a 20 mg/mL solution). The tubes were then placed on ice and the test article (2 μL of a 0.25 mM solution in DMSO) was added. The mixture was preincubated at 37° C. for 3 to 5 minutes (shaking at 150 rpm) then the reaction was initiated by adding 50 μL NADPH. An aliquot of samples (100 μL) were collected at 0 and 30 min and 200 μL of an acetonitrile mixture containing IS (compound 914) was added to quench the reaction. After centrifuging for 10 min at 4000 rpm, a mixed solution of the 20 μL of the supernatant (20 μL) plus 100 μL ACN/H₂O (1:1) were injected for LC-MS/MS analysis. Liver microsome stability is assessed by the % remaining of compound at 30 min which is calculated using the following equation: [(AUCanalyteT=30/AUCIS)/(AUCanalyteT=0/AUCIS)]*100

Results for select compounds provided herein are shown in Table 1, below. For chemical structures that include one or more stereoisomers, but are illustrated without indicating stereochemistry, the assay data refers to a mixture of stereoisomers.

Transiently Expressed Dox Induced Signal Sequence-Gluc Assay

FIp-In 293 T-REx™ cells were transfected with 500 ng pcDNA™5/FRT/TO plasmids inserted with cDNA encoding Gaussia Luciferase fused to the 3′ end of cDNA encoding target signal sequences plus 10 amino acids. Transfected cells were incubated overnight then cells were trypsinized and plated in 384-well tissue culture plates. The next day, compound dilutions in DMSO/media containing doxycycline were added to the wells and incubated at 37° C., 5% CO₂. 24 hours later, coelenterazine substrate was added to each well and luciferase signal was quantified using Tecan Infinite M1000 Pro for potency determination.

Signal +10 Peptide Amino Target Sequence Acids A87 A137 A151 TNFR1 MGLSTV LVPHL 307 152 1625 PDLLLP GDREK LVLLEL (SEQ ID tVGIYP NO: 4) SGVIG (SEQ ID NO: 3) TNFR2 MAPVAV LPAQV 564 186 2114 WAALAV AFTPY GLELWA (SEQ ID AAHA NO: 6) (SEQ ID NO: 5) IL-17a MTPGKT GITIPR 447 216 1816 SLVSLL NPGC LLLSLE (SEQ ID AIVKA NO: 8) (SEQ ID NO: 7) IL-17Ra MGAARS LRLLD 424 176 1862 PPSAVP HRALV GPLLGL (SEQ ID LLLLLG NO: 10) VLAPGGAS (SEQ ID NO: 9) IL-23a MLGSRA RAVPG 567 223 1924 VMLLL GSSPA LLPWTAQG (SEQ ID (SEQ ID NO: 12) NO: 11) IL-12b MCHQQL IWELKK 155 74 913 (p40) VISWFS DVYV LVFLAS (SEQ ID PLVA NO: 14) (SEQ ID NO: 13) IL-23R MNQVTI GITNIN 111 47 666 QWDAVI CSGH ALYILF (SEQ ID SWCHG NO: 16) (SEQ ID NO: 15) IL-6 MNSFST VPPGED 66 38 437 SAFGPV SKDV AFSLGL (SEQ ID LLVLPA NO: 18) AFPAP (SEQ ID NO: 17) IL-6R MLAVGCA LAPRRC 78 48 445 LLAALL PAQE AAPGAA (SEQ ID (SEQ ID NO: 20) NO: 19) GP130 MLTLQT ELLDPC 201 161 969 WLVQAL GYIS FIFLTT (SEQ ID ESTG NO: 22) (SEQ ID NO: 21) IL-1R1 MKVLLR LEADKC 374 282 1474 LICFIA KERE LLISS (SEQ ID (SEQ ID NO: 24) NO: 23) IL-1R2 MLRLY FTLQP 23 17 168 VLVMG AAHTG VSA (SEQ ID (SEQ ID NO: 26) NO: 25) IL-1Ra MEICR RPSGR 111 47 666 (isoform GLRSH KSSKM 1) LITLL (SEQ ID LFLFH NO: 28) SETIC (SEQ ID NO: 27) IL-2Ra MDSYL ELCDD 159 55 876 (CD25) LMWGL DPPEI LTFIM (SEQ ID VPGCQA NO: 30) (SEQ ID NO: 29) IFN-a1 MASPF CDLPE 128 57 820 ALLMV THSLD LVVLS (SEQ ID CKSSC NO: 32) SLG (SEQ ID NO: 31) IFN-a2 MALTF CDLPQ 51 44 404 ALLVA THSLG LLVLS (SEQ ID CKSSC NO: 34) SVG (SEQ ID NO: 33) IFN-a4 MALSF CDLPQ 221 89 1129 SLLMA THSLG VLVLS (SEQ ID YKSIC NO: 36) SLG (SEQ ID NO: 35) IFN-b MTNKC MSYNL 818 288 4305 LLQIA LGFLQ LLLCF (SEQ ID STTALS NO: 38) (SEQ ID NO: 37) IFNAR1 MMWLL KNLKS 14 6 145 GATTL PQKVE VLVAV (SEQ ID APWVL NO: 40) SAAAG G (SEQ ID NO: 39) IFNAR2 MLLSQN ISYDSP 133 42 778 AFIFRS DYTD LNLVLM (SEQ ID VYISLV NO: 42) FG (SEQ ID NO: 41) CTLA-4 MACLGF KAMHV 259 112 1145 QRHKAQ AQPAV LNLATR (SEQ ID TWPCTL NO: 44) LFFLLF IPVFC (SEQ ID NO: 43) PD-L1 MRIFAV FTVTV 56 19 366 FIFMTY PKDLY WHLLNA (SEQ ID (SEQ ID NO: 46) NO: 45) LAG3 MWEAQF VPVVW 75 48 464 LGLLFL AQEGA QPLWVA (SEQ ID PVKPLQ NO: 48) PGAE (SEQ ID NO: 47) TIM3 MFSHLP SEVEY 282 132 1354 FDCVLL RAEVG LLLLLL (SEQ ID TRS NO: 50) (SEQ ID NO: 49) TIGIT MRWCLL MMTGT 162 79 737 LIWAQG IETTG LRQAPL (SEQ ID ASG NO: 52) (SEQ ID NO: 51) CD96 MEKKWK VWEKT 12 7 107 YCAVYY VNTEE IIQIHF (SEQ ID VKG NO: 54) (SEQ ID NO: 53) VISTA MGVPTA FKVAT 211 150 911 LEAGSW PYSLY RWGSLL (SEQ ID FALFLA NO: 56) ASLGPV AA (SEQ ID NO: 55) B7H3 MLRRRG LEVQV 27 9 201 SPGMGV PEDPV HVGAAL (SEQ ID GAL NO: 58) WFCLTGA (SEQ ID NO: 57) CD73 MCPRAA WELTIL 58 44 375 RAPATL HTND LLALGA (SEQ ID VLWPAA NO: 60) GA (SEQ ID NO: 59) PDGFRa MGTSHP QLSLP 90 37 565 AFLVLG SILPN CLLTGL (SEQ ID SLILC NO: 62) (SEQ ID NO: 61) VGFR2 MQSKVL ASVGL 684 213 2591 LAVALW PSVSL LCVETRA (SEQ ID (SEQ ID NO: 64) NO: 63) IL-7R MTILGT ESGYA 58 16 392 TFGMVF QNGDL SLLQVV (SEQ ID SG NO: 66) (SEQ ID NO: 65) EGFR MRPSGT LEEKK 60 47 412 AGAALL VCQGT ALLAAL (SEQ ID CPASRA NO: 68) (SEQ ID NO: 67) HER3 MRANDA SEVGN 89 57 522 LQVLGL SQAVC LFSLARG (SEQ ID (SEQ ID NO: 70) NO: 69) VEGF MNFLLS APMAE 111 51 645 WVHWSL GGGQN ALLLYL (SEQ ID HHAKWS NO: 72) QA (SEQ ID NO: 71) TACE MRQSLL PRPPD 66 40 391 (ADAM17) FLTSVV DPGFG PFVLA (SEQ ID (SEQ ID NO: 74) NO: 73) ADAM10 MVLLRV QYGNP 231 127 849 LILLLS LNKYI WAAGMGG (SEQ ID (SEQ ID NO: 76) NO: 75) Human Peripheral Blood Mononuclear Cell (PBMC) Cytokine Assay

Human PBMC were freshly isolated from whole blood collections of 3 normal donors utilizing density gradient centrifugation followed by red blood cell lysis. PBMC from each donor were assayed separately. Cells were suspended in RPMI 1640 media supplemented with 5% fetal bovine serum, 2 mM L-glutamine, 10 mM HEPES, and 1× penicillin/streptomycin. PBMC were seeded at 200,000 cells/well in 96-well round-bottom plates either without stimulation or with stimulation by lipopolysaccharide (LPS, 1 μg/mL) or antibodies against human CD3 (plate-bound, 2 μg/mL) and human CD28 (soluble, 2 μg/mL). Serial dilutions of compound in DMSO/media were simultaneously added and PBMC were incubated at 37° C., 5% CO₂ for 24 hours. After 24 hours, plates were centrifuged and half of the supernatant volume removed for cytokine analysis by electrochemiluminescent immunoassay (U-PLEX® Biomarker Multiplex, Meso Scale Discovery). For viability analysis, CellTiter-Glo® (Promega) was added to the remaining material in each well and quantified via luminescent plate reader.

Mean IC50 (nM) [Stimulation Condition] A87 A137 A133 A177 GM-CSF [Anti-CD3/CD28] 165 25 404 19 IFNγ [Anti-CD3/CD28] 152 21 234 19 IL-1β [LPS] >25000 >25000 >25000 >25000 IL-2 [Anti-CD3/CD28] 31 8 197 10 IL-6 [LPS] 61 12 193 24 IL-23 [LPS] 200 79 1054 54 TNFα [Anti-CD3/CD28] 82 17 216 13 CellTiter-Glo Viability [No >25000 >25000 >25000 >25000 Stimulation] Efficacy Study: Effect of Compound A87 on Tumor Growth and Body Weight in a B16F10 Model Comparted to Anti-PD-1 Therapy.

Female C57BL/6 mice (7-8 week old) were injected in the flank subcutaneously with 5×10⁶ B16F10 cells in 0.1 ml on Day 0. On Day 3, compound A87 formulated in 10% ETOH/10% Kolliphor EL was administered IV 30 mg/kg QW, IV 10 mg/kg D1D2, or IP 15 mg/kg QOD. Anti-PD1 antibody treatment (RMP1-14 from Bioxcell, 200 μg) was administered i.p. on a QOD×3 dose schedule. Tumor size was monitored with a digital caliper (Fowler) every 2-3 d until reaching a size of 1.5-2.0 cm and expressed as volume (length×width×height). B16F10, a melanoma line, was obtained from ATCC. C57/BL6 mice were purchased from Charles rivers laboratories.

TABLE 1 Activities of Compounds Liver Microsome Stability-% Left after 24 hr Dox 24 hr Dox 24 hr Dox 24 hr Dox 30 min w/ Inducible Inducible Inducible Inducible 48 hr H929 48 hr U266 NADPH (%) PD1ssGluc PD1FLFluc TNFaFLGluc IL2FLGluc Viability Viability Mouse 293FRT/TO: 293FRT/TO: 293FRT/TO: 293FRT/TO: Celltiter-Glo: Celltiter-Glo: Rat Mean IC50 Mean IC50 Mean IC50 Mean IC50 Mean EC50 Mean EC50 Monkey No. (nM) (nM) (nM) (nM) (nM) (nM) Human A1 1026.3 1396.1 I.A. 1170.58 I.A. I.A. 0.21 0.12 0.18 0.18 A2 344.75 807.39 I.A. 10141 I.A. 0.09 0.59 0.09 0.04 A3 241.49 637.58 11412 5080.51 I.A. 0.09 0.37 0.83 0.25 A4 93.87 310.79 3763.69 1220.45 I.A. 0.56 1.17 1.17 0.25 A5 651.38 I.A. 8429.37 I.A. 0.27 0.24 0.31 0.24 A6 4747.33 I.A. 24073.2 I.A. 0.12 0.17 0.44 0.53 A7 2314.7 I.A. 22428.6 I.A. 0.17 0.23 0.99 0.29 A8 2681.93 I.A. I.A. I.A. 0.17 0.61 0.19 0.09 A9 1106.83 I.A. I.A. I.A. 0.34 0.14 0.66 0.09 A10 123.42 4687.09 2863.07 I.A. 0.2 8.85 0.14 0.77 A11 365.31 865.78 I.A. 623.7 I.A. I.A. 0.18 0.17 0.08 0.21 A12 857.59 I.A. I.A. I.A. 0.1 0.07 0.22 0.11 A13 25.01 1471.73 987.14 I.A. 0.04 0.1 0.1 0.65 A14 640.11 1234.03 I.A. 1163.27 I.A. I.A. 5.39 1.13 1.4 0.08 A15 95.1 3063.1 2955.87 14604.7 0.29 0.061 0.13 0.07 A16 108.07 6341.65 4977.83 I.A. 2.09 2.62 41.1 0.11 A17 942.97 I.A. I.A. I.A. 0.41 1.06 0.36 0.49 A18 I.A. I.A. I.A. 15473.2 0.05 0.11 0.05 0.04 A19 325.83 I.A. I.A. 21895.5 0.24 0.1 0.08 0.05 A20 206.77 I.A. 12798.2 I.A. 0.07 0.19 0.06 0.05 A21 184.02 10002.6 8288.81 I.A. 1.77 0.62 0.11 0.14 A22 155.66 404.42 6377.93 370.18 6673.8 I.A. 0.12 0.4 0.11 0.16 A23 758.88 I.A. I.A. I.A. 0.17 0.13 0.03 0.04 A24 I.A. I.A. I.A. I.A. 0.13 0.04 0.03 0.03 A25 435.17 I.A. I.A. I.A. 0.32 4.16 0.2 0.12 A26 224.49 I.A. 16068.5 I.A. 3.4 1.84 0.13 6.65 A27 492.55 I.A. I.A. I.A. 2.15 0.98 2.07 2.52 A28 5251.11 I.A. 10426 I.A. 0.06 0.14 0.06 — A29 241.1 591.29 I.A. 446.59 I.A. I.A. 32.4 43.3 19.5 39.6 A30 792.84 I.A. I.A. I.A. 0.35 0.28 0.03 0.12 A31 619.25 I.A. I.A. I.A. 0.25 0.09 0.03 0.05 A32 I.A. I.A. I.A. I.A. 0.51 0.27 0.09 0.06 A33 I.A. I.A. I.A. I.A. 0.08 0.13 0.07 0.05 A34 I.A. I.A. I.A. I.A. 0.24 0.12 0.09 0.03 A35 83.03 243.99 >11897.98 I.A. I.A. 20.9 30 13.6 24.8 A36 118.49 319.35 >21809.41 300.59 >15385.93 I.A. 1.85 0.94 1.54 6.69 A37 202.16 I.A. I.A. I.A. 6.03 13.5 5.69 8.26 A38 75.12 5490.99 >11844.59 I.A. 12.6 24.2 9.04 11.4 A39 761.18 I.A. I.A. 10421.2 0.26 6 0.11 0.05 A40 308.26 >15070.18 I.A. I.A. 0.19 0.12 0.04 0.04 A41 17532.8 I.A. I.A. I.A. 0.2 0.14 0.1 0.08 A42 696.43 I.A. I.A. I.A. 0.79 7.69 0.81 2.65 A43 46.87 160.55 1208.05 132.63 2974.53 I.A. 20.1 22.3 12 15.4 A44 132.1 12652.5 I.A. I.A. 43.8 54 38 47.6 A46 50.13 1758.33 3336.62 I.A. 3.63 4.46 1.44 6.12 A47 258.84 I.A. I.A. I.A. 5.68 10.7 1.68 12.6 A48 991.35 I.A. I.A. I.A. 0.07 0.4 0.1 0.19 A49 407.05 I.A. I.A. I.A. 11.8 16.4 9.36 3.5 A50 22.21 74.12 660.73 56.97 1007.74 6536.29 70.1 3.6 0.79 1.32 A51 61.36 3068.97 6153.41 I.A. 28 34.7 23.6 26.7 A52 45.56 1035.16 2105.88 I.A. 29.3 40.1 38.3 31 A53 35.33 1014.07 1717.71 >10260.36 39.2 50.5 39 38 A54 26.51 952.37 1907.23 I.A. 34.6 42.4 30.5 33.8 A55 1540.39 I.A. I.A. I.A. 1.18 0.97 0.34 4.87 A56 32.76 1255.87 1634.05 I.A. 53.2 57.3 42.6 44.5 A57 73.41 7807.65 I.A. I.A. 60.2 84 28.5 31.9 A58 72.14 8500.05 I.A. I.A. 72.8 66.7 53.1 31.6 A59 24.23 615.54 1442.63 I.A. 3.73 3.9 1.94 1.89 A60 18.54 886.17 1483.8 I.A. 60.8 50.3 38.7 46.7 A61 955.94 I.A. I.A. I.A. 17.9 19.6 8.96 13.3 A63 43.65 1873.85 7433.97 I.A. 85.2 88.2 84.4 76.4 A64 74.98 3293.48 6402.59 I.A. 53.1 63.1 48 53.3 A65 153.77 8715.63 I.A. I.A. 73.4 78 57.8 53.1 A66 187.59 3495.74 9211 I.A. 0.02 0.39 0.35 0.13 A67 40.77 937.29 2398.75 I.A. 28 45.4 27.6 33.2 A68 156.12 6440.61 I.A. I.A. 55.1 57.1 57.1 50.5 A69 136.39 I.A. I.A. I.A. 64.6 74.3 58.2 63 A70 46.08 1301.94 3023.7 I.A. 3.14 6.75 3.26 1.36 A71 63.32 2014.74 7724.78 I.A. 11.5 17.2 6.75 5.55 A72 96.18 6972.14 10286.3 I.A. 43.3 54.6 53.2 62.5 A73 37.27 1861.53 3471.61 I.A. 16.3 71.5 25.4 18.2 A74 77.38 257.97 I.A. 248.26 I.A. I.A. 53.7 55.7 60.6 56.3 A75 104.41 255.94 3782.3 233.05 3029.96 I.A. 2.75 7.54 0.28 3.08 A76 I.A. I.A. I.A. I.A. I.A. I.A. 28.6 33.9 35.7 53.1 A77 95.05 338 5544.21 359.68 4012.61 I.A. 37.3 32.5 20.8 30.1 A78 359.83 I.A. I.A. I.A. 0.15 0.25 0.11 0.2 A79 408.23 I.A. I.A. I.A. 10.6 0.1 0.06 0.16 A80 272.95 I.A. I.A. I.A. 13.4 14.1 2.56 10.8 A81 476.93 I.A. I.A. I.A. 0.12 0.12 0.03 0.2 A82 30.52 1547.55 2298.14 I.A. 0.08 0.16 0.23 0.3 A83 28.17 961.05 959.61 I.A. 23.4 47.6 34.9 39.3 A84 175.94 I.A. I.A. I.A. 68.3 67.3 65.8 60.6 A85 87.46 I.A. I.A. I.A. 52.2 64.9 42.9 25.6 A86 428.72 I.A. 394.88 5625.91 I.A. 34.1 39.9 29.2 41.3 A87 19.15 492.19 50.23 223.57 I.A. 49.6 43.6 32.7 39.7 A88 4330.54 I.A. I.A. I.A. I.A. 15.9 15.2 1.33 11.7 A89 82.05 1208.13 186.53 1751.25 I.A. 17.1 22.2 13.5 18.5 A90 207.02 2413.57 493.18 3786.86 I.A. 28.2 20.2 14.1 20.1 A91 193.42 2459.27 376.81 3011.92 14653.1 25.4 21.6 21.8 23.7 A92 304.02 I.A. 518.65 I.A. I.A. 40.8 51.8 40.4 44.3 A93 670.27 I.A. 911.37 10427.9 I.A. 0.4 0.51 0.18 0.84 A94 36.37 550.17 78.29 800.16 I.A. 45.7 45.5 30.3 42.1 A95 198.02 4897.04 390.92 6711.7 I.A. 54.2 43.1 46.1 43.9 A96 121.85 1847.65 231.78 5104.13 I.A. 37.6 41.9 32.8 40.5 A97 41.78 565.68 87.04 725.76 I.A. 77.7 71.4 66.1 71.1 A98 201.79 7335.28 351.2 I.A. I.A. 55.2 32.8 26.9 57.5 A99 115.58 3535.19 349.8 I.A. I.A. 60.8 50.8 37 41.9 A100 1150.93 I.A. 1560.04 I.A. I.A. 0.1 2.18 0.04 0.22 A101 220.23 3425.89 564.3 I.A. I.A. 20.8 25.4 18.8 30.2 A102 33.39 477.31 90.53 558.29 I.A. 86.6 101.9 70 62.3 A103 445.68 I.A. 698.23 I.A. I.A. 42.2 36.5 38.5 31.6 A106 52.35 1118.61 126.18 902.63 I.A. 8.81 18.9 30.7 7.18 A107 26.11 609.25 72.97 1176.64 I.A. 16.1 19.3 25.0 83.9 A108 29.58 546.31 68.29 420.52 I.A. 0.62 2.05 0.88 1.06 A118 67.79 2093.86 172.7 5345.11 I.A. 22.1 18.3 14.7 14.2 A119 52.34 1077.79 170.3 7675.81 I.A. 50.8 66.1 53.9 71.7 A120 15.58 238.67 27.34 672.16 I.A. 19.2 28.5 16.3 4.78 A122 51.93 885.26 134.57 2420.21 I.A. 36.4 0.17 0.15 0.38 A123 13.98 424.92 45.93 834.51 I.A. 6.13 7.41 3.47 5.02 A124 606.76 I.A. 802.05 I.A. I.A. 1.01 1.25 1.91 18.9 A125 829.42 11524.98 1090.55 I.A. I.A. 0.14 0.37 8.67 0.2 A131 145.44 2403.07 426.19 4744.68 I.A. 101 73.9 70.2 84.5 A133 36.84 748.55 134.51 5121.95 I.A. 82.2 87.3 67.3 71.3 A134 11.04 309.22 27.28 540.66 I.A. 27.9 41.3 9.76 31.9 A135 21.58 625.08 48.58 1239.26 I.A. 26.1 56.3 39.2 9.36 A136 26.46 543.65 101.39 1726.93 I.A. 14.3 26.6 23.2 65.3 A137 8.30 191.24 21.45 281.93 I.A. 28 31.6 14.2 48.8 A138 73.91 947.28 156.27 2396.92 I.A. 13.2 17.1 12.5 8.84 A140 491.56 3009.42 808.08 I.A. I.A. 3.68 0.56 1.56 0.41 A141 431.02 4235.2 862.9 9106.16 I.A. 0.48 1.14 0.66 0.26 A142 38.25 741.05 67.02 1446.85 I.A. 16 22.6 3.89 11.8 A147 4122.89 I.A. I.A. I.A. I.A. 0.74 1.16 0.99 2.76 A148 925.61 I.A. 1117.32 I.A. I.A. 1.59 1.29 0.67 0.52 A149 I.A. I.A. I.A. I.A. I.A. 0.83 0.47 0.96 0.44 A150 30.29 467.79 41.34 2000.66 I.A. 1.38 2.02 2.2 4.6 A151 152.57 1216.54 305.64 2711.98 I.A. 4.55 4.2 3.98 4.28 A152 81.5 1028.9 173.82 2171.97 I.A. 5.06 3.6 3.22 3.69 A153 1293.98 I.A. 1255.35 I.A. I.A. 0.87 6.23 1.26 2.57 A154 14.94 504.45 58.66 749.43 I.A. 17.5 12.3 10.2 7.33 A155 1350.05 3484.03 7795.99 I.A. 16.8 38.8 4.86 17.8 A156 92.46 1825.18 206.72 3707.48 I.A. 75.6 82.1 80.6 81.3 A157 23.33 584.47 77.41 858.16 I.A. 23.3 32.2 27.3 21.1 A160 152.83 10687.02 452.72 I.A. I.A. 61.3 51.1 46.1 71.8 A161 577.46 I.A. 725.52 I.A. I.A. 26.5 27.3 16.7 20.2 A162 101.25 6263.53 200.98 I.A. I.A. 62.5 69.6 60.3 70.5 A163 55.56 1928.36 81.21 13622.1 I.A. 72.8 54.9 57.5 64.2 A164 454.69 I.A. 974.47 I.A. I.A. 69.0 57.9 40.9 64.8 A165 131.14 1857.05 293.51 4086.76 I.A. 14.9 11.9 12.8 2.23 A166 16.68 278.28 30.25 547.83 I.A. 26.4 31.3 18.7 14.0 A167 200.61 2656.44 412.45 6495.51 I.A. 18.3 9.19 73 5.68 A168 1491.98 I.A. 1144.17 I.A. I.A. 42 42.1 73 25.7 A169 81.52 1048.04 192.27 3272.71 I.A. 22.5 13.1 4.23 34.7 A170 56.13 797.63 133.66 1775.44 I.A. 3.65 10.8 1.37 7.2 A171 I.A. I.A. I.A. I.A. I.A. 0.91 0.90 0.26 0.60 A172 29.18 436.2 66.4 1750.08 I.A. 3.65 2.23 2.63 3.46 A173 78.83 5638.24 248.3 I.A. I.A. 49.2 53.8 55.9 56.1 A174 15.79 565.56 53.31 1861.24 I.A. 36.9 44.4 28.4 41.7 A175 9.35 393.21 40.35 1436.98 I.A. 6.73 6.28 2.27 4.26 A176 17.11 631.2 62.1 3109.99 I.A. 32.4 23.0 15.2 31.9 A177 4.95 154.54 12.57 179.88 I.A. 11.6 14.5 2.8 13.7 A178 134.76 4820.51 255.26 I.A. I.A. 22.8 29.2 25.8 24.0 A179 269.79 3249.91 72.57 11347.74 I.A. 0.5 0.18 0.26 0.04 A180 2742.03 I.A. 13843.24 20179.62 I.A. 0.44 1.97 0.08 0.80 A181 38.69 983.85 122.41 1479.93 I.A. 17.1 22.0 27.9 23.3 A182 78.84 1957.98 255.55 I.A. I.A. 61.7 41.9 41.5 53.7 A183 1443.55 2524.48 6116.1 I.A. 7.39 3.17 0.75 10.1 A184 100.13 1079.53 232.68 6916.08 I.A. 5.64 7.47 1.23 2.56 A185 43.18 573.1 85.38 1468.19 I.A. 30.1 37.8 10.0 21.8 A187 427.09 6171.01 1087.5 3866.88 I.A. 0.03 0.07 0.15 0.05 A188 38.94 714.46 99.28 1555.52 I.A. 4.48 27.8 12.4 27 A189 512.4 8138.23 1358.47 10609.19 I.A. 0.14 0.07 0.01 0.06 A190 16.23 294.54 45.7 867.11 I.A. 69.3 85.3 71.6 74.1 A191 57.62 1095.62 144.64 6734.93 I.A. 55.3 65.0 68.3 48.6 A192 1153.54 I.A. 2332.92 9362.89 I.A. 0.18 0.08 0.10 0.02 A193 23.8 748.16 81.77 6806.9 I.A. 10.1 11.3 7.72 34.2 A194 261.32 I.A. 401.51 I.A. I.A. 68.5 59.2 65.0 63.6 A195 210.96 11201.43 668.05 I.A. I.A. 58.5 63.3 32.8 53.6 A196 30.96 1474.7 104.78 I.A. I.A. A197 34.25 666.07 95.53 4125.97 I.A. 65.4 76.6 92.8 70.7 A198 18.54 372.95 53.28 1170.31 I.A. 68.2 61.4 65.1 39.2 A199 80.8 1420.53 162.14 I.A. I.A. 23.7 28.3 25.5 8.0 A200 11.23 284.85 27.87 435.72 I.A. 71.9 83.1 73.9 78.1 A201 117.7 7086.36 282.88 I.A. I.A. 39.1 35.4 26.5 32.8 A202 56.59 2052.14 175.52 2914.63 I.A. 55.0 50.8 38.3 13.3 A203 14.76 434.38 30.44 396.26 I.A. 80.3 78.7 77.9 83.4 A204 58.42 981.88 157.89 1487.11 I.A. 62.6 58.3 49.7 48.4 A205 128.76 1806.9 305.32 2362.23 I.A. 38.9 38.7 31.7 37.2 A206 17.37 395.41 38.95 657.05 I.A. 84.3 80.5 65 54.7 A207 7.93 221.47 10.6 105.74 I.A. 84.3 98.8 63.0 62.7 A208 343 I.A. 615.95 I.A. I.A. 51.8 68.9 37.5 23.3 A209 326.73 I.A. 672.98 I.A. I.A. 31.8 44.7 45.7 22.6 A210 202.76 I.A. 446.86 I.A. I.A. 76.0 54.6 55.4 47.4 B1 423.7 I.A. I.A. I.A. 0.02 0.01 0.02 0.04 B2 1721.99 I.A. I.A. I.A. 0.55 1.46 0.23 0.35 B3 7382.27 I.A. 9441.64 12597.4 0.15 0.1 0.08 0.26 B4 I.A. I.A. I.A. 16627.8 2.21 2.79 1.7 12.1 B5 1497.99 I.A. I.A. I.A. 0.24 7.08 0.21 0.54 B6 416.05 I.A. I.A. I.A. 81.8 13.2 4.57 7.66 B7 6900.19 24323 6858.59 7481.69 1.47 0.58 0.04 0.03 B8 I.A. I.A. I.A. I.A. 17.1 23.8 15.5 22.1 B9 3642.93 I.A. I.A. I.A. 0.36 3.74 0.26 0.49 B10 16476.4 I.A. 6923.68 I.A. I.A. B11 I.A. I.A. I.A. I.A. I.A. B12 5655.74 I.A. I.A. I.A. I.A. B16 449.25 13885 825.91 I.A. I.A. 58.4 72.3 44.7 55.2 B19 220.99 15364.2 I.A. I.A. 13.5 15.7 0.98 9.46 B20 794.07 I.A. I.A. I.A. 3.41 11.1 1.73 5.43 B21 3951.77 I.A. I.A. I.A. I.A. 0.16 0.06 0.03 0.17 B22 31.31 519.36 80.48 1648.2 I.A. 8.31 10.1 1.77 1.77 *I.A. means and IC50 or EC50 of greater than 25 μM 

I claim:
 1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof:

wherein: each of R^(a) and R^(b) is independently H or C₁₋₃alkyl; R¹ is H, OH, C₁₋₃alkyl, OC₁₋₃alkyl, ═CH₂, or ═NOR⁵; or R¹ is C₃₋₆cycloalkyl or C₃₋₆ heterocycloalkyl and forms a spiro group with the ring carbon to which it is attached; each of R^(1a) and R^(1b) is independently H or C₁₋₃ alkyl; R² is C₃₋₉heterocycloalkyl or C₃₋₉heterocycloalkenyl; R³ is H, C₁₋₆alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, C₃₋₇heterocycloalkyl, or C₂₋₆heteroaryl; R⁴ is C₃₋₈cycloalkyl, C₃₋₉heterocycloalkyl, C₆₋₁₀aryl, or C₂₋₆heteroaryl; each R⁵ independently is H, C₁₋₃alkyl, or C₀₋₂alkylene-C₆₋₁₀aryl; X is absent, C₁₋₃alkylene, C═O, or (C═O)O; each Y is independently SO or SO₂; and each heterocycloalkyl, heterocycloalkenyl, and heteroaryl group independently has 1, 2, or 3 ring heteroatoms selected from N, O, and S.
 2. The compound or salt of claim 1, wherein each Y is SO₂.
 3. The compound of claim 1, wherein R^(a) is H.
 4. The compound of claim 1, wherein R^(b) is H.
 5. The compound or salt of claim 1, wherein R¹ is C₁₋₃alkyl or OC₁₋₃alkyl.
 6. The compound or salt of claim 5, wherein R¹ is CH₃ or OCH₃, and R¹ exhibits S stereochemistry.
 7. The compound or salt of claim 1, wherein R¹ is C₃₋₆cycloalkyl or C₃₋₆heterocycloalkyl and forms a spiro group with the ring carbon to which it is attached, or R¹ is ═CH₂.
 8. The compound or salt of claim 1, wherein each of R^(1a) and R^(1b) is H.
 9. The compound or salt of claim 1, wherein R² comprises oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, pyranyl, piperidinyl, piperazinyl, azepanyl, or tetrahydropyridinyl.
 10. The compound or salt of claim 1, wherein the C₃₋₇heterocycloalkyl or C₃₋₇heterocycloalkenyl of R² comprises a bridge or a spiro group.
 11. The compound of claim 10, wherein the C₃₋₉heterocycloalkyl comprising a bridge or a spiro group is selected from the group consisting of

and R⁶ is C₁₋₆alkyl, C₃₋₈cycloalkyl, or C₆₋₁₀aryl or R⁶ is phenyl optionally substituted with one to three groups independently selected from halo, C₁₋₃alkyl, C₁₋₃alkoxy, and CN.
 12. The compound or salt of claim 1, wherein R² is selected from the group consisting of


13. The compound or salt of claim 12, wherein R² is selected from the group consisting of


14. The compound or salt of claim 1, wherein X is C₁₋₃alkylene.
 15. The compound or salt of claim 14, wherein X is CH₂, CH₂CH₂, or CH(CH₃).
 16. The compound or salt of claim 14, wherein R³ comprises C₃₋₈cycloalkyl, C₃₋₈cycloalkenyl, C₃₋₇heterocycloalkyl, or C₂₋₆heteroaryl.
 17. The compound or salt of claim 16, wherein R³comprises cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, tetrahydropyranyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, furanyl, thiophenyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrazinyl, or pyrimidinyl.
 18. The compound or salt of claim 17, wherein X—R³ is selected from the group consisting of


19. The compound or salt of claim 18, wherein X—R³ is


20. The compound or salt of claim 1, wherein R⁴ comprises C₆₋₁₀aryl or C₂₋₉heteroaryl, and R⁴ is substituted with one to three groups independently selected from halo, C₁₋₃alkyl, C₁₋₃alkoxy, C(O)N(R^(N))₂, and N(R^(N))₂, and each R^(N) is independently H or C₁₋₃alkyl.
 21. The compound or salt of claim 20, wherein R⁴ is selected from the group consisting of


22. The compound or salt of claim 21, wherein R⁴ is


23. The compound or salt of claim 1, wherein: R^(a), R^(b), R^(1a), and R^(1b) are each H; R¹ is ═CH₂ or CH₃; R² is

X—R³ is isobutyl,

R⁴ is

and each Y is SO₂.
 24. A compound listed in Table A, or a pharmaceutically acceptable salt thereof. TABLE A No. Structure A5

A13

A17

A19

A20

A21

A22

A23

A24

A25

A26

A27

A28

A29

A30

A31

A32

A33

A34

A35

A36

A37

A38

A39

A40

A41

A42

A43

A44

A46

A47

A48

A49

A50

A51

A52

A53

A54

A55

A56

A57

A58

A59

A60

A61

A63

A64

A65

A66

A67

A68

A69

A70

A71

A72

A73

A74

A75

A76

A77

A78

A79

A80

A81

A82

A83

A84

A85

A86

A87

A88

A89

A90

A91

A92

A93

A94

A95

A96

A97

A98

A99

A100

A101

A102

A104

A105

A106

A107

A108

A109

A110

A111

A112

A113

A114

A115

A116

A117

A118

A119

A120

A121

A122

A123

A124

A125

A126

A127

A128

A129

A130

A134

A135

A136

A137

A138

A140

A141

A142

A143

A144

A145

A146

A147

A148

A149

A150

A151

A152

A153

A154

A155

A157

A160

A161

A162

A163

A164

A165

A166

A167

A168

A169

A170

A171

A172

A173

A174

A175

A176

A177

A178

A179

A180

A181

A182

A183

A185

A188

A190

A191

A193

A194

A195

A196

A197

A198

A199

A200

A201

A202

A203

A204

A206

A207

A208

A209

A210


25. The compound or salt of claim 24, wherein the compound is selected from the group consisting of:


26. A method of inhibiting PD1, TNF-α, or IL-2 protein secretion in a cell comprising contacting the cell with the compound or salt of claim 1 in an amount effective to inhibit secretion of the protein.
 27. The compound or salt of claim 25, having a structure of


28. The compound or salt of claim 25, having a structure of


29. The compound or salt of claim 25, having a structure of


30. The compound or salt of claim 25, having a structure of


31. The compound or salt of claim 25, having a structure of


32. The compound or salt of claim 25, having a structure of 